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1.1 Prenatal Genetic Diagnosis 
1.1.1 Historical Introduction 
Karyotyping (from the Greek karyon, meaning kernel, seed or nucleus), describes the visual 
assessment of chromosome number and appearance in the cells under a light microscope.  In 1959, 
Lejeune et al correctly identified that an additional copy of chromosome 21, trisomy 21, was the 
cause of Downs syndrome in humans (Lejeune et al., 1959).  In 1966, Steel and Breg demonstrated 
that the chromosomal constitution of the foetus could be determined from the analysis of cultured 
cells obtained from amniotic fluid sampling (Steel and Breg, 1966).  The following year, Jacobsen and 
Barter reported the first prenatal diagnosis of a chromosomal abnormality (Jacobson and Barter, 
1967).  Following the continued realisation that chromosome abnormalities are a major cause of 
congenital anomalies and developmental disorders, karyotyping became the gold standard for the 
genome-wide detection of genomic imbalances in prenatal diagnosis.  Though karyotyping allows for 
the genome-wide detection of large chromosomal abnormalities and translocations, it has a number 
of inherent limitations; (i) the culturing of cells requires a minimum of 8-10 days, and can lead to a 
selective advantage of specific cell lines; (ii) the resolution is limited to 5-10Mb, at very best; and (iii) 
the visual screening for numerical or structural chromosome anomalies requires skilled analysts and 
is time consuming.   
In the presence of specific ultrasound findings, a single gene (monogenic) disorder may be suspected 
as a cause.  This directs the appropriate genetic testing to analysis of a specific gene which may be 
undertaken by PCR based methods or conventional Sanger sequencing.  Alternatively, a prior family 
history may lead to predictive testing of the foetus for the respective mutation(s).  One of the most 
frequent PCR based tests applied in the prenatal setting is for identification of commonly observed 
mutations in the CFTR gene which causes the autosomal recessive disorder cystic fibrosis.  The 
finding of an echogenic bowel on prenatal ultrasound suggests an intestinal obstruction caused by 
abnormal meconium.  Among fetuses who have hyperechogenic bowel on prenatal ultrasound, 
about 1 in 10 will have CF.  One in 25 people of European descent are carriers for a mutation in the 
CFTR gene, with the ΔF508 allele being the most frequently observed mutation. 
1.1.2 The Emergence of Molecular Cytogenetics 
As genetic techniques have advanced there has been a natural progression in applying DNA-based 
molecular genetics techniques to conventional cytogenetic investigations leading to the emergence 
of ‘molecular cytogenetics’, bringing the two disciplines closer than ever.  Several novel molecular 
biology techniques have been applied to rapid aneuploidy detection, notably, quantitative-
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fluorescent PCR (qf-PCR) (Adinolfi et al., 1997; Mann et al., 2001) and multiplex ligation-dependent 
probe amplification (MLPA) (Schouten et al., 2002; Schouten and Galjaard, 2008) which are able to 
provide a result in 1-2 days.  These techniques apply DNA-based methods to determine genomic 
copy number changes, but have the same locus-specific disadvantages as for FISH (Shaffer and Bui, 
2007; Wang and Cui, 2010). 
1.1.2.1. FISH 
Fluorescent in situ hybridisation (FISH) analysis utilises fluorescently labelled DNA probes 
complementary to the locus of interest which are hybridised to the respective chromosomal location 
and visualised with fluorescent microscopy.  In the normal diploid situation, 2 fluorescent signals are 
observed per cell examined whereas deletions show only a single signal and duplications three 
signals.  The vast majority of prenatal genetic diagnosis is aimed at the detection of a limited number 
of aneuploidies due mainly to the increased risk associated with advanced maternal age.  FISH 
probes targeted to loci on chromosomes 21, 18, 13, X & Y became the method of choice due to the 
ability to provide a rapid result in only 2-3 days for the common trisomies and sex chromosome 
aneuploidies (termed rapid aneuploidy detection) (Philip et al., 1994; Bryndorf et al., 1996; Bryndorf 
et al., 2000; Tepperberg et al., 2001).  Furthermore, specific ultrasound anomalies, or prior family 
history, may direct targeted analysis to a specific genomic locus.  One of the most common targeted 
FISH tests requested in the prenatal setting is for the detection of 22q11 deletion (DiGeorge / 
velocardiofacial syndrome) in the presence of congenital heart defects and /or cleft palate. 
1.1.2.1. qf-PCR 
qf-PCR utilises multiplexing of polymorphic STR markers located on chromosomes of interest to 
determine aneuploidy status.  Fluorescently labeled primers are used for PCR amplification of 
individual STR markers which are then characterised using fragment analysis by capillary 
electrophoresis allowing for the detection of normal or aneuploidy status.  Informative alleles will 
show an allelic ratio of 1:1, whereas trisomic samples will show the presence of an additional allele 
as three peaks in a 1:1:1 ratio or as two peaks in a 2:1 or 1:2 ratio.  Multiplexing of STR markers can 
thus provide a single tube assay for chromosomes 13, 18, 21, X & Y. 
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1.1.2.2 MLPA 
MLPA utilises two separate oligonucleotides, which hybridise to immediately adjacent target 
genomic sequences.  If both oligonucleotides hybridise to their adjacent targets they are ligated and 
subsequently exponentially amplified during the PCR reaction.  The numbers of probe ligation 
products are thus a measure of the number of target sequences in the sample investigated allowing 
for detection of duplications or deletions of the respective locus.  Similar to qf-PCR capillary 
electrophoresis is used to separate and quantify the differently sized amplification products in a 
single run. 
1.1.3 Chromosomal Microarrays 
Chromosomal microarrays allow for ‘molecular karyotyping’ (Vermeesch et al., 2005), and overcome 
the resolution, locus-specific, and time limitations of the aforementioned techniques.  Chromosomal 
microarrays provide a genome-wide screen for gains and losses of genomic regions at a far superior 
resolution to karyotyping; the resolution is only dependent upon the number and size of the targets 
on the array.  Current diagnostic platforms typically achieve resolutions of several kilobases to 
several hundreds of kilobases.  Chromosomal microarrays have revolutionised genetic diagnosis over 
recent years and have led to the discovery of a number of new recurrent microdeletion and 
microduplication syndromes (Sharp et al., 2006; Mefford et al., 2007; Shaffer et al., 2007; Mefford et 
al., 2008; Rudd et al., 2009; Wat et al., 2010; Dittwald et al., 2013).  Aside from those recurrent 
microdeletion / microduplication syndromes, novel copy number variations (CNVs) are also 
identified.  The ‘genotype first’ approach (Mefford, 2009) allows to define a ‘minimal 
deleted/duplicated region’ (MDR) or ‘smallest region of overlap’ (SRO) by comparing overlapping 
CNVs from multiple patients with similar phenotypic features.  Examples include the SRO at 15q26 
and 1q41-42, both of which are associated with multiple congenital anomalies (MCA) including 
congenital diaphragmatic hernia (CDH) in some affected individuals (Slavotinek et al., 2006; 
Klaassens et al., 2005; Rosenfeld et al., 2011; Kantarci et al., 2010; Shaffer et al., 2007). 
There are two types of array technologies available; array CGH (comparative genomic hybridisation); 
and SNP (single nucleotide polymorphism) arrays.   
1.1.3.1 Array CGH 
For array CGH, patient DNA and reference DNA are differentially labelled with fluorescent dyes and 
co-hybridised to complementary oligonucleotide targets, with known genomic coordinates, which 
are printed, i.e. an array, on a solid substrate, typically a glass slide.  The fluorescent signal intensity 
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ratio of patient DNA to reference DNA from individual targets is measured using a laser scanner, and 
the results can be plotted and visualised by the respective consecutive genomic locations of the 
target oligonucleotides, allowing gains or losses of chromosomal material in comparison to a normal 
reference to be determined.  The schematic shown in Figure 1.1.1 provides an overview of the 
workflow, and Figure 1.1.2 shows an image of a genomic array result in which both deleted and 
duplicated regions are visualised. 
1.1.3.2 SNP Arrays 
SNP arrays were originally designed to detect common (>1% in the population) single nucleotide 
polymorphisms (SNPs) and were mainly used in genotyping individuals for studies aimed at genome-
wide association studies (GWAS) of many common multifactorial diseases (Klein et al., 2005; 
Wellcome Trust Case Control Consortium, 2007; Sladek et al., 2007).  In addition to SNP typing, these 
platforms can also be used to perform copy number analysis by comparing the patient target signal 
intensities to those of a reference dataset, as opposed to the comparative dual hybridisation used in 
array CGH.  Gains & losses of genomic regions can therefore be detected as is the case for CGH 
arrays.  SNP array manufacturers have added additional oligonucleotide targets not aimed at 
detecting SNPs, but to provide an even coverage of the genome for improved CNV detection.  SNP 
identification is performed by calculation of the B-allele frequency (BAF), a measurement of the 
presence of allele ‘B’ and allele ‘A’.  Homozygous sites are called as AA (BAF=0) or BB (BAF=1), whilst 
heterozygous sites are called as ‘AB’ (BAF=0.5).  The B-allele frequency (BAF) of the respective SNP 
targets also allows SNP arrays to detect copy neutral LOH (or absence of heterozygosity, AOH), 
uniparental disomy (UPD), and regions identical by descent (IBD).  However, whilst SNP arrays will 
detect uniparental isodisomy, parental samples are required for the detection of uniparental 
heterodisomy.  Figure 1.1.3 provides a representation of how different types of copy number and 
SNP data from genomic arrays can be plotted and visualised. 
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Figure 1.1.1.  An overview of the array workflow is presented.  Patient DNA (blue, top left) and Reference DNA 
(red, top right) are fluorescently labelled with Cy5 and Cy3 dyes, respectively.  Equal quantities of DNA are 
mixed and co-hybridised to complementary oligonucleotide probes printed onto a microarray.  After washing 
unbound DNA from the array, a laser scanner is used to generate a high resolution TIFF image with the 
fluorescent signal intensities.  This data is further processed and plotted by the genomic position of the 
oligonucleotide probe on the x-axis and by the patient:reference normalised log2 signal intensity ratio on the 
y-axis. 
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Figure 1.1.2.  Displays an image from a genomic array used for array CGH analysis of a prenatal sample.  
Chromosome 4 is shown, where individual targets are plotted by genomic position on the x-axis and by 
normalised Log2 signal intensity ratio on the y-axis.  Deletion of 4p16.3 (with values approaching -1) as well as 
duplication of the remaining 4p arm (with values approaching 0.58) can be seen highlighted as aberrant 
regions by the analysis software, as a result of an inverted duplication deletion of chromosome arm 4p.  The 
4q chromosome arm displays normal copy number, with Log2 ratios close to zero. 
 
Figure 1.1.3.  A representation of the types of data plots from genomic arrays.   
Top graph displays a typical plot of array CGH data, where individual targets are plotted by genomic position 
on the x-axis, and by the normalised Log R signal intensity ratios on the y-axis.  Bottom graph displays a typical 
plot of the B-allele frequency (BAF) from SNP arrays experiment, with individual SNP targets plotted by 
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genomic position on the x-axis also, and with the B-allele frequency plotted on the y-axis.  The plots display the 
expected values for both copy number and SNP targets for genomic regions which show (from left to right) 
deletion, normal copy number, duplication, or copy neutral LOH (e.g. UPD).  For the analysis of copy number, 
the expected normalised Log R signal intensity ratio values are -1, zero, and +0.56 for deletion, normal, and 
duplication, respectively.  For SNP analysis, deletions display only homozygous regions (AA or BB), normal 
regions display both homozygous and heterozygous sites (AA, AB, BB), and duplications display skewed BAFs 
indicating the presence of an additional allele (AAB and ABB).  Also shown is an example of copy neutral LOH, 
apparently normal when only performing copy number analysis, but displaying LOH for the same region 
indicating UPD. 
 
1.1.4 Application of Chromosomal Microarrays to Genetic Diagnosis  
Chromosomal microarrays were shown in a number of studies to increase the diagnostic yield to as 
much as 15-20% for individuals with multiple congenital anomalies (MCA), and unexplained 
developmental delay (DD) / intellectual disability (ID), and autistic spectrum disorders (ASD) 
(Menten et al., 2006; Stankiewicz and Beaudet, 2007; Sagoo et al., 2009), as opposed to ~3-5% by 
conventional karyotyping (excluding trisomy 21, and other recognisable chromosomal syndromes).  
Many recurrent microdeletion / microduplication syndromes, previously unidentifiable by karyotype, 
were discovered by the use of chromosomal microarrays (Sharp et al., 2006; Mefford et al., 2007; 
Shaffer et al., 2007; Mefford et al., 2008; Rudd et al., 2009; Wat et al., 2010; Dittwald et al., 2013).  
These findings along with increased use in diagnostic laboratories led to the international consensus 
statement from the scientific and medical community that chromosomal microarray analysis be 
offered diagnostically as the first-tier test for this cohort of patients (Miller et al., 2010), and the 
formation of the ISCA consortium (The International Standards For Cytogenomic Arrays Consortium; 
https://www.iscaconsortium.org/).   
With the introduction of chromosomal microarrays into routine postnatal diagnostic use, prenatal 
diagnosis was left lagging behind somewhat.  Clearly, genome-wide screening for submicroscopic 
CNVs by chromosomal microarray analysis is an attractive alternative in the prenatal diagnostic 
setting also, providing; (i) detection of all the known recurrent microdeletion / microduplication 
syndromes (at a resolution of ~400kb), (ii) a more precise delineation of rearrangement breakpoints 
and thus gene content, and (iii) with no need for cell culture, a faster report time (3-5 days is 
achievable).  To this end, several early studies demonstrated the use of different types of genomic 
arrays for prenatal diagnosis with a variety of sample types.  In an early proof of principle 
experiment, Rickman et al (Rickman et al., 2006) demonstrated the feasibility of performing array-
based comparative genomic hybridisation (array CGH) for prenatal diagnosis on DNA extracted from 
uncultured amniotic fluid (AF) cells.  Cell-free fetal DNA in AF supernatant has also been shown to be 
suitable for performing array CGH (Larrabee et al., 2004; Miura et al., 2006; Lapaire et al., 2007).  In 
10 
 
addition, whole genome amplification (WGA) has been applied to small quantities of DNA to 
providing results from limited amounts of starting material (Bi et al., 2008). 
1.1.5 Detection of mosaicism 
Mosaicism can be detected with the use of genomic arrays (Scott et al., 2010; Hoang et al., 2011; 
Valli et al., 2011) and does not represent an inherent limitation of genomic arrays.  However, the 
level at which mosaicism can be detected is dependent on various quality parameters, mainly the 
standard deviation (SD) or derivative Log ratio (DLR) spread and the dynamic range, as opposed to 
the absolute number of cells counted with karyotyping or FISH.  Maternal cell contamination (MCC) 
can be a confounding factor in prenatal diagnosis, and will reduce the dynamic range of true 
imbalances (which will appear to be in mosaic form). 
1.1.6 Limitations of Microarrays 
Inherent to the technique, balanced chromosomal rearrangements (balanced translocations and 
inversions) are not identified by genomic arrays.  When a balanced rearrangement is detected 
prenatally on karyotype, the parents are usually tested and if the same rearrangement is present in 
the ‘normal’ parent then the translocation is typically considered likely benign.  However, if the 
rearrangement is de novo, genetic counselling is more challenging, and the empiric risk for 
developmental defects has been estimated to be 6% (Warburton, 1991).  The study of Giardino et al 
(Giardino et al., 2009) on rates of de novo balanced chromosome rearrangements in prenatal 
diagnosis reports frequencies of 0.09%, 0.08%, and 0.05% for amniotic fluid (AF), chorionic villus 
sample (CVS) and foetal blood samples, respectively. 
Interestingly, array CGH analysis of patients with developmental anomalies and apparently balanced 
translocations has revealed causal submicroscopic gains and losses which disrupt genes at the 
translocation sites, or affecting a chromosome not involved in the translocation (De Gregori et al., 
2007; Baptista et al., 2008; Schluth-Bolard et al., 2009).  The study of De Gregori et al (De Gregori et 
al., 2007), found that ~40% of patients with a ‘chromosomal phenotype’ and an apparently balanced 
translocation were in fact unbalanced, and a similar study by Schluth-Bolard et al (Schluth-Bolard et 
al., 2009), confirms the figure of ~40% of apparently balanced chromosome rearrangements being in 
fact unbalanced.  In light of these findings, genomic arrays can provide important information in 
cases of apparently balanced translocations.  However, karyotyping and FISH remain essential tools 
for the identification of truly balanced rearrangements as well as for visualization of chromosomal 
structure and location at the microscopic level. 
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In addition to truly balanced rearrangements, triploidies (69,XXX and 69,XXY) and tetraploidies are 
not detectable by array CGH.  However, the use of DNA from a patient with Klinefelter syndrome 
(47,XXY) will result in aberrant X and Y chromosome intensity ratios, enabling the detection of XXX 
triploidies and tetraploidy (Ballif et al., 2006).  An exception to this is the use of SNP arrays which can 
allow for the detection of triploidy (Tyreman et al., 2009). 
1.1.7 Interpretation of CNVs in the prenatal setting: 
The introduction into routine prenatal diagnosis has remained slow since genomic arrays have the 
potential to reveal ‘incidental’ findings, including; (i) pathogenic CNVs exhibiting variability in 
phenotypic expression or disease penetrance, and for which the future phenotype cannot therefore 
be predicted, (ii) CNVs which are unrelated to the principal referral reason but which may have 
clinical consequences for the future child or the parents and additional members, and (iii)  CNVs for 
which the clinical significance is currently not known – becoming more commonly known as Variants 
of Uncertain Significance (VOUS).  This naturally creates challenges for genetic counselling, 
particularly in the prenatal setting (Beaudet, 2010; Dondorp et al., 2012; McGillivray et al., 2012; 
Wapner et al., 2012a).  More specifically, it is the detection of VOUS in the prenatal setting that has 
been one of the major criticisms (Kohane et al., 2006; Shuster, 2007).  Early studies have estimated 
an increase in diagnostic yield above karyotyping alone of over 5%, with the incidence of VOUS in 
the region of 1-2% (Coppinger et al., 2009; Hillman et al., 2011; Shaffer et al., 2008; Strassberg et al., 
2011; Van den Veyver et al., 2009; Hillman et al., 2013; Wapner et al., 2012b). 
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1.2 Congenital Diaphragmatic Hernia 
1.2.1 The Diaphragm 
The diaphragm is a ‘parachute’ shaped structure which has several roles; (i) it forms a physical 
barrier separating the thoracic cavity from the abdominal cavity; (ii) it assists with respiration by 
contraction of the muscular portion thus enlarging the thoracic cavity, reducing intra-thoracic 
pressure and drawing air into the lungs.  Upon relaxation, air is exhaled by elastic recoil of the lung in 
conjunction with the abdominal muscles; and (iii) it assists several non-respiratory functions, such as 
expelling vomit, faeces, and urine from the body by increasing intra-abdominal pressure, and 
preventing acid reflux by exerting pressure on the esophagus as it passes through the esophageal 
hiatus.  The mature diaphragm is show in Figure 1.2.1, from which it can be seen that a muscular rim 
surrounds a central area of connective tissue, with three necessary passages for the oesophagus, 
aorta, and inferior vena cava.  The foramen of Bochdalek and foramen of Morgagni are labelled, and 
the location of the common posterlateral Bochdalek diaphragmatic hernia is highlighted. 
The development of the normal diaphragm is still poorly understood.  Perry et al have recently 
reviewed possible hypotheses on the evolutionary origins of the mammalian diaphragm (Perry et al., 
2010).  An early ‘muscular hypothesis proposes that the diaphragm is primarily muscular in origin, 
originating by the lung invading the space between the rib cage and existing body wall musculature.  
The central tendon, lacking musculature, is caused by muscle atrophy.  However, increasing 
evidence from a variety of sources suggests that the historical view of diaphragm development, 
mainly based upon histological sections, is incorrect.  It has become apparent that the opposite is 
true; the diaphragm originates from a membranous structure, which becomes secondarily 
muscularised through development.  Clugston et al investigated the embryogenesis of the 
pleuroperitoneal folds (PPFs) in the rodent model of CDH and in archived human embryo sections 
providing support for a defect in the developing PPFs as the underlying cause of the subsequent 
diaphragm defect later in development (Clugston et al., 2009).  Interestingly, the authors identify 
that PPF development occurs at around 4-6 weeks gestation in humans, and thus the potential origin 
of CDH is earlier in gestation than previously thought.  Recently, Mayer et al performed scanning 
electron microscopy of the developing diaphragm in a normal rodent and nitrofen rodent model of 
CDH adding further support to the view that the normal diaphragm mainly develops from the 
posthepatic mesenchymal plate or pleuroperitoneal folds (PPFs), and abnormal development of 
these primordial tissues results in a diaphragmatic defect (Mayer et al., 2011).   
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Figure 1.2.1.  The Diaphragm viewed from below.  Adapted from Grays Anatomy Plate 391 (sourced from; 
http://en.wikipedia.org/wiki/File:Gray391.png under the creative commons licence).   
 
1.2.2 The Diaphragm Abnormality; CDH 
Congenital Diaphragmatic hernia (CDH) is a defect in the development of the diaphragm leading to a 
‘hole’ through which the abdominal contents are able to herniate, resulting in pulmonary hypoplasia 
due to lack of available space for the lungs to properly develop and grow, Figure 1.2.2.  It is the 
variable degrees of pulmonary hypoplasia and postnatal pulmonary hypertension which account for 
the high mortality and most of the morbidity observed for this severe birth defect.  In humans the 
incidence of CDH varies from 1.7 to 5.7 per 10,000 live-born infants depending on the study 
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population (Kotecha et al., 2011; Torfs et al., 1992; Skari et al., 2000).  CDH can be anatomically 
divided into three main subtypes; a posterolateral ‘Bochdalek’ hernia representing around 70% of 
cases, an anterior ‘Morgagni’ type, accounting for around 27% of cases, and a central septum 
transversum hernia which totals around 3% of cases.  The vast majority of hernias occur on the left 
side (85%), whilst the remainder are right sided (13%) or bilateral (2%) (Torfs et al., 1992; van 
Loenhout et al., 2009; Pober, 2007).  CDH occurs as an isolated defect in around 50% of cases, or as 
non-isolated CDH for the remainder in which additional congenital malformations are present (Stoll 
et al., 2008).  Non-isolated CDH is associated with abnormalities in a number of other systems 
including; cardiovascular system (27.5%), urogenital system (17.7%), musculoskeletal system 
(15.7%), and central nervous system (9.8%) (Stoll et al., 2008).   
1.2.3. Current Prenatal Therapy by Fetoscopic Endoluminal Tracheal Occlusion (FETO) 
Since the lung growth and function are the major factors responsible for the neonatal mortality and 
much of the morbidity observed in CDH, methods to correct, or at least minimise, these ‘secondary’ 
but potentially life-threatening effects in utero have been developed.  The Fetal Medicine Unit of UZ 
Leuven (led by Professor Deprest) in collaboration with teams in London (Professor Nicolaides) and 
Barcelona (Professor Gratacos) have pioneered the use of FETO to accelerate lung growth and 
function in the moderate-severe group of CDH foetuses (measured from the lung to head ratio, LHR) 
(Jani et al., 2009; Deprest et al., 2011).  This technique involves the insertion of a balloon into the 
trachea of the foetus as show in Figure 1.2.3.  The foetal lungs produce fluid which accumulates in 
the airways, because the vocal cords at the top of the windpipe prevent it from flowing out.  This 
fluid accumulation increases the pressure inside the lungs and stretches the airways.  Foetal 
breathing movements (FBMs) are an essential aspect of lung development and maturation in 
readiness for birth and respiration, in which lung fluid escapes because of the higher pressure within 
the lungs.  This cyclical pressure change in the airways provides the mechanotransduction signals to 
the lungs for necessary growth and differentiation in preparation for birth.   
It is important to understand the role genetics has to play in cases that are today considered as 
‘isolated’ CDH.  Since these patients, when they also have a poor prognosis, are the focus of foetal 
therapy, it is this cohort of isolated CDH patients who are likely to benefit most from future 
therapeutic targets.  Improving our understanding of the pathogenesis of CDH will reveal novel 
targets and pathways for future foetal therapies. 
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Figure 1.2.2.  Congenital diaphragmatic hernia. 
The illustration shows a left-sided CDH in a newborn.  The hole on the left-side of the diaphragm allows the 
abdominal organs such as the intestines and liver to herniate and grow into the chest cavity, reducing the 
available space for the lungs and heart which are displaced, with the ipsilateral lung most severely affected. 
 
 
 
Figure 1.2.3.  Illustrates the FETO procedure (adapted from www.totaltrial.com, ©UZ Leuven).   
A 5mm incision is made in the maternal skin and a 3.3mm sheath is entered into the uterus under ultrasound 
guidance.  Through this sheath a fetoscope is inserted in the uterus allowing the surgeon to visualise the 
foetus inside the uterus on a video screen.  The foetal mouth is identified initially, and at the tracheal 
bifurcation into two branches for the two lungs, a small balloon is inserted.  The balloon is inflated and 
detatched to leave in place, the surgical instruments withdrawn, and a single stitch is used to seal the entry 
hole.  After a short hospital stay of 1 or 2 days, the mother is allowed to leave the hospital. 
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1.2.4 Genetics of CDH 
There are more than 70 syndromes in which diaphragmatic hernias have been observed (Slavotinek, 
2007).  However, whether CDH has a genetic cause for all of these disorders or is merely an 
incidental occurrence with unique genetic aetiology in addition to the other observed malformations 
is uncertain.  For a number of these disorders a single gene has been identified.  These include genes 
for transcription factors, molecules involved in cell migration, and extracellular matrix components 
(Bielinska et al., 2007).  The elucidation of the genetic mechanisms by which these genes exert their 
phenotypic effects may shed light on the cause of isolated diaphragmatic defects and the specific 
role that these genes play in diaphragm development.   
Non-isolated CDH may occur as part of a recognised genetic syndrome for which a single causal gene 
may be identified, for example; STRA6 in Matthew-Wood syndrome (Golzio et al., 2007; Pasutto et 
al., 2007; Chassaing et al., 2009; Segel et al., 2009), WT1 in Denys-Drash syndrome (Devriendt et al., 
1995; Antonius et al., 2008), LRP2 in Donnai-Barrow syndrome (Kantarci et al., 2007; Kantarci et al., 
2008), or EFNB1 in craniofrontonasal syndrome (Wieland et al., 2004; Vasudevan et al., 2006).  
Alternatively, non-isolated CDH may be associated with rearrangements in specific genetic loci, 
including 8p23.1 (Faivre et al., 1998; Wat et al., 2009), and 15q26 (Klaassens et al., 2005; Slavotinek 
et al., 2006; Klaassens et al., 2007), or with a clinically recognised syndrome of currently unknown 
genetic cause such as Fryns syndrome (Fryns et al., 1979; Fryns et al., 1989; Neville et al., 2002; 
Slavotinek, 2004).  While much information has been gained from the study of syndromic CDH, the 
exact genetic causes of isolated CDH remain largely unknown.  The use of techniques such as 
chromosomal microarrays to search for submicroscopic CNVs in isolated CDH patients may help to 
unravel the contribution of genetic factors in cases of isolated CDH. 
1.2.5 Animal Models  
A wealth of information has been obtained from teratogen- or surgically-induced CDH animal 
models, as well as from genetic and transgenic models of CDH.  Much research efforts, particularly 
those using surgically induced CDH models, have focussed on the pathogenesis of the altered 
pulmonary airway and vascular development.  This is understandable since it is the lung hypoplasia 
and pulmonary hypertension which are the factors responsible for the immediate mortality and 
contribute largely to the long term morbidity often seen in CDH patients.  Aside from the 
disadvantages of using teratogen-induced models to study the genetics of CDH, the nitrofen-induced 
CDH model has provided a better understanding of normal and abnormal diaphragm development 
at the anatomical level.  Furthermore, the nitrofen model has also highlighted differences in gene 
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expression in the diaphragm and lungs, as well as providing further evidence of the retinoic acid 
pathway as having a causative role in the pathogenesis of CDH.  The mechanism of action of nitrofen 
which was for long uncertain has now been demonstrated to occur by inhibition of the rate-limiting 
enzymes involved in retinoic acid synthesis, most likely by suppression of RALDH2 activity and thus 
retinoid signalling (Mey et al., 2003; Noble et al., 2007; Clugston et al., 2010). 
Among the most interesting research developments using teratogen-induced animal models is the 
recent investigation of abnormal retinoid signalling from Clugston et al (Clugston et al., 2010).  In this 
study, a number of teratogens were used to induce CDH in RARE-lacZ transgenic mice providing 
further evidence that disruption of retinoid signalling causes CDH, and is not specific to the nitrofen 
model alone.  In common with other studies, dietary supplementation of retinoic acid (RA) was 
shown to reduce the incidence of diaphragm defects from 58.7% to 1.3% supporting the concept of 
possible therapeutic intervention through maintaining normal retinoid levels, and thus retinoid 
dependent signalling, during development.  Expression analysis in the pleuroperitoneal folds (PPFs) 
showed that proteins involved in the retinoid signalling pathway are expressed within this structure 
which will be discussed later.  Of particular interest, this study generated a novel CDH model using 
the pan-RAR antagonist BMS493 to pharmacologically block retinoic acid receptor (RAR) signalling.  
This model produced a Bochdalek CDH phenotype, which is the most common type observed in 
humans.  Furthermore, the timing of teratogen exposure correlated with the side of the diaphragm 
defect, i.e. early administration (E8-E9) generated predominantly left-sided CDH, whilst late 
administration (E11-E13) generated predominantly right-sided CDH, and exposure on E10 produced 
left and right-sided CDH as well as bilateral CDH.  These results are suggestive of different critical 
time periods in development of the left or right side of the diaphragm. 
Historical evidence from vitamin A deficient (VAD) models have long implicated the retinoic acid 
pathway as having an important role in diaphragm development and therefore being a potential 
target for foetal therapy.  More recently, genetic models have demonstrated the phenotypic effects 
of faults in specific genes, and further research in these models and the development of novel 
genetic models has the potential to pinpoint the roles that individual candidate genes play in 
diaphragm and lung development.  Table 1 summarises the genetic mouse models in which 
diaphragm defects have been observed. 
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ID Gene Symbol Genotype Ontology 
Term 
Ontology Annotation 
Term Name 
Reference 
MGI:105377 Adam19 Adam19
tm1Asf
/Adam19
tm1Asf
 MP:0000761 thin diaphragm muscle (Kurohara et al., 2004) 
MGI:109617 Barx2 
Barx2 / Dmd (Myod) 
Barx2
tm1Rsd
/Barx2
tm1Rsd
 
[Barx2
tm1Rsd
/Barx2
tm1Rs 
Dmd
mdx
/Dmd
mdx
] 
[Barx2
tm1Rsd
/Barx2
tm1Rsd 
Dmd
mdx
/Y] 
MP:0000761 thin diaphragm muscle (Meech et al., 2012) 
MGI:88294 Cacna1s Cacna1s
mdg
/Cacna1s
mdg
 MP:0000761 thin diaphragm muscle (PAI, 1965) 
MGI:1888950 Cdkn1a Cdkn1a
tm1Led
/Cdkn1a
tm1Led
 
Cdkn1c
tm1Sje
/Cdkn1c
+
 
MP:0000761 thin diaphragm muscle (Zhang et al., 1999) 
MGI:88392 Chat Chat
tm1.1Jrs
/Chat
tm1.1Jrs
 MP:0003924 
MP:0000761 
herniated diaphragm 
thin diaphragm muscle 
(Misgeld et al., 2002) 
MGI:87895 Chrng Chrng
tm2(Chrne)Vwi
/Chrng
tm2(Chrne)Vwi
 MP:0000761 thin diaphragm muscle (Pacifici et al., 2011) 
 Chtop   Diaphragmatic hernia* (Veenma, 2012. PhD Thesis)  
MGI:94885 Des Des
tm1Cba
/Des
tm1Cba
 MP:0000761 thin diaphragm muscle (Li et al., 1996) 
 
 
MGI:1329019 Dnase2a Dnase2a
tm1Aea
/Dnase2a
tm1Aea
 MP:0003924 
MP:0000761 
herniated diaphragm 
thin diaphragm muscle 
(Krieser et al., 2002) 
MGI:2429765 Dock1 Dock1
tm1Jfco
/Dock1
tm1Jfco
 MP:0000761 thin diaphragm muscle (Laurin et al., 2008) 
MGI:1343461 Ecel1 Ecel1
tm1Hiki
/Ecel1
tm1Hiki
 MP:0000761 thin diaphragm muscle (Nagata et al., 2010) 
MGI:1891209 Efemp2 Efemp2
tm1.2Tynk
/Efemp2
tm1.2Tynk
 MP:0003924 herniated diaphragm (Horiguchi et al., 2009) 
MGI:95489 Fbn1 Fbn1
tm2Rmz
/Fbn1
tm2Rmz
 MP:0003924 herniated diaphragm (Pereira et al., 1999) 
MGI:1099809 Fgf10 Fgf10
tm1Ska
/Fgf10
tm1Ska
 MP:0003924 herniated diaphragm (Min et al., 1998; Babiuk and 
Greer, 2002; Arkovitz et al., 
2005; Sekine et al., 1999) 
MGI:2150920 Fgfrl1 Fgfrl1
tm1True
/Fgfrl1
tm1True
 MP:0003924 
MP:0000761 
herniated diaphragm 
thin diaphragm muscle 
(Baertschi et al., 2007; Catela 
et al., 2009) 
MGI:2670972 Frem1 Frem1
eyes2
/Frem1
eyes2
 MP:0003924 herniated diaphragm (Beck et al., 2013b; Beck et al., 
2013a) 
MGI:1917550 Fuz Fuz
b2b1273Clo
/Fuz
b2b1273Clo
 MP:0003924 herniated diaphragm  
MGI:95664 
MGI:3526856 
Gata4 Gata4
tm1Eno
/Gata4 
+
 
Gata4
tm1.2Wtp
/Gata4 
+
 
MP:0003924 herniated diaphragm (Jay et al., 2007) 
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MGI:95728 
MGI:95729 
Gli2 / Gli3 Gli2 (-/-) mice 
Gli3 (-/-) mice 
Gli2 (-/-) Gli3(+/-) double knockout mice 
 Diaphragmatic hernia* (Motoyama et al., 1998; Kim 
et al., 2001) 
MGI:96109 Hlx Hlx
tm1Rph
/Hlx
tm1Rph
 MP:0003924 herniated diaphragm (Hentsch et al., 1996) 
MGI:96185 
MGI:1857390 
Hoxb4 Hoxb4
tm1Nrm
/Hoxb4
tm1Nrm
 
Hoxb4
tm1Bay
/Hoxb4
tm1Bay
 
MP:0003924 herniated diaphragm (Ramirez-Solis et al., 1993; 
Manley et al., 2001) 
MGI:1339973 Ilf3 Ilf3
tm1Pnk
/Ilf3
tm1Pnk
 MP:0000761 thin diaphragm muscle (Shi et al., 2005) 
 Kif7   Diaphragmatic hernia* (Coles and Ackerman, 2013) 
MGI:96795 Lmnb1 Lmnb1
tm1Yxz
/Lmnb1
tm1Yxz
 
[Lmnb1
tm1Yxz
/Lmnb1
tm1Yxz 
Lmnb2
tm1Yxz
/Lmnb2
tm1Yxz
] 
MP:0000761 thin diaphragm muscle (Kim et al., 2011) 
MGI:5313524 
MGI:3610732 
MGI:2657016 
Lox Lox
b2b370.2Clo
/Lox
b2b370.2Clo
 
Lox
tm1Soin
/Lox
tm1Soin
 
Lox
tm1Ikh
/Lox
tm1Ikh
 
MP:0003924 
 
MP:0000761 
herniated diaphragm 
 
thin diaphragm muscle 
(Hornstra et al., 2003; Maki et 
al., 2005) 
MGI:1857655 
 
MGI:1858019 
Met Met
tm1Cbm
/Met
tm1Cbm
 
 
Met
tm1Cpo
/Met
tm1Cpo
 
MP:0003924 
MP:0000761 
MP:0011883 
herniated diaphragm 
thin diaphragm muscle 
absent diaphragm 
(Babiuk and Greer, 2002) 
MGI:3046860 
MGI:2386252 
Mmp14 / Mmp2 [Mmp14
tm1Noda
/Mmp14
tm1Noda 
Mmp2
tm1Ito
/Mmp2
tm1Ito
] MP:0000761 thin diaphragm muscle (Oh et al., 2004) 
MGI:3655692 
MGI:2148205 
Msc (MyoR-) / 
Tcf21 (capsulin
LacZ
) 
[Msc
tm1Eno
/Msc
tm1Eno 
Tcf21
tm2Eno
/Tcf21
tm2Eno
] MP:0003924 herniated diaphragm (Lu et al., 2002) 
MGI:2182358 
MGI:2182361 
MGI:2182363 
Mnx1 Mnx1
tm1Tmj
/Mnx1
tm1Tmj
 
Mnx1
tm2Tmj
/Mnx1
tm2Tmj
 
Mnx1
tm3Tmj
/Mnx1
tm3Tmj
 
MP:0000761 thin diaphragm muscle (Arber et al., 1999) 
MGI:103581 Musk Musk
tm1.1Vwi
/Musk
tm2Vwi
 MP:0000761 thin diaphragm muscle (Chevessier et al., 2008) 
MGI:1856328 Myod (Dmd) Dmd
mdx
/Dmd
mdx
 
mdx:MyoD -/- 
9th
  
  (Inanlou et al., 2003; Inanlou 
and Kablar, 2003) 
MGI:97276 Myog Myog
tm1Whk
/Myog
tm1Whk
 MP:0000761 thin diaphragm muscle (Tseng et al., 2000; Hasty et 
al., 1993) 
MGI:3579117 Nr2f2  
(Couptf-II
Flox
) 
[Nkx3-2
tm1(cre)Tsa
/Nkx3-2 
+  
Nr2f2
tm2.1Tsa
/Nr2f2
tm2.1Tsa
] MP:0003924 herniated diaphragm (You et al., 2005) 
MGI:96083 Nrg1 Nrg1
tm1Lwr
/Nrg1
tm1Lwr
 MP:0000761 thin diaphragm muscle (Wolpowitz et al., 2000) 
MGI:97487 Pax3 Pax3
tm1Mrc
/Pax3 
+
 MP:0000761 thin diaphragm muscle (Keller et al., 2004; Li et al., 
1999) 
MGI:97491 Pax7 Pax7
tm1Pgr
/Pax7
tm1Pgr
 MP:0000761 thin diaphragm muscle (Seale et al., 2000) 
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 Pbx1   Diaphragm defects* (Russell et al., 2012) 
MGI:97530 Pdgfra Pdgfra
tm2Sor
/Pdgfra
tm2Sor
 MP:0003924 herniated diaphragm (Sun et al., 2000; Bleyl et al., 
2007) 
MGI:2158795 
MGI:2158757 
Ptprd / Ptprs Ptprd
tm1Yiw
/Ptprd
tm1Yiw
 
Ptprs
tm1Mtr
/Ptprs
tm1Mtr
 
MP:0000761 thin diaphragm muscle (Uetani et al., 2006) 
MGI:1857622 
MGI:1857851 
Rara / Rarb [Rara
tm1Ipc
/Rara
tm1Ipc  
Rarb
tm1Mma
/Rarb
tm1Mma
]  MP:0003924 herniated diaphragm (Mendelsohn et al., 1994a; 
Lohnes et al., 1995) 
MGI:1274781 Robo1   Diaphragmatic hernia* (Xian et al., 2001) 
MGI:102780 Six1 Six1
tm1Mair
/Six1
tm1Mair
 MP:0000761 
MP:0011883 
thin diaphragm muscle 
absent diaphragm 
(Laclef et al., 2003b; Laclef et 
al., 2003a) 
MGI:2679499 
MGI:2662346 
MGI:1315202 
Slit3 Slit3
Gt(OST106158)Lex
/Slit3
Gt(OST106158)Lex
 
Slit3
tm1Dor
/Slit3
tm1Dor
 
Slit3
tm1.1Dor
/Slit3
tm1.1Dor
 
MP:0003924 
 
MP:0000761 
herniated diaphragm 
 
thin diaphragm muscle 
(Liu et al., 2003; Yuan et al., 
2003) 
MGI:98331 Snap25 Snap25
tm1Mcw
/Snap25
tm1Mcw
 MP:0000761 thin diaphragm muscle (Washbourne et al., 2002) 
MGI:98369 Sox7 Sox7
tm1.1Dsco
/Sox7 
+
 MP:0003924 herniated diaphragm (Wat et al., 2012) 
MGI:3587413 Zfpm2 
(Fog2
lil
) 
Zfpm2
lil
/Zfpm2
lil
 MP:0003924 herniated diaphragm (Ackerman et al., 2005) 
MGI:98968 Wt1 Wt1
tm1Jae
/Wt1
tm1Jae
 MP:0003924 herniated diaphragm (Kreidberg et al., 1993; 
Clugston et al., 2006) 
Table 1.2.1 
Summarises the mouse models in which specific diaphragm abnormalities were observed; herniated diaphragm (CDH); thin diaphragm muscle; absent diaphragm. 
Information retrieved from MouseMine (http://www.mousemine.org/); Mouse Genome Informatics, MGI (http://www.informatics.jax.org/). 
* From literature; Diaphragmatic defects or CDH observed.   
Additional reference sources for Fuz, Lox:  Modelling the genetic basis for human congenital heart disease in mice. 
(http://www.devbio.pitt.edu/research/mouse_muta.html). 
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ID Gene Symbol Genotype Ontology 
Term 
Ontology Annotation Term 
Name 
Reference 
MGI:87961 Agrn [Agrn
tm1Rwb
/Agrn
tm1Rwb
 Tg(Pax3-cre)1Joe/?] MP:0002279 abnormal diaphragm 
morphology 
(Harvey et al., 2007) 
MGI:105058 Atp2a1 Atp2a1
tm1Dhm
/Atp2a1
tm1Dhm
 MP:0002279 abnormal diaphragm 
morphology 
(Pan et al., 2003) 
MGI:107437 Capn3 Capn3
Gt(OST141731)Lex
/Capn3
Gt(OST141731)Lex
 MP:0002279 abnormal diaphragm 
morphology 
(Kramerova et al., 2004) 
MGI:1923936 Clip3 Clip3
tm1.1Ics
/Clip3
tm1.1Ics
 MP:0002279 abnormal diaphragm 
morphology 
(Couesnon et al., 2013) 
MGI:88459 Col6a1 Col6a1
tm1Gmb
/Col6a1 
+
 
Col6a1
tm1Gmb
/Col6a1
tm1Gmb
 
MP:0002279 abnormal diaphragm 
morphology 
(Bonaldo et al., 1998) 
MGI:2183644 
MGI:2183646 
Ctbp1 / Ctbp2 [Ctbp1
tm1Sor
/Ctbp1
tm1Sor 
Ctbp2
Gt(ROSA61)Sor
/Ctbp2
+
] MP:0002279 abnormal diaphragm 
morphology 
(Hildebrand and Soriano, 
2002) 
MGI:102720 Ednrb Ednrb
s-15DttMb
/Ednrb
s-15DttMb
 
Ednrb
s-1Acrg
/Ednrb
s-9ThW
 
MP:0002279 abnormal diaphragm 
morphology 
(Burgess et al., 2004) 
MGI:95557 Flnc Flnc
tm1Lmk
/Flnc
tm1Lmk
 MP:0002279 abnormal diaphragm 
morphology 
(Dalkilic et al., 2006) 
MGI:108088 Gab1 Gab1
tm1Wbm
/Gab1
tm1Wbm
 MP:0002279 abnormal diaphragm 
morphology 
(Sachs et al., 2000) 
MGI:1354951 Gne [Gne
tm1Sngi
/Gne
tm1Sngi
 Tg(ACTB-GNE*D176V)9Sngi/?] MP:0002279 abnormal diaphragm 
morphology 
(Malicdan et al., 2007) 
MGI:2135593 Hadha Hadha
tm1Jib
/Hadha
tm1Jib
 MP:0002279 abnormal diaphragm 
morphology 
(Ibdah et al., 2001) 
MGI:3576010 hpld hpld/hpld MP:0002279 abnormal diaphragm 
morphology 
(Herron et al., 2002) 
MGI:99954 Ighmbp2 Ighmbp2
nmd-2J
/Ighmbp2
nmd-2J
 MP:0002279 abnormal diaphragm 
morphology 
(Grohmann et al., 2004) 
MGI:102700 Itga7 Itga7
tm1Burk
/Itga7
tm1Burk
 
Itga7
tm1Umr
/Itga7
tm1Umr 
[Itga7
tm1Burk
/Itga7
tm1Burk 
Sspn
tm1Kcam
/Sspn
tm1Kcam
]  
MP:0002279 abnormal diaphragm 
morphology 
(Marshall et al., 2012; Mayer 
et al., 1997) 
MGI:1342270 Large Large
myd
/Large
myd
 
Large
vls
/Large
vls
 
MP:0002279 abnormal diaphragm 
morphology 
(Lee et al., 2005) 
MGI:96794 Lmna Lmna
tm1Gbon
/Lmna
tm1Gbon
 MP:0002279 abnormal diaphragm 
morphology 
(Arimura et al., 2005) 
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MGI:1928394 Mtor [Mtor
tm1.2Koz
/Mtor
tm1.2Koz
 Tg(ACTA1-cre)79Jme/?] MP:0002279 abnormal diaphragm 
morphology 
(Risson et al., 2009) 
MGI:2179432 Mycbp2 Mycbp2
tm1.1Adia
/Mycbp2
tm1.1Adia
 MP:0002279 abnormal diaphragm 
morphology 
(Bloom et al., 2007) 
MGI:1100535 Myt1 Myt1
tm1.1Ggu
/Myt1
tm1.1Ggu
 MP:0002279 abnormal diaphragm 
morphology 
(Wang et al., 2007) 
MGI:2444155 Nmnat2 Nmnat2
Tn(sb-Tyr)2172.P9KK4BOve
/Nmnat2
Tn(sb-Tyr)2172.P9KK4BOve
 MP:0002279 abnormal diaphragm 
morphology 
(Hicks et al., 2012) 
MGI:5427579 
MGI:2156086 
Pik3ca / Pten [Pik3ca
tm1.1Waph
/Pik3ca
tm1.1Waph
 
Pten
tm1Hwu
/Pten
tm1Hwu
] 
MP:0002279 abnormal diaphragm 
morphology 
(Kinross et al., 2012) 
MGI:96522 Rbpj [Pax3
tm1(cre)Joe
/Pax3
 +
 Rbpj
tm1Hon
/Rbpj
tm1Hon
] MP:0002279 abnormal diaphragm 
morphology 
(Vasyutina et al., 2007) 
MGI:99659 Ryr1 Ryr1
tm1.1Dhm
/Ryr1
tm1.1Dhm
 MP:0002279 abnormal diaphragm 
morphology 
(Zvaritch et al., 2007) 
MGI:1346524 Sgcg Sgcg
tm1Mcn
/Sgcg
tm1Mcn
 
Sgcg
tm1Oza
/Sgcg
tm1Oza
 
MP:0002279 abnormal diaphragm 
morphology 
(Hack et al., 1998; Sasaoka et 
al., 2003) 
MGI:106658 Srf [Srf
tm2.1Nor
/Srf
tm2.1Nor
 Tg(Myog-cre)1Eno/?] MP:0002279 abnormal diaphragm 
morphology 
(Li et al., 2005) 
MGI:98725 Tgfb1 Tgfb1
tm1Doe
/Tgfb1
tm1Doe
 MP:0002279 abnormal diaphragm 
morphology 
(Shull et al., 1992) 
Table 1.2.2. 
Summarises the additional mouse models in which abnormal diaphragm morphology was observed.  Information from MouseMine (http://www.mousemine.org/); Mouse 
Genome Informatics, MGI (http://www.informatics.jax.org/); and from recent literature. 
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1.2.6 Current Hypotheses on the Developmental Origins of CDH. 
Over recent years three main concepts emerge; the retinoid hypothesis, the mesenchymal-
hit hypothesis, and the dual-hit hypothesis.  These three hypotheses are supported by 
growing evidence from dietary, teratogenic (nitrofen, BMS493), and genetic animal models, 
and from identification of genetic abnormalities in human CDH. 
1.2.6.1 The Retinoid Signalling Pathway and the Retinoid Hypothesis 
Vitamin A is essential for various aspects of early embryonic development, as demonstrated 
by the spectrum of abnormalities observed in vitamin A deficient (VAD) animal models 
(Wilson et al., 1953).  The observation that CDH is associated with VAD models, and with 
teratogen-induced models such as nitrofen, which disrupt the retinoic acid (RA), or retinoid 
signalling pathway, provides strong evidence for a link with diaphragm development and this 
pathway (Thebaud et al., 1999; Babiuk et al., 2004; Oshiro et al., 2005; Nakazawa et al., 
2007b; Nakazawa et al., 2007a; Noble et al., 2007; Clugston et al., 2010).  More recently, 
genetic models for various genes known to be involved in the RA pathway have provided 
further evidence of a link to CDH.  These models include the FOG2 ENU mutant, the COUP-
TFII knockout model, the heterozygous GATA4+/Δex2 model, and the retinoic acid receptor 
(RAR) double knockout models (see table 1).  However, it is of interest that the Bochdalek-
type hernias, which account for the vast majority of human CDH cases, have not been 
observed in the FOG2 or GATA4 mutants.  The retinoic acid pathway has been described in a 
number of publications, including (Clagett-Dame and DeLuca, 2002; Montedonico et al., 
2008; Niederreither and Dolle, 2008; Klaassens et al., 2009; Theodosiou et al., 2010; Goumy 
et al., 2010), and an overview is presented in Figure 1.2.4. 
FOG2 (also known as ZFPM2) is a zinc finger transcription cofactor which modulates the 
activity of GATA transcription factors, in particular GATA4, and is located on 8q23, a region 
associated with CDH in humans (OMIM 610187, DIH3).  Using mice treated with N-ethyl-N-
nitrosourea (ENU), Ackerman et al identified a FOG2 mutation generating a truncated 
protein and causing pulmonary hypoplasia and abnormal diaphragmatic development 
(Ackerman et al., 2005).  Furthermore, the authors identified a de novo mutation in 1 of 30 
deceased children with diaphragm defects, in which severe bilateral pulmonary hypoplasia 
and an abnormally muscularised diaphragm were observed.  Bleyl et al later identified novel 
sequence alterations in 2 of 96 patients with isolated CDH, however were unable to  
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Figure 1.2.4.  An overview of the retinoic acid pathway.   
Retinol is transported to target cells in a complex with RBP, with transfer into the cell occurring by the 
cell surface receptor STRA6.  Within the target cell, retinol is bound to CRBP, and can be converted to 
retinal by ADH (in a reversible reaction), or to retinyl esters by LRAT.  Retinal is oxidised to retinoic 
acid (RA) by RALDH in an irreversible reaction, whereby RA can complex with CRABP which enables 
transport to the nucleus.  Within the nucleus RA forms a complex with RAR/RXR heterodimers, which 
in turn bind to a short DNA sequence, the retinoic acid response element (RARE) thereby activating 
transcription of the target gene.  COUP-TFII can inhibit the heterodimerisation of RAR/RXR, thus 
inhibiting gene transcription.  FOG2 interacts with both COUP-TFII and GATA4, thereby modulating 
the activity of GATA4 transcription factors.  Excess cellular RA can be presented to CYP26 enzymes for 
degradation to Hydroxy RA.  Nitrofen is believed to exert its effects through inhibition of RALDH 
activity. 
Abbreviations:  RBP (retinol binding proteins). STRA6 (stimulated by retinoic acid 6). CRBP (cellular 
retinol binding proteins). ADH (alcohol dehydrogenases). RDH (retinol dehydrogenases). RALDH 
(retinaldehyde dehydrogenases). RA (retinoic acid). CRABP (cellular retinoic acid binding proteins). 
RAR (retinoic acid receptors). RXR (retinoid X receptors). RARE (retinoic acid response element). LRAT 
(lecithin:retinol acetyltransferase). CYP26 (cytochrome P450 family 26). 
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confidently determine the variants as causal mutations due to the lack of parental samples 
(Bleyl et al., 2007). 
COUP-TFII is a transcription factor and orphan nuclear receptor which can interact with 
FOG2.  COUP-TFII can inhibit gene transcription by preventing heterodimerisation of retinoic 
acid receptors (RARs) and retinoid X receptors (RXRs), as well as modulate the 
transcriptional activity of GATA proteins, particularly GATA4.  You et al generated tissue-
specific null mutants of COUP-TFII which displayed the common Bochdalek type of CDH.  
Targeted ablation of COUP-TFII in the foregut mesenchyme, including the posthepatic 
mesenchymal plate (PHMP), which is also referred to as the PPF, resulted in malformation of 
the diaphragm and the failure of the PHMP to attach to the body wall (You et al., 2005).  The 
location of COUP-TFII also known as NR2F2, on chromosome 15q26, a region recurrently 
associated with CDH patients makes this gene an interesting candidate for human CDH 
(Klaassens et al., 2005; Slavotinek et al., 2006). However, the study of Scott et al was unable 
to identify COUP-TFII mutations in 73 CDH samples (Scott et al., 2007).  In another study, 
Slavotinek et al studied 6 candidate genes in the 15q26 critical region in over 100 CDH 
patients (Slavotinek et al., 2006).  However, although mis-sense changes were identified, 
none of these alterations could be assigned as definitively causal for CDH.  This data may be 
suggestive of chromosome deletions at 15q26 being a contiguous gene deletion syndrome, 
or may be due to the suggested multi-factorial etiology of CDH.   
GATA4 is a zinc finger transcription factor known to interact with FOG2 (Crispino et al., 2001) 
and involved in regulating gene expression (Molkentin, 2000).  GATA4 null mutant mice are 
embryonic lethal due to the essential role of this gene in heart development (Kuo et al., 
1997; Molkentin et al., 1997).  However, Jay et al generated a mouse model with a 
heterozygous deletion in exon 2 of GATA4 which displayed CDH and primary lung 
abnormalities.  GATA4 is located in the critical region of the 8p23.1 deletion syndrome which 
shows a strong association with CDH (Wat et al., 2009) as well as heart defects.  However, in 
humans GATA4 mutations are typically associated with heart abnormalities and not with 
CDH (Garg et al., 2003; Okubo et al., 2004; Tomita-Mitchell et al., 2007; Rajagopal et al., 
2007; Reamon-Buettner and Borlak, 2005; Reamon-Buettner et al., 2007).   
Several studies have not observed defects in embryological development for individual RAR 
knockout models (Li et al., 1993; Mendelsohn et al., 1994b), indicating a degree of 
overlapping function and compensation by the α, β, and γ forms of receptor.  However, 
generation of compound null RAR mutants were shown to have a spectrum of VAD-like 
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defects including diaphragm defects (Lohnes et al., 1994; Mendelsohn et al., 1994a; Lohnes 
et al., 1995), confirming the importance of these receptors for early development in a 
number of systems.  It has recently been proposed that the unique expression pattern of 
RARα in the PPF may be of particular importance for diaphragm development (Clugston et 
al., 2010). 
In humans, mutations in STRA6 (stimulated by retinoic acid 6), a retinol binding protein 
(RBP) receptor, have recently been linked to a spectrum of defects including diaphragmatic 
and pulmonary defects known collectively as Matthew Wood syndrome (Golzio et al., 2007; 
Pasutto et al., 2007; Chassaing et al., 2009), providing evidence for the involvement of this 
pathway in human CDH. 
Collectively there is an increasing amount of evidence which supports the hypothesis that 
abnormal retinoid signalling plays an important role in the development of CDH.  Further 
investigation and the generation of additional novel models which are targeted to specific 
components of the retinoid signalling pathway will increase our understanding of the 
pathogenesis of CDH and of the role that retinoid signalling and the downstream targets of 
this pathway play in diaphragm development.  However, given the spectrum of defects seen 
in humans with STRA6 mutations, as well as the evidence for the RSP having roles in various 
aspects of embryological development (reviewed in (Niederreither and Dolle, 2008)), it 
remains to be determined whether defects at the higher levels of this pathway are 
responsible for isolated CDH. 
1.2.6.2 PPF development and the Mesenchymal Hit Hypothesis 
There is a body of evidence from animal models that CDH originates from a malformation of 
the PPFs, which are a key structure in the embryogenesis of the diaphragm being the target 
for muscle precursor cells and for the phrenic nerve.  It has been hypothesised that 
abnormal PPF development may underlie Bochdalek CDH (Allan and Greer, 1997; Clugston 
and Greer, 2007; Clugston et al., 2009).  A number of histological studies have compared this 
structure in both normal and abnormal situations, and 3D reconstructions have also been 
generated by some groups (Clugston et al., 2006; Clugston et al., 2009; Ackerman and Greer, 
2007).  Through the use of histological investigations, Clugston et al have demonstrated that 
teratogen-induced, dietary and genetic models of CDH appear to share a common 
mechanism of pathogenesis originating from defects in the PPF (Clugston et al., 2006).  More 
recently, the same group investigated the timeframe of PPF formation in rat embryos and 
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human embryos, identifying a critical period of normal diaphragm development at 4-6 weeks 
gestation.  Importantly, this time period is earlier in gestation than conventionally thought 
and occurs before the typical time-point of pregnancy determination.  Through additional 
investigations using nitrofen-exposed NIH 3T3 cells in vitro, it is proposed that impaired cell 
proliferation, and not increased apoptosis, contributes to abnormal diaphragm development 
in the nitrofen model of CDH (Clugston et al., 2009).   
Expression analysis in the diaphragm has revealed interesting results supporting the 
mesenchymal hit hypothesis.  Analysis of wild-type mouse embryos demonstrated co-
expression of GATA4 and FOG2 in mesenchymal cells of the developing diaphragm, lungs 
and heart (Jay et al., 2007).  Double immuno-labelling for COUP-TFII and WT1 has shown 
that these proteins co-localise within the non-muscular mesenchymal cells of the developing 
PPF (Clugston et al., 2006).  These co-expression data indicate that the COUP-TFII, FOG2, 
GATA4 and WT1 models provide support for the mesenchymal hit hypothesis. 
Clugston et al found that RALDH2 is the only retinal dehydrogenase isoform expressed in the 
developing PPF.  Examination of retinoid receptor expression in the PPF for the α, β, and γ 
isoforms of both the RARs and RXRs revealed positive expression for only RARα, RARγ, and 
RXRα.  These receptors were shown to be strongly expressed within the non-muscular 
mesenchymal cells (WT1 positive), with weak expression in the muscle precursor cells (PAX3 
positive).  Interestingly, whilst the RARγ and RXRα expression was relatively uniform and 
widespread, the expression pattern of RARα was largely restricted to the caudal region of 
the PPF, corresponding to the affected region of the PPF in nitrofen-exposed embryos.  It is 
therefore now proposed that RARα signalling in the developing PPF may be of particular 
importance for normal diaphragm development (Clugston et al., 2010).  The finding that the 
PPF is a centre for retinoid signalling further implicates this pathway and provides a 
potential link to defective retinoid signalling causing abnormal PPF development and thus 
CDH by affecting the mesenchymal component of this tissue early in diaphragm 
development (Clugston et al., 2010). 
Additional research has shown that the 15q26 region contains a cluster of genes that are 
expressed in the developing diaphragm in rodents, supporting the association of CDH with 
deletions of 15q26.  Further examination of protein expression within the developing 
diaphragm has shown that genes strongly associated with CDH (COUP-TFII, FOG2, GATA4, 
and WT1) are expressed only in the non-muscular mesenchymal component of the 
diaphragm, supporting the mesenchymal hit hypothesis, and well as demonstrating that 
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these factors are all co-expressed in the same cells.  This is suggestive of different genetic 
causes leading to a common defect in the mesenchymal cells of the PPF which causes CDH, 
supporting the theory that unique genetic defects affecting a common pathway can lead to 
CDH (Clugston et al., 2008). 
Given the apparent defective development of the PPF in multiple animal models of 
Bochdalek type CDH, as well as in archived human embryo specimens (Clugston et al., 2009) 
further investigation of the role that this structure plays, and in particular the role of the 
non-muscular mesenchymal cells in the pathogenesis of isolated CDH is needed.  It will also 
provide an improved understanding of the embryogenesis of the diaphragm, and the 
influence that defects in the PPFs have on the development of CDH in humans.  It is essential 
for us to understand the genetic factors involved in normal PPF development and how 
genetic defects can affect the PPF and further development of the diaphragm. 
1.2.6.3 Diaphragm and Lungs – the Dual Hit Hypothesis 
Keijzer et al demonstrated using lung explants that nitrofen interferes with early lung 
development before and separate from aberrant diaphragm development.  The authors 
postulate the dual-hit hypothesis to explain pulmonary hypoplasia in CDH by two 
mechanisms, the first affecting both lungs before diaphragm development and a second 
affecting the ipsilateral lung after defective diaphragm development (Keijzer et al., 2000).  
Nitrofen is however damaging at high doses to a number of developing organs which are 
dependent on retinoid signalling.  It is possible that the diaphragm may be particularly 
sensitive to disruption of retinoid signalling in the case of CDH. 
The FOG2 ENU mouse model implicates the role of this gene in the pathogenesis of isolated 
CDH, and its necessity for pulmonary development validates the hypothesis that neonates 
with CDH may also have primary pulmonary developmental abnormalities.  Furthermore, 
expression analysis of Gata4 and Fog2 in wild-type mouse embryos has demonstrated co-
expression in the mesenchymal cells of the developing diaphragm, lungs and heart (Jay et 
al., 2007).   
Recently, it has also been shown that WT1 is specifically expressed in the embryonic 
mesothelium.  WT1 expressing cells were abundant from the origin of the lung buds to 
postnatal stages contributing significantly to pulmonary endothelial and smooth muscle 
cells, bronchial musculature, tracheal and bronchial cartilage.  Thus, Wt1cre-YFP 
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mesenchymal cells show the very same differentiation potential than the splanchnopleural 
mesenchyme surrounding the lung buds.  We have also found defects in pulmonary 
development in Wt1-/- embryos, which showed abnormally fused lung lobes, round-shaped 
and reduced pleural cavities and diaphragmatic hernia.  Our results suggest a novel role for 
the embryonic mesothelium-derived cells in lung morphogenesis and involve the Wilms' 
tumor suppressor gene in the development of this organ (Cano et al., 2013) 
The overlapping function of certain genes and pathways in both diaphragm and lung 
development supports the dual-hit model, however, exactly how defects in retinoid 
signalling and mesenchymal cell function may contribute to cases of isolated CDH remains to 
be determined. 
1.2.7 The Contribution of Environmental Factors  
It has become increasingly evident that genetic factors play an important role in the 
aetiology of CDH (Slavotinek, 2007; Bielinska et al., 2007).  However, it is still uncertain 
whether complex genetic factors are the sole cause of CDH.  The evidence from teratogen- 
and dietary-induced CDH animal models is suggestive of environmental and/or nutritional 
factors also playing a role (reviewed in (Beurskens et al., 2009)).  A recent study which 
investigated the Vitamin A status of mothers and their newborns in association with CDH 
found a strong association with low retinol and RBP independent of maternal retinol levels 
(Beurskens et al., 2010).  These findings are more consistent with there being an abnormality 
in embryological retinoid homeostasis in the foetus, rather than maternal vitamin A 
deficiency being a risk factor.  More research in this area is certainly warranted since 
maternal malnutrition and lifestyle factors are easily modified, which may potentially reduce 
the risk of CDH and other congenital malformations. 
The variable penetrance of CDH in teratogen-induced and genetic models of different strains 
(Jay et al., 2007; Beck et al., 2013a) is suggestive of a genetic background which confers a 
susceptibility to the development of CDH.  The same is true in humans.  The observation that 
CDH does not display full penetrance for genetic disorders or genomic loci adds further 
weight to as yet unidentified regulatory factors or environmental influences also playing an 
important role.   
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Chapter 2.  Research Objectives 
We propose that a significant proportion of congenital malformations are caused by 
genomic imbalances, and that a number of these CNVs are undetectable by prenatal 
karyotype.  We hypothesise that the application of high resolution genome-wide array CGH 
for prenatal diagnosis will reveal novel submicroscopic loci which are important for foetal 
development.  Furthermore, the higher resolution provided by array CGH in comparison to 
conventional karyotyping, and the faster result time, will improve the standard of analysis 
offered for prenatal genetic diagnosis.  In Chapter 3 we present the results of our study into 
the clinical utility of chromosomal microarray analysis for prenatal diagnosis in referrals with 
abnormal ultrasound findings, and our approach to the reporting of VOUS and risk loci 
during pregnancy. 
One developmental disorder for which the genetic basis in humans remains poorly 
understood is congenital diaphragmatic hernia (CDH).  While much information has been 
gained from the study of model organisms, the genetic causes of isolated CDH remain largely 
unknown.  Currently those foetuses with moderate-severe isolated CDH are the focus of 
foetal therapy.  Since a subset of these patients may have a poor prognosis due to an 
underlying genetic abnormality, it is important to make a diagnosis where possible allowing 
better informed decisions for possible therapies.  Moreover, improving our understanding of 
the pathogenesis of CDH will reveal novel targets and pathways for future foetal therapies.  
We propose that genetic causes underlie a significant proportion of isolated CDH cases and 
that chromosomal microarray analysis will identify genomic imbalances revealing candidate 
loci and genes associated with isolated CDH.  In Chapter 4 we present the results of our 
retrospective study of isolated CDH using a custom design array.  In the second part of 
Chapter 4 we present the results from our prospective prenatal study of isolated CDH 
foetuses using a genome-wide array. 
Exome sequencing allows for screening of the entire coding portion of the genome and has 
the potential to identify causal mutations involved in development of CDH.  In Chapter 5 we 
present our findings from exome sequencing in cases of familial CDH. 
In Chapter 6 we present the results of an exploratory study using RNA-Sequencing to 
investigate gene expression patterns in amniotic fluid cells of isolated CDH foetuses.  The 
dysregulated genes and pathways identified can potentially be used to identify subtypes of 
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CDH based upon the gene expression profiles which may correlate with, for example, 
severity of disease or response to treatment. 
Finally, in Chapter 7 we discuss the implications of our findings and consider future 
perspectives. 
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Chapter 3.  Prenatal Chromosomal Microarray Analysis. 
Genetics in Medicine. 2013. Published online Oct 31 2013. 
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Abstract 
Purpose:  To evaluate the clinical utility of chromosomal microarrays for prenatal diagnosis 
by a prospective study of foetuses with abnormalities detected on ultrasound.   
Methods:  Patients referred for prenatal diagnosis due to ultrasound anomalies underwent 
analysis by array CGH as the first-tier diagnostic test. 
Results:  A total of 383 prenatal samples underwent analysis by array CGH.  Array analysis 
revealed causal imbalances in a total of 9.6% of patients (n=37).  Submicroscopic copy 
number variations (CNVs) were detected in 2.6% of patients (n=10/37), and arrays added 
valuable information over conventional karyotyping in 3.9% of patients (n=15/37).  We 
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highlight a novel advantage of arrays; a 500kb paternal insertional translocation is the likely 
driver of a de novo unbalanced translocation, thus improving recurrence risk calculation in 
this family.  Variants of uncertain significance were revealed in 1.6% of patients (n=6/383).   
Conclusion:  We demonstrate the added value of chromosomal microarrays for prenatal 
diagnosis in the presence of ultrasound anomalies.  We advocate reporting back only CNVs 
with known pathogenic significance.  Although this approach might be considered opposite 
to the ideal of full reproductive autonomy of the parents, we argue why providing all 
information to parents may result in a false sense of autonomy. 
Introduction 
Conventional karyotyping has been considered the gold standard for routine prenatal 
genetic diagnosis for many decades now, allowing for microscopic visualisation and 
inspection of chromosomes and thus detection of numerical and structural chromosomal 
rearrangements.  The main limitations are the resolution achieved by G-banding, which is 
limited to 5-10Mb at best, and the requirement for cultured cells, needing a minimum of 8-
10 days.  The introduction of targeted methods of analysis such as fluorescence in situ 
hybridisation (FISH) and multiplex ligation-dependent probe amplification (MLPA) overcome 
the time constraints and resolution limitations inherent to karyotyping, but do not provide a 
genome-wide analysis (Goumy et al., 2010).  More recently, molecular karyotyping using 
genomic microarrays has reached mainstream use in the postnatal diagnostic setting 
providing a genome-wide screen for genomic imbalances at a far superior resolution to 
karyotyping (Miller et al., 2010).  A number of studies have demonstrated the feasibility of 
prenatal diagnosis by genomic arrays using a variety of platforms (Coppinger et al., 2009; 
Faas et al., 2010; Srebniak et al., 2011; Breman et al., 2012; Shaffer et al., 2012), but 
challenges remain in applying high resolution genomic arrays to prenatal diagnosis (Vetro et 
al., 2012; Wapner et al., 2012a; Breman et al., 2012).  One of the major ethical issues often 
raised is how to deal with variants of uncertain significance (VOUS) or risk loci, the detection 
of which leads to additional challenges for genetic counselling of parents.  Furthermore, 
array analysis may reveal an imbalance for known ‘risk loci’ where the future penetrance is 
uncertain or may be associated with variable expression.  The penetrance risks for a number 
of recurrent CNVs have been estimated based upon the frequencies in patients and controls 
(Kaminsky et al., 2011; Cooper et al., 2011; Rosenfeld et al., 2013).  However, while it is 
possible to calculate a population-based risk, it is impossible in the prenatal setting to 
predict the phenotypic outcome in the child. 
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Here, we present results of a prospective study on the routine use of array CGH for foetuses 
with congenital abnormalities detected prenatally by ultrasound from 2 Belgian genetics 
centres.  We also discuss our approaches to the interpretation and reporting of genomic 
array results in the prenatal setting. 
Methods 
Referral Criteria and Time Period 
Samples were received over a 3-year period at the Centre for Human Genetics (CME), KU 
Leuven, UZ Leuven and the Centre for Medical Genetics Ghent (CMGG), Ghent University 
Hospital (herein referred to as KUL and UG, respectively).  For both centres, criteria for 
inclusion were either (i) multiple abnormalities, or (ii) isolated abnormality observed on 
ultrasound for which invasive testing and genetic analysis is advised.  Ethical approval was 
granted for this study in both centres. 
Sample Types 
Chorionic Villi Samples (CVS), Amniotic Fluid (AF) samples and foetal blood samples were 
received.  In all cases backup cultures were initiated for further DNA requirements and for 
conventional karyotype.  When available, genomic DNA was immediately isolated from fresh 
material (including all foetal blood samples).  Where required, DNA was isolated from 
cultured cells (AF and CVS only).  Villi from CVS were separated from maternal tissue under a 
microscope to minimise maternal cell contamination (MCC).  Two to four villi were provided 
for DNA extraction.  Between 2ml and 13ml (mean=7; median=8) of AF was provided for 
DNA extraction.  AF samples were centrifuged and cell pellets washed twice in PBS.  
Genomic DNA was extracted by both centres using the DNA mini kit (QIAGEN Benelux B.V. – 
Belgium, Venlo, Netherlands) following the manufacturers recommendations.  For CVS, 
incubation at 56°C with proteinase K and tissue lysis buffer (Buffer ATL) was performed for 
at least 1 hour for efficient digestion and lysis of the complete sample.  For AF, incubation at 
56°C with proteinase K and lysis buffer (Buffer AL) was performed for 10 minutes.  Amicon 
YM-30 Spin Columns (Merck Millipore S.A./N.V., Overijse, Belgium) were used for 
concentrating DNA samples (KUL).  Total DNA yields for the first 100 samples including 
uncultured CVS and AF ranged from 1µg to 6µg, and from 100ng to 2µg (mean=800ng), 
respectively.  MCC was assessed on DNA for all CVS by using the DNA Purity Assay 
(Multiplicom, Niel, Belgium), or the PowerPlex system (Promega Benelux B.V., Leiden, 
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Netherlands), both of which utilise polymorphic STR marker analysis.  MCC was assessed on 
DNA for heavily blood-stained AF only.   
Genomic Array Platforms 
KUL applied the CytoSure Syndrome Plus 105K array and CytoSure Syndrome Plus 180K array 
(Oxford Gene Technology, Oxford, UK).  This platform has genome-wide coverage with 
enrichment of target regions.  Details of the array designs are available from Oxford Gene 
Technology (http://www.ogt.co.uk/) or the authors.  UG applied the Agilent 60K platform 
(AMADID 21924) or the Agilent 180K platform (AMADID 27676) (Agilent Technologies 
S.A./N.V., Diegem, Belgium) which is the International Standards for Cytogenomic Arrays 
(ISCA) Consortium  design, supplemented with selected genes / loci of interest.  Details of 
the array designs are available from Agilent Technologies or the authors.   
Array CGH Analysis and Interpretation 
Genomic DNA was labelled for 4hrs using the CytoSure Labelling Kit (Oxford Gene 
Technology), with no enzyme digestion.  Hybridisation was performed from 24 – 60 hours, in 
a rotator oven (SciGene, CA, USA) at 65’C.  Washing of arrays was performed using Agilent 
wash solutions manually or with a Little Dipper Microarray Processor (SciGene), and dried 
using acetonitrile.  Arrays were scanned using an Agilent microarray scanner at 2µm 
resolution, followed by calculation of signal intensities using Feature Extraction software 
(Agilent Technologies).  Visualisations of results and data analysis were performed using the 
CytoSure Interpret Software (Oxford Gene Technology) and the CBS algorithm.  The calling 
thresholds were deviation of a circular binary segmentation (CBS) segment from zero log 
ratio of; +0.36 for duplications and -0.72 for deletions, and containing ≥5 oligonucleotide 
probes.  All samples were hybridized twice in dye swap experiments, labelled with Cy5 and 
Cy3 and hybridized versus Cy3 and Cy5 labelled reference DNA, respectively.  The dye swap 
increases the sensitivity which, in turn, allows a more accurate detection of smaller 
imbalances, refinement of the breakpoint and mosaicism.  No major discrepancies are 
observed between hybridisations.  Results were then classified with CytoSure Interpret 
Software (Oxford Gene Technology) and with BENCH software (Cartagenia N.V., Leuven, 
Belgium).  Quality control metrics are monitored with CytoSure Interpret software (Oxford 
Gene Technology).  For UG, arrays were hybridised and analysed as previously described 
(Buysse et al., 2009).  Genomic coordinates are based upon build hg18. 
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Pre-test Counselling and Informed Consent 
Following detection of an abnormality on ultrasound investigation, array analysis was 
offered as the first-tier test with additional multidisciplinary counselling and informed 
consent at a tertiary centre.  Traditional chromosome analysis by conventional karyotyping 
was not routinely performed.  Rapid aneuploidy detection (RAD) was performed by FISH or 
qf-PCR for all patients prior to array analysis to timely exclude common autosomal and sex 
chromosome aneuploidies, as well as to exclude triploidy.  Parental samples may be 
required for full interpretation of array results, and were provided along with the prenatal 
sample where possible.  Parental samples were only analysed after detection of a prenatal 
imbalance, and only for those regions of interest.  Patients agree during the informed 
consent that all causal and clinically significant imbalances, but not all variants of uncertain 
significance (VOUS) or (inherited) likely benign CNVs are reported (routinely).  This data is 
retained by the laboratory and available on request.  VOUS were defined as CNVs which 
have not been described before in the literature as pathogenic nor contain genes known to 
cause haploinsufficiency syndromes, but are likely deleterious, based on the functional 
evidence known about the genes in the CNVs.  The published recommendations and 
guidelines for classification and interpretation of CNVs for constitutional postnatal genetic 
diagnosis, including VOUS, form the basis for our CNV classification in the prenatal setting 
also (Vetro et al., 2012; Kearney et al., 2011; Vermeesch et al., 2012; de Leeuw et al., 2012).  
CNVs without genes or known to be common in the population are considered benign.  A list 
of common polymorphic CNVs is curated by the laboratory based upon in-house data and 
prior experience, supported by additional evidence from the database of genomic variants 
(DGV), DECIPHER and ISCA databases (Table S2, online supplementary information).  A 
clinical geneticist assists the laboratory in the final decision of CNV classification and advises 
which imbalances to report to the referring clinician and patient in challenging cases.  
Confirmation of findings 
All pathogenic CNVs were confirmed by conventional karyotype, FISH analysis, MLPA, and / 
or qf-PCR. 
Results 
A combined total of 403 prenatal samples underwent analysis by array CGH.  Of these 403 
samples received, an interpretable result was obtained in 383 cases.  For 20 samples the 
array result could not be interpreted due to either maternal cell contamination (MCC) (n=4), 
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or a poor quality array result with a derivative log ratio (DLR) value beyond an acceptable 
range of 0.3 (n=16).  Of total samples received 65% (n=262) were AF, 21% (n=85) were CVS 
and 14% (n=56) were foetal blood samples.  Only common polymorphic and likely benign 
CNVs were observed for 289/383 (75.5%) of patients and a normal array result was 
reported.  In the remaining 24.5% of patients (n=94), rare and/or likely pathogenic CNVs 
were detected, which are further detailed below.  For 51/383 (13.3%) of patients, the 
findings were classified as rare inherited and likely benign CNVs following parental array 
analysis.  The information about those variants was deemed not of clear ‘clinical relevance’ 
based upon current knowledge and hence was not reported back to parents. However, it 
cannot be excluded that such inherited variants could be pathogenic in the offspring due to 
incomplete penetrance or due to variable expressivity   (for the rationale, see discussion).  
Array analysis revealed causal imbalances in 37/383 (9.6%) of patients, 10 of which (2.6%) 
were submicroscopic.  This means around ¼ of all causal imbalances are submicroscopic and 
thus undetectable by conventional karyotype alone.  In 3.1% (n=12) of patients with 
abnormal array results (30% of causal imbalances) concordance with the subsequent 
abnormal karyotype was observed.  For 1.6% of patients (n=6), VOUS were detected and the 
decision of whether to report these VOUS or not was determined on a case-by-case basis, 
for which the rationale is described further below.  
The workflow shown in Figure 1 summarises our results, with further details of causal 
imbalances revealed by array analysis, as well as incidental findings of clinical significance 
and variants of uncertain significance (VOUS) provided in Table S1 (online supplementary 
information).  Notable examples are discussed in more detail below. 
Submicroscopic CNVs 
A 6Mb deletion of 1p36 was observed in foetus KUL 2 with an Ebstein malformation and 
cerebral ventriculomegaly.  Interestingly, 1p36 deletions have occasionally been associated 
with this rare malformation and this case adds further evidence of a link between this rare 
heart abnormality and haploinsufficiency of one or more genes at 1p36 (Witters et al., 2002; 
Digilio et al., 2011).  In foetus KUL 4, referred due to semi-lobar holoprosencephaly, a novel 
2 Mb de novo deletion of 10q24.31-q24.32 was observed.  Within the deleted region several 
genes are located.  However, we consider SUFU haploinsufficiency as the most likely cause 
for this phenotype since SUFU is a negative regulator of hedgehog signalling (Humke et al., 
2010; Kim et al., 2011).  Genetic variants in this signalling pathway, including in SHH 
(OMIM#142945) and GLI2 (OMIM#610829), are linked to holoprosencephaly in humans.  
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Figure 1.  Workflow of chromosomal microarray results. 
Arrays Reveal Additional Information above Karyotype 
In 15/383 (3.9%) of foetuses, array analysis revealed additional information above 
karyotyping alone.  These are listed in Table S1 (online supplementary information), and 
include inverted deletion duplications (inv del dups), unbalanced translocations and marker 
chromosomes.  One case of interest was foetus KUL 17 for which deletion of 21q22.3, 
amplification (i.e. 4 or more copies) of 21q22.2-q22.3, and duplication of 21q21.3q22.2 were 
observed on both uncultured and cultured CVS material (Figure 2).  The duplicated region 
displays a reduced dynamic range (i.e. reduced deviation of Log2 signal intensity ratios from 
zero, as opposed to the theoretical deviation of +0.58, and the experimentally observed 
deviations of +0.45 to +0.55), suggestive of mosaicism.  MCC was excluded by STR marker 
analysis of foetal and parental material.  Confined placental mosaicism could not be fully 
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excluded since no AF, foetal blood or foetal skin fibroblast sample was obtained.  The initial 
rapid aneuploidy testing by FISH analysis with a centromeric probe for chromosome 21 
revealed 3 signals, and the subsequent karyotype revealed 1 normal and 1 abnormal 
(possible ring) chromosome 21.  This finding represents a mosaicism with different cell lines 
which have undergone different numbers of breakage-fusion-bridge cycles (Voet et al., 
2011), which has, to our knowledge, not been described previously in a constitutional 
disorder. 
In foetus KUL 15 referred due to cardiac anomalies a 17.5 Mb duplication of 22q12.3-q13.33 
was detected (Figure 3A).  Subsequent prenatal karyotype revealed translocation of the 
duplicated 22q fragment to the 22p arm (Figure 3C).  Parental karyotypes were both normal. 
However, parental array analysis revealed a 500 kb duplication of 22q12.3 in the paternal 
sample (Figure 3B).  This 500kb region overlaps with the proximal region of the terminal 22q 
duplication present in the foetus.  We hypothesised this 500kb region to be an insertional 
translocation within the 22p microsatellite, which was confirmed by subsequent FISH 
analysis of the paternal sample (probe RP11-413J08) (Figure 3D).  The translocation was thus 
most likely due to a crossing over in the insertional translocation in the father.  This may be 
the first direct support that a submicroscopic insertional translocation can generate a 
quadrivalent and thus be the cause of a chromosomal rearrangement following 
recombination.    
Detection of Mosaicism 
In 6/383 (1.6%) of patients we observe reduced dynamic range (signal intensity ratios with 
reduced deviation from log2 ratio of zero) for duplicated and deleted regions.  These are 
listed in Table S1 (online supplementary information) along with details of the FISH 
(uncultured) and / or karyotype (cultured) confirmatory results.   We also observe complete 
discordance between different foetal samples analysed.  For foetus KUL 28, referred due to 
heart abnormalities, we received both an amniocentesis and foetal blood sample.  A large 
amplification of the 16q arm was observed by array analysis on foetal blood but not in AF 
(both from DNA of uncultured cells).  Karyotyping subsequently revealed an additional 
marker chromosome 16 in foetal blood but not in cultured amniocytes.  Hence, this is a true 
foetal mosaicism for a marker chromosome 16q.  Interestingly this finding would not have 
been identified if AF alone was received.  In foetus G 2, a male foetus referred due to 
increased nuchal translucency, an intragenic 50kb deletion of the DMD gene was observed 
with reduced dynamic range, confirmed as mosaic by MLPA analysis on the same CVS DNA.   
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Figure 2.  A complex rearrangement of chromosome 21. Duplication of 21q21.3q22.2, amplification of 
21q22.2-q22.3, and terminal deletion of 21q22.3 are visible.  Oligonucleotide probes are plotted by 
genomic position on the x-axis, and by normalised Log2 signal intensity ratios on the y-axis.  The 
duplicated and deleted regions are highlighted, with genes displayed in the lower track and 
chromosome 21 shown at top of image. 
 
Figure 3.  Paternal insertional translocation as driver of a chromosomal translocation. (a) A 17.5Mb 
duplication of 22q12.3-q13.33 in the foetus; (b) A 500kb duplication of 22q12.3 in the paternal 
sample.  Oligonucleotide probes are plotted by genomic position on the x-axis, and by normalised 
Log2 signal intensity ratios on the y-axis.  The duplicated region is highlighted in (a) and (b), with genes 
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displayed in the lower track and chromosome 22 shown at top of image; (c) Displays the foetal 
karyotype with the derivative chromosome 22 (labelled with arrow); (d) Displays the FISH result in the 
paternal sample, using labelled BAC Clone RP11-413J08, showing 3 signals, with the additional signal 
on the derivative chromosome 22. 
Subsequent analysis by array CGH and MLPA on both uncultured and cultured AF could not 
detect this microdeletion.  Coincidentally, the conventional karyotype on both cultured CVS 
and AF revealed a balanced reciprocal translocation 46,XY,t(3;20)(q27;q11.2) inherited from 
the father.  This translocation apparently has no direct phenotypic consequences, and no 
deletion of material was observed at the breakpoint by array analysis.  Array CGH and MLPA 
performed postnatally on DNA from neonatal blood revealed no evidence of this 
microdeletion in the dystrophin gene.  Hence, this represents a confined placental 
mosaicism for a DMD microdeletion. 
Array Analysis of Apparently Balanced Rearrangements 
In 2 familial cases of apparently balanced complex rearrangements, deletions are detected 
by array analysis at one or more of the breakpoints.   
Variants of Uncertain Significance (VOUS) 
Variants of uncertain significance were observed in 6/383 (1.6%) of foetuses.  These are 
listed in Table S1 (online supplementary information), and consist of both inherited and de 
novo imbalances.  In foetus KUL 37 the 2Mb deletion of 4q32 was shown to be inherited 
from the father.  The same deletion was previously observed in an affected sibling. However, 
this child also had a de novo 17q deletion considered pathogenic.  The deleted region on 
4q32 harbours the TLL1 gene, in which heterozygous mutations have been associated with 
atrial septal defects (Stanczak et al., 2009), and large deletions of 4q have also been 
reported in association with congenital heart defects (Xu et al., 2012).  Since the father was 
already aware of this deletion, the variant was reported.  For foetus G 7 the 2.6Mb deletion 
of 18q12.3, although relatively large and de novo, harbours only a single gene PIK3C3.  
Similar sized deletions have not been observed in normal individuals or patients.  The PIK3C3 
gene is a candidate for schizophrenia, but its relation with the ultrasound findings in this 
foetus remains unclear.  PIK3C3 is known to regulate various intracellular membrane 
trafficking events.  Zhou et al observed that PIK3C3 is required for early embryogenesis and 
cell proliferation in mice (Zhou et al., 2011).  Since this CNV was de novo, this was reported.  
In foetus KUL 34 we detected a 434 kb deletion of 15q11.2 in the PWAS BP1/BP2 region, 
subsequently also detected in the unaffected mother following parental array analysis.  
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Deletions of this region have been associated with developmental delay and behavioural 
problems as well as other features including schizophrenia (Doornbos et al., 2009; Sahoo et 
al., 2011).  Strong phenotypic variability and reduced penetrance are characteristic of 
deletions of this region which make predictions of the future phenotype impossible.  The 
most recent and largest study of Rosenfeld et al report deletions of this region having a 
penetrance risk of 10.4% (from 203/25,113 cases [0.81%], and 84/22,246 controls [0.38%]) 
(Rosenfeld et al., 2013).  This CNV was not reported back to the patient based upon the lack 
of any family history of neurodevelopmental or psychological abnormalities, the low 
penetrance risk, and a lack of evidence for a link to the increased nuchal translucency 
observed and future penetrance of any phenotypic features.  KUL33 was reported since this 
CNV occurred de novo, and also contains the BRWD3 gene.  Mutations in BRWD3 
(OMIM*300553) are associated with X-linked mental retardation (MR) and macrocephaly.  
Four copies of 2q21.3 were detected in KUL35, however no parental DNA was available.  
Only 6 genes are within the region, and hence this CNV was not reported.  For KUL36, the 
referral reason of death in utero influenced the decision to report this VOUS with no known 
OMIM genes to the parents. 
Discussion 
Our findings demonstrate a 2.6% (1.0-4.2%, 95% confidence interval) increase in the 
diagnostic yield of causal genomic imbalances by discovery of pathogenic submicroscopic 
CNVs undetectable by conventional karyotype.  Novel CNVs, as well as known microdeletion 
and microduplication syndromes were observed.  Our results are slightly lower than those 
observed in a recent meta-analysis which found an increased diagnostic yield of 
chromosomal microarrays over karyotyping of 10% (8-13%, 95% confidence interval) in the 
presence of ultrasound anomalies (Hillman et al., 2013).  Several recent large-scale 
prospective studies found rates between 6-8% in the presence of ultrasound anomalies 
(Shaffer et al., 2012; Breman et al., 2012; Wapner et al., 2012b).  However, we demonstrate 
that arrays provide additional information over karyotyping in 3.9% of patients.  
Chromosomal microarrays: (i) provide more precise delineation of deletion and duplication 
breakpoints for structural rearrangements allowing for a more accurate assessment of gene 
content; (ii) accurately identify the origin of additional (euchromatic) chromosomal material; 
and (iii) can reveal pathogenic imbalances at the rearrangement breakpoints in apparently 
balanced rearrangements.  Combining these findings gives a diagnostic yield of 6.5% above 
karyotyping alone, which is in line with other published studies.  We also show that the 
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identification and localisation of CNVs can help in understanding the mechanism causing 
certain chromosomal rearrangements. This is important to estimate the recurrence risk for 
future pregnancies.  A submicroscopic paternal CNV is an insertional translocation which 
confers a significant risk to future pregnancies and would have gone unnoticed by 
conventional karyotype alone.  This highlights some previously reported and novel 
unexpected advantages of array analysis for the investigation of apparently balanced 
rearrangements. 
We observed VOUS in 1.6% of patients, which included both inherited and de novo 
imbalances.  Rates of VOUS ranged from 0.39%-4.2% dependent on whether de novo 
imbalances were included (Shaffer et al., 2012; Breman et al., 2012; Wapner et al., 2012b; 
Hillman et al., 2013).  The risk of detecting a pathogenic CNV in the absence of any 
ultrasound anomalies has been estimated at between 0.5% and 1.7% in several studies 
which have included the use of chromosomal microarrays for general screening (Wapner et 
al., 2012b; Armengol et al., 2012; Lee et al., 2012).  Hillman et al comment in their meta-
analysis the high degree of heterogeneity in results of different array studies (Hillman et al., 
2013), which may be due to a number of factors including the type of cohort studied and the 
type of platform used. 
We demonstrate the ability to detect mosaicism of varying degrees and size by array analysis 
in 1.5% of patients, an important requirement if arrays are to be used in place of karyotype.  
Arrays provide an advantage over conventional karyotyping in the ability to measure 
mosaicism in DNA from uncultured material, providing an assessment of the level of 
mosaicism not influenced by the cell culture process.   A recent study found mosaicism in a 
total of 1.2% of patients (n=43/3710) investigated by array and karyotype (Bi et al., 2012).  
Mosaicism was observed by karyotype alone in 39% of those mosaic cases (n=17/43); 11 of 
which showed very high levels (>80% mosaicism) and an abnormal array result, and 6 of 
which showed a normal array result due to very low levels (<10% mosaicism); 12% of those 
mosaic cases (n=5/43) were detected by array alone.  Apparently balanced rearrangements 
were detected in 0.8% of cases (n=30/3710) (Bi et al., 2012).  However, only approximately 
6% of de novo apparently balanced rearrangements are considered to be pathogenic 
(Warburton, 1991), and studies have shown that approximately 40% of apparently balanced 
rearrangements harbour pathogenic CNVs at the breakpoints, or elsewhere (De Gregori et 
al., 2007; Schluth-Bolard et al., 2009).  Taken together, it is clear that karyotyping and FISH 
remain essential tools for accurate prenatal genetic diagnosis, and parental cytogenetic 
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analysis may also be required to achieve a correct diagnosis of recurrence risk as 
demonstrated by our results and others.  Karyotype is required for any family with a known 
family history of a balanced rearrangement only identifiable by conventional karyotype.  In 
addition, those families with a prior abnormal pregnancy / child for which conventional 
karyotyping was not performed should also be eligible for karyotyping in order to exclude an 
unidentified balanced rearrangement as the cause. 
Approach to genetic counselling: 
Given that prenatal screening should be aimed at providing pregnant women with 
opportunities for meaningful reproductive choices, it is important to determine which types 
of information regarding CNVs may expand or otherwise even undermine these 
opportunities.  Three main approaches to the reporting of information revealed by array 
analysis can be discerned.  A first approach is to give patients the option during the pre-test 
counselling and informed consent process of which types of information they do / do not 
wish to be informed of following analysis (Siegal et al., 2012).  A second approach is to reveal 
all information including the detection of VOUS.  In a third approach, only information 
relating to the purpose of the analysis is provided (i.e. causal and/or clinically significant 
findings), and information deemed not of clear ‘clinical relevance’ based upon current 
knowledge is not reported to the patient (e.g. VOUS and inherited likely benign CNVs), who 
agrees to this during the pre-test counselling and informed consent process.  This third 
approach is that adopted by the groups involved in this present study.  All three approaches 
require thorough pre-test counselling (Wapner et al., 2012a; de Jong et al., 2011; Dondorp et 
al., 2012; McGillivray et al., 2012). 
In recent years, case-control studies have enabled the quantification of the penetrance risk 
for certain recurrent microdeletions and microduplications, such as the 16p11.2 deletion 
and reciprocal duplication (Kaminsky et al., 2011; Cooper et al., 2011; Rosenfeld et al., 2013).  
Our approach is that those CNVs with penetrance risk factors below 25% were not reported 
back routinely, unless deemed to be clinically actionable.  Examples of these situations 
include; the 15q11.2 deletion (NIPA1 gene), with penetrance risk 10.4% which was detected 
in KUL34 and not reported; and the 22q11.2 duplication (TBX1 gene), with penetrance risk 
21.9% which was detected in KUL7 in association with cardiac anomalies; in the absence of 
cardiac anomalies on the clinical referral, this would nevertheless be reported and follow-up 
with detailed ultrasound examination for the presence of cardiac defects would be advised).  
The main difference between our approach and the laboratories providing all information 
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revealed by arrays to the pregnant women is that the latter will report back (1) rare/novel 
large (typically over 500 kb)  inherited CNVs and (2) imbalances for known ‘risk loci’ where 
the future penetrance is uncertain and with low odds.  Of note, in Mikhaelian et al’s survey 
of prenatal genetic counsellors in the USA and Canada (Mikhaelian et al., 2013), the most 
prevalent ethical issue was the potential for ambiguous results, with 69% (n=111) of 
respondents expressing concerns, including about their ability to accurately interpret such 
results, the possibility a patient may terminate a pregnancy because of such results, and that 
such results may lead to psychosocial ‘harm’ to a patient. 
Conclusion 
Our results add support to other recent studies for the use of genomic arrays as the first-tier 
test for prenatal diagnosis of ultrasound abnormalities, as evidenced by the increased 
diagnostic yield of pathogenic submicroscopic imbalances as well as the additional 
information and faster reporting time offered in comparison to conventional karyotype.  
Considering the increased diagnostic yield in case of increased risk but in the absence of 
abnormal ultrasound, the use of chromosomal arrays as the first tier test for all invasive 
prenatal referrals seems warranted.  Nevertheless, the workflow for classification of CNVs, 
the subsequent interpretation and reporting back of results warrants further societal 
research to determine the best provision of care. 
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Patient Phenotype G.A. 
wks 
Sample 
Type 
Chr/cyto band Size Gain/Loss No. of 
Genes 
[OMIM 
Genes] 
Overlapping 
Syndrome                                                                                      
Inherited
/ de
novo 
Causal Original karyotype 
result 
Molecular karyotype 
Genome build hg18 
Submicroscopic 
KUL1 Facial abnormalities 21 AF (C) 3q26.2-q26.31 
15q11.2-q13.1 
2.6 Mb 
4.8 Mb 
Deletion 
Duplication 
21 [3] 
100 [7] 
 
PWAS 
De novo 
De novo 
Likely 
Yes 
46,XY arr 3q26.2-
q26.31(172,166,063-
174,754,887)x1 dn, 15q11.2-
q13.1(21,248,261-
26,067,061)x3 dn 
KUL2 Ebstein 
malformation, 
cerebral 
ventriculomegaly 
NR AF (C) 1p36 5.3 Mb Deletion 105 [4] 1p36 
microdeletion 
De novo Yes 46,XX arr 1p36.33-p36.31(622,816-
5,901,907)x1 dn 
KUL3 Mild 
ventriculomegaly 
24 AF (UC) 7q22.1-q31.1 9.06 Mb Deletion 200 [13] Lissencephaly 
with 
cerebellar 
hypoplasia 
De novo Yes 46,XX,del(7)(q?) arr 7q22.1q31.1(98,831,183-
107,893,880)x1 dn 
KUL4 Semi-lobar 
holoprosencephaly 
14 CVS 
(UC) 
10q24.31-
q24.32 
2.13 Mb Deletion 56 [7] SHFM-3 De novo Yes 46,XY arr 
10q24.31q24.32(102,194,435
-104,329,241)x1 dn 
KUL5 Abnormal foetal 
central nervous 
system 
16 AF (UC) 13q33.1-q34 10.51 Mb Deletion 72 [8]  De novo Yes Not done arr 13q33.1q34(103,614,991-
114,123,757)x1 dn 
KUL6 Familial ATRX dup NR CVS 
(UC) 
Xq21.1 168 kb Duplication 1 [1]  Maternal Yes Not Done arr Xq21.1(76,703,047-
76,870,877)x3 mat 
KUL7 Complex 
cardiopathy 
NR AF (UC) 
& FB 
(UC) 
22q11.2 2.5 Mb Duplication 94 [7] DGS/VCFS De novo Yes 46,XX arr 22q11.21(17,270,162-
19,771,944)x3 dn 
KUL8 Polyhydramnios, 
cardiopathy, small 
stomach, short 
nasal bone 
31 AF (UC) 22q11.2 2.6 Mb Deletion 98 [7] DGS/VCFS De novo Yes Not done arr 22q11.21(17.256.605-
19.870.347)x1 dn 
G1 Heart and renal 
anomalies 
21 AF (UC) 22q11.21 2.5 Mb Deletion 93 [7] DGS/VCFS De novo Yes 46,XX 
 
arr 
22q11.21q11.21(17,274,835-
19,794,060)x1 dn 
 
G2 Increased NT (4,4 
mm) 
13 CVS 
(UC) & 
AF (UC) 
Xp21.2p21.2 50 kb Deletion 1 [1] DMD De novo No 
CPM 
46,XY,t(3;20)(q27;q
27.2)pat 
arr Xp21.2p21.2(31,134,695-
31,184,180)x0 dn 
 
Array CGH provides additional information over karyotype 
KUL9 MCA NR AF (C) 5pter-p13.3 
9pter-p13.2 
31.8 Mb 
38.5 Mb 
Deletion 
Duplication 
146 [11] 
494 [24] 
CDC De novo 
De novo 
Yes 
Yes 
46,XY,der(5)(p13;?) arr 5pter-p13.3(69,497-
31,811,114)x1 dn, 9pter-
p13.2(198,982-38,526,895)x3 
56 
 
dn 
KUL10 MCA NR AF (C) 4p16.3-p16.2 
4p16.2-p12 
5.1 Mb 
43.5 Mb 
 
Deletion 
Duplication 
97 [10] 
266 [17] 
WHS De novo 
De novo 
Yes 
Yes 
46,XX,der(4)add(4)(
p16) 
 
arr 4p16.3-p16.2(34,021-
5,135,978)x1 dn, 4p16.2-
p12(5,187,465-48,761,351)x3 
dn 
KUL11 Cystic hygroma, 
IUGR 
NR AF (C) 4pter-p16.3 
7pter-p21.3 
1.8 Mb 
16 Mb  
Deletion 
Duplication 
47 [5] 
160 [5] 
WHS De novo 
De novo 
Yes 
Yes 
46,XX,add(4)(p16) 
 
arr 4pter-p16.3(34,021-
1,871,953)x1 dn, 7pter-
p21.3(136,180-16,012,990)x3 
dn 
KUL12 Foetal hydrothorax NR AF (C) 17q21.31-q25.3 
17q25.3 
138 kb 
36.3 Mb 
Deletion 
Duplication 
3 [0] 
625 [55] 
 
Campomelic 
dysplasia 
De novo 
De novo 
Yes 
Yes 
46,XX,der(17)add(q
25.3)  
arr 17q21.31-
q25.3(42,141,819-
78,445,623)x3 dn, 
17q25.3(78,513,526-
78,651,671)x1 dn 
KUL13 Cardiac defect, 
advanced maternal 
age 
NR AF(UC) 7q33-q36.3 22.3 Mb Deletion 382 [20] HPE3; 
Currarino 
De novo Yes 46,XX,del(7)(q33) arr 7q33q36.3(136,496,304-
158,817,239)x1 dn 
KUL14 Increased NT 
(>2.5mm) 
NR AF (UC) 8q21.11-q22.3 24.8 Mb Duplication 205 [11]  De novo  46,XY,der(8)add(8)(
p?) 
arr 
8q21.11q22.3(77,820,698-
102,626,232)x3 dn 
KUL15 Cardiac defect 25 AF (UC) 22q12.3-q13.33 17.5 Mb Duplication 364 [28] Waardenburg 
syndrome 4; 
Phelan 
Mcdermid 
syndrome 
Paternal 
Insertion
al 
transloca
tion 
Yes 46,XY,der(22)(qter-
>q12.3::p11.2-
>qter) 
 
arr 
22q12.3q13.33(32,069,468-
49,567,789)x3 dn 
G3 oligohydramnios, 
hypoplastic 
cerebellum, short 
femur 
NR AF (UC) 5p15.33p13.3 
9q33.3q34.3 
30.5 Mb 
11.3 Mb 
Deletion 
Duplication 
141 [11] 
280 [25] 
CDC 
Walker 
Warburg 
syndrome; 
Tuberous 
sclerosis 1; 
Kleefstra 
syndrome 
De novo Yes 46,XX, 
der(5)t(5;9)(5p13.3;
9q33.3) 
arr 5p15.33p13.3(0-
30,814,401)x1 dn, arr 
9q33.3q34.3(129,771,347-
141,053,475)x3 dn 
 
G4 Flat facies & nasal 
bridge, 
holoprosencephaly 
16 AF (UC) 18p11.32p11.21 14 Mb Deletion 131 [3] HPE4 De novo Yes 45,XX,der(15)t(15;1
8)(q10;q10) 
arr 18p11.32p11.21(108,760-
14,685,777)x1 dn 
G5 Congenital 
diaphragmatic 
hernia 
30 AF (UC) 14q24.2q24.3 17 Mb Deletion 157 [14]  De novo Yes 46,XY,del(14)(q24.2
q32.11) 
arr 
14q24.2q32.11(72,785,898-
90,195,516)x1 dn 
 
G6 Spontaneous 
pregnancy after 
ovarian failure 
16 AF (UC) 8p23..2-p23.1 
9q34.3 
12 Mb 
1.8 Mb 
Duplication 
Deletion 
167 [5] 
90 [6] 
8p23.1 
deletion 
syndrome 
Kleefstra 
De novo Yes  46,XX,der(9)t(9;?)(q
34;?) 
arr 8p23.2p23.1(0-
11,990,253)x3 dn, arr 
9q34.3q34.3(138,338,249-
140,138,746)x1 dn  
57 
 
syndrome 
Complex rearrangements where array CGH reveals additional imbalances over karyotype 
KUL16 Known familial 
rearrangement 
NR AF (C) 6p12.3-p12.1 
6q14.1 
4.1 Mb 
840 kb  
Deletion 
Deletion 
70 [6] 
3 [0] 
 De novo 
De novo 
Likely 
Unlikely 
46,XX,t(4;13;6)(p15;
q12;p12) 
 
arr 6p12.3-p12.1(49,588,389-
53,694,390)x1 dn, 
6q14.1(77,421,309-
78,266,274)x1 dn 
KUL17 Abnormal FISH & 
Karyotype chr 21 
13 CVS 
(UC & 
C) 
21 q arm Complex 
Mosaic 
314 [20]  De  novo Yes 46,XX,der(21) .nuc 
ish(LSI21) x3 
arr 
21q21.3q22.2(29,719,730-
40,252,214)x3 [40%], arr 
21q22.2q22.3(40,287,127-
45,586,329)x4, arr 
21q22.3(45,608,516-
46,920,235)x1 
KUL18 Echogenic bowel, 
oligohydramnios 
NR AF (C) 2p21-p16.3 
6q23.1-q23.2 
11q24.3-qter 
16q21 
20p12.2-p12.1 
3.49 Mb 
663 kb 
5.88 Mb 
690 kb 
1.71 Mb 
Deletion 
Deletion 
Deletion 
Deletion 
Deletion 
34 [6] 
3 [0] 
35 [2] 
1 [0] 
15 [2] 
HNPCC 
 
 
 
Alagille 
syndrome 
De novo 
De novo 
De novo 
De novo 
De novo 
Likely 
Unlikely 
Likely 
Unlikely 
Likely 
46,XX,t(2;16;6;20)(p
21;q21;q23;p12) 
arr 2p21p16.3(47,409,205-
50,897,685)x1, arr 
6q23.1q23.2(131,022,300-
131,685,322)x1, arr 
11q24.3q25(129,404,216-
134,444,557)x1, arr 
16q21(59,389,418-
60,079,595)x1, arr 
20p12.2p12.1(10,275,200-
11,984,125)x1 
KUL19 Hydrops, NT 6mm NR CVS 
(UC) 
4p15.31-pter 
8p23.3 
8p23.2-23.1 
8q24.11-qter 
15q24.1-qter 
18.75 Mb 
2.13 Mb 
8.38 Mb 
27.36 Mb 
27.70 Mb 
Mosaic Dup 
Deletion 
Mosaic Del 
Mosaic Dup 
Mosaic Dup 
204 [19] 
12 [2] 
128 [2] 
252 [16] 
340 [18] 
 
WHS 
 
8p23.1 
deletion 
syndrome 
 
De novo 
 
Yes 
Yes 
Yes 
Yes 
Yes 
46,XY,der(8)(qter-
>q24.11::p23->qter) 
arr 4p16.3-p15.31(27,336-
19,197,100)x3 [30%], arr 
8p23.3-p23.2(176,785-
2,311,066)x1, arr 8p23.2-
p23.1(2,347,991-
10,726,753)x1 [30%], arr 
8q24.11-q24.3(118,902,689-
146,102,353)x3 [30%], arr 
15q11.2(19,108,674-
19,433,141)x3 [30%] 
Concordant with karyotype 
KUL20 Increased NT 
(4.2mm),  absent 
nasal bone 
14 CVS 
(UC) 
22 Entire 
chromos
ome  
Duplication 951 [56]  De novo Yes 47,XY,+22 arr (22)x3 dn 
KUL21 Hyperechogenic 
focus, left & right 
ventricles 
NR AF (UC) 13 Entire 
chromos
ome 
Duplication 
(Mosaic) 
884 [45]  De novo Yes 47,XY,+13[4]/46,XY[
5] 
arr (13)x3 [60%] dn 
KUL22 Cleft Lip & Cleft 
Palate, 
21 AF (UC) 16p 
Xq12-qter 
p arm; 35 
Mb 
89 Mb 
Duplication 
Duplication 
672 [49] 
1222 [90] 
 De novo Yes Not Done arr 16p13.3-p11.1(12,768-
35,006,660)x3 dn, arr Xq12-
q28(65,965,956-
58 
 
154,899,837)x2 dn 
KUL23 ventriculomegaly, 
aortic dilation 
ascites 
28 AF (UC) 9 Entire 
chromos
ome 
Duplication 
(Mosaic) 
1853 [92]  De novo Yes nuc 
ish(CEP9x3)[39]/(CE
P9x2)[11] 
No karyotype 
arr (9)x3[25%] dn 
KUL24 Fryns Syndrome. 
Bilateral Hernia, 
VSD, MCA 
18 AF (UC) 1q 
Yq 
103 Mb 
35.3 Mb 
Duplication 
Deletion 
1895 
[116] 
161 [2] 
 De novo Yes 46,X,der(Y)t(Yq;1q)[
11]/46,XY[4] 
arr 1q21.1-qter(144,106,092-
247,199,719)x3 [60%] dn, arr 
Yq11.223-qter(22,402,032-
57,772,954)x0 [60%] dn 
KUL25 Ventriculomegaly, 
ambiguous 
genitalia, midline 
defect 
32 AF (UC) X Entire 
chromos
ome 
Deletion 
(Mosaic) 
2051 
[159] 
 De novo Yes 45,X[9]/47,XXX[1] 
.nuc 
ish(CEPXYx1)[19]/(C
EPXYx3[68]/(CEPXYx
2)[13] 
arr (X)x1 [60%]/ arr (X)x2 
[40%] 
KUL26 Increased NT 
(4.4mm), hygroma 
colli, 
hydronephrosis 
14 CVS 
(UC) 
8q13.3-q24.13 55 Mb Duplication 424 [24]  De novo Yes Not done arr 8q13.3-
q24.13(70,747,122-
126,110,305)x3 dn 
KUL27 MCA, heart defect 11 CVS 
(UC) 
16p13.3-q24.3 Entire 
chromos
ome 
Duplication 1202 [98]  De novo Yes Not done arr 16p13.3q24.3(24,543-
88,794,888)x3 dn 
KUL28 AVSD, Unbalanced 
left hypoplastic 
heart 
23 Foetal 
blood 
(UC) 
& AF 
(UC) 
16q22.1-q24.3 23.59 Mb Amplificati
on 
360 [33]  Both 
parents 
have 
fragile 
chr 16 
(mosaic) 
Yes 46,XX (on AF 
sample) 
47,XX,i(16)(q10) (on 
fetal blood) 
arr 
16q22.1q24.3(65,101,656-
88,690,913)x4 
KUL29 MCA 20 AF (UC) 13 Entire 
chromos
ome 
Duplication 884 [45]  De novo Yes 47,XX,+13 arr 13q12.11q34(18,400,387-
114,123,757)x3 dn 
KUL30 Death in utero 16 CVS 
(UC) 
21q11.2-q22.3 32.5 Mb Duplication 419 [23]  De novo Yes 47,XX,+21 arr 
21q11.2q22.3(14,400,995-
46,920,235)x3 dn 
KUL31 Microcephaly, 
microphthalmia 
30 AF (UC) 13 Entire 
chromos
ome 
Duplication 884 [45]  De novo Yes 47,XY,+13 arr 13q11q34(18.348.559-
114.123.757)x3 dn 
Incidental findings unrelated to phenotype 
G2 Paternal balanced 
translocation 
inherited by foetus 
13 CVS 
(UC) & 
AF (UC) 
3; 20     NOT 
TESTED 
 46,XY,t(3;20)(q27;q
27.2)pat 
 
KUL32 Paternal iso(Xq) 
NOT PRESENT IN 
FOETUS 
  Xq     NOT 
TESTED 
 46,XY 
 
arr Xq11qter(61,848,425-
154,883,082)x3 [40%] 
Unclassified Variants 
KUL33 Arthrogryposis, 19 AF (UC) Xq21.1 352 kb Duplication 6 [1]  De novo VOUS 46,XX arr Xq21.1(79,664,552-
59 
 
 hypokinesia, 
Cerebral 
malformation 
 80,017,026)x3 dn 
KUL34 Increased NT (7mm) 13 CVS 
(UC) 
15q11.2 434 kb Deletion 6 [1] 15q11.2 
PWAS BP1-
BP2 
microdeletion 
Maternal 
 
VOUS Not Done arr 15q11.2(20,305,022-
20,739,252)x1 mat 
 
KUL35 Cerebral 
abnormalities, 
cerebellar 
hypoplasia 
18 AF (UC) 2q21.3 656 kb Amplificati
on 
6 [1]  Father 
not 
available 
 
VOUS Not Done arr 2q21.3(135,436,770-
136,093,172)x4 
KUL36 Death in utero 21 AF (UC) 15q26.1 747 kb Duplication 5 [0]  Paternal 
 
VOUS Not Done arr 15q26.1(91,253,495-
92,000,368)x3 pat 
KUL37 Microdeletion in 
sister 
12 CVS 
(UC) 
4q32.3 2.165 Mb Deletion 21 [1]  Paternal 
 
VOUS Not Done arr 4q32.3(165,525,955-
167,691,444)x1 pat 
G7 Cerebral and ocular 
abnormalities, 
median cleft, 
duodenal atresia  
 
25 AF (UC) 18q12.3q12.3 2.6 Mb Deletion 3 [0]  De novo 
 
VOUS 46,XY arr 
18q12.3q12.3(35,697,785-
38,169,137)x1 dn 
Supplementary Table S1.   
AF=amniotic fluid sample; CVS=chorionic villus sample; (C)=Cultured cells; (UC)=uncultured cells; NT=nuchal translucency; CPM=confined placental mosaicism; 
MCA=multiple congenital anomalies; IUGR=intrauterine growth retardation; VSD=ventricular septal defect; AVSD=atrioventricular septal defect 
PWAS=Prader-Willi / Angelman syndrome; SHFM-3=Split Hand / Foot Malformation-3; DGS/VCFS=DiGeorge syndrome / Velo-cardio-facial syndrome; DMD=Duchenne 
Muscular Dystrophy; CDC=Cri Du Chat syndrome; WHS=Wolf Hirschhorn syndrome; HPE3=Holoprosencephaly 3; HPE4=Holprosencephaly 4; DSCR=Downs syndrome critical 
region; HPE1=Holoprosencephaly 1; HNPCC=Hereditary non-polyposis colon cancer;  
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Chapter 4.  Application of Chromosomal Microarrays for Gene Discovery in  
         Congenital Diaphragmatic Hernia 
Prenatal Diagnosis. 2010 Dec;30(12-13):1198-206. 
Targeted array comparative genomic hybridisation (array CGH) identifies genomic 
imbalances associated with isolated congenital diaphragmatic hernia (CDH). 
Kasemsri Srisupundit1,2 ,3 †, Paul D Brady1 †, Koenraad Devriendt1, Jean-Pierre Fryns1, Rogelio 
Cruz-Martinez4, Eduard Gratacos4, Jan A Deprest2, Joris R Vermeesch1. 
1 Centre for Human Genetics, K.U. Leuven, Leuven, Belgium. 
2 Fetal Medicine Unit, Division Gynaecology and Obstetrics, Department Woman and Child, 
U.Z. Leuven, Leuven, Belgium. 
3 Maternal Fetal Medicine Unit, Department of Obstetrics and Gynaecology, Faculty of 
Medicine, Chiang Mai University, Thailand. 
4 Department of Maternal-Fetal Medicine (ICGON) Hospital Clinic-IDIBAPS, University of 
Barcelona and Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBER-ER), 
Barcelona, Spain. 
† These two authors contributed equally to this work. 
Abstract 
Objective:  Congenital diaphragmatic hernia (CDH) is a congenital birth defect affecting 
around 1/3000 births.  We propose that a significant number of isolated CDH cases have an 
underlying genetic cause, and that a subset of these result from copy number variations 
(CNVs) identifiable by array CGH.  Methodology:  We have designed a custom array targeted 
at genes and genomic loci associated with CDH.  79 isolated CDH patients were screened 
using this targeted array.  Results:  In 3 patients we detect genomic imbalances associated 
with the observed diaphragmatic hernia; a deletion of 8p22-p23.3, 14.2Mb in size, a 340kb 
duplication of Xq13.1 including the ephrin-B1 gene (EFNB1), and mosaicism for trisomy 2.  
Conclusion:  Using this approach, we detect genomic imbalances associated with CDH in 3/79 
(4%) isolated CDH patients.  Our findings further implicate 8p deletions as being associated 
with CDH.  The duplication of EFNB1 further highlights this gene as a potential candidate 
involved in diaphragm development.  Mosaicism for trisomy 2 is a rare event and unlikely to 
be a common cause of CDH.  Further investigations of isolated CDH patients by array CGH 
will continue to identify novel submicroscopic loci and refine genomic regions associated 
with CDH.  
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Introduction 
Congenital Diaphragmatic Hernia (CDH) is a congenital birth defect with an incidence of 
around 1/3000 births (Torfs et al., 1992; Skari et al., 2000).  CDH can be anatomically divided 
into three main hernia subtypes; a posterolateral ‘Bochdalek’ hernia in around 70% of cases, 
an anterior ‘Morgagni’ hernia in around 27% of cases, and a central septum transversum 
hernia in around 3% of cases.  The vast majority of hernias are left sided (85%), whilst the 
remainder are right sided (13%) or bilateral (2%) (Torfs et al., 1992; van Loenhout et al., 
2009; Pober, 2007).  Next to the diaphragm defect, the lung developmental anomaly is an 
essential part of the phenotype.  It results in variable degrees of pulmonary hypoplasia and 
postnatal pulmonary hypertension which account for the high mortality and morbidity in 
survivors.   
CDH occurs as an isolated defect in around 50% of cases, or as non-isolated CDH for the 
remainder in which additional congenital malformations are present (Stoll et al., 2008).  Non-
isolated CDH is associated with abnormalities in a number of other systems including; 
cardiovascular system (27.5%), urogenital system (17.7%), musculoskeletal system (15.7%), 
and central nervous system (9.8%) (Stoll et al., 2008).  It may also occur as part of a 
recognised syndrome for which a single causal gene may be identified.  Examples include; 
STRA6 in Matthew-Wood syndrome (Golzio et al., 2007; Pasutto et al., 2007; Chassaing et al., 
2009; Segel et al., 2009), WT1 in Denys-Drash syndrome (Devriendt et al., 1995; Antonius et 
al., 2008), and EFNB1 in craniofrontonasal syndrome (Wieland et al., 2004; Vasudevan et al., 
2006).  Alternatively, non-isolated CDH may be associated with specific genetic loci, including 
8p23.1 (Faivre et al., 1998; Wat et al., 2009), and 15q26 (Klaassens et al., 2005; Slavotinek et 
al., 2006; Klaassens et al., 2007), or with a clinically recognised syndrome of currently 
unknown genetic cause such as Fryns syndrome (Fryns et al., 1979; Fryns et al., 1989; Neville 
et al., 2002; Slavotinek, 2004). 
It is still uncertain whether genetic factors are the sole cause of CDH or if they merely 
provide a genetic susceptibility to abnormal diaphragm development in concert with other 
environmental influences.  The dual-hit hypothesis has been proposed, which speculates that 
the lung abnormality is a primary developmental defect, firstly affecting both lungs before 
diaphragm development and subsequently affecting the ipsilateral lung after defective 
diaphragm development (Keijzer et al., 2000).  Chromosomal abnormalities have been 
reported to be present in as much as 30% of individuals with CDH (Howe et al., 1996; Tonks 
et al., 2004; Thorpe-Beeston et al., 1989; Geary et al., 1998; Pober, 2007) and it has been 
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postulated that these cytogenetic abnormalities can provide positional information about 
the genomic locations for CDH-causing genes.   
In view of the relative rarity of Mendelian pedigrees in families with CDH, isolated CDH is 
considered to have multi-factorial inheritance with gene mutations, environmental factors, 
gene-gene and gene-environment interactions contributing to exceed a threshold in 
susceptible individuals.  A number of candidate genes are involved in the retinoic acid 
pathway (Montedonico et al., 2008; Klaassens et al., 2009).  Previous research using animal 
models has demonstrated that environmental factors including vitamin A deficient (VAD) diet 
or exposure to teratogenic agents, particularly nitrofen, can disrupt the retinoid signalling 
pathway resulting in CDH (Wilson et al., 1953; Thebaud et al., 1999; Babiuk et al., 2004; 
Oshiro et al., 2005; Nakazawa et al., 2007b; Nakazawa et al., 2007a; Noble et al., 2007; 
Clugston et al., 2010a).  Further evidence of the involvement of this pathway comes from 
knockout or mutant mouse models in which genes involved in retinoid signaling are shown 
to cause CDH when silenced, including compound null retinoic acid receptor (RAR) mutants 
which were shown to have a spectrum of VAD-like defects including diaphragm defects 
(Lohnes et al., 1994; Mendelsohn et al., 1994; Lohnes et al., 1995) .   
For the majority of CDH patients, particularly isolated cases, the genetic cause remains 
unknown.  It has been shown recently that copy number variations (CNVs) underlie many 
genetic disorders and that a subset of all monogenic diseases is caused by CNVs rather than 
mutations.  The causal genes for isolated CDH in humans remain largely unknown, and given 
the large number of potential candidate genes and pathways, mutation screening may be of 
limited value at this time.  One approach to identify the genes involved in diaphragm 
development is to study genomic regions recurrently associated with CDH patients.  The 
technique of array comparative genomic hybridisation (array CGH) is one such method which 
has demonstrated the ability to refine the critical regions associated with various disorders, 
including CDH (Klaassens et al., 2005; Slavotinek et al., 2006; Shaffer et al., 2007; Scott et al., 
2007). 
As opposed to applying genome-wide cytogenomic arrays which have an average resolution 
of 30-50kb (Miller et al., 2010), a targeted array would enable higher resolution coverage of 
regions of interest, and as a consequence be able to uncover smaller CNVs in relevant genes.  
In order to identify novel genetic causes of isolated CDH, we have therefore developed a 
targeted oligonucleotide array.  This array is designed to provide coverage of genomic 
regions recurrently associated with non-isolated CDH in humans, supplemented by candidate 
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genes associated with diaphragm and lung development.  We hypothesised that by applying 
high resolution targeted array comparative genomic hybridisation (array CGH) to cases of 
isolated CDH we would identify causal genomic imbalances, refine genomic regions causal 
for CDH, and identify candidate genes important for diaphragm development. 
Methods 
Patients 
A total of 88 fetuses with isolated CDH, who were managed in the prenatal period by the 
fetal medicine units from the University Hospital Gasthuisberg, Leuven, Belgium (n=72), and 
the Hospital Clinic-IDIBAPS, University of Barcelona and Centre for Biomedical Research on 
Rare Diseases (CIBER-ER), Barcelona, Spain (n=16), were analysed using the targeted array.  
Samples from Leuven were either stored genomic DNA extracted from cultured amniotic 
fluid (AF) (n=49), or frozen AF cultures from which genomic DNA was extracted following 
thawing and re-culturing (n=16), or genomic DNA extracted from neonatal cord blood (n=7).  
Those from Barcelona (n=16) were uncultured AF samples which had been frozen, and from 
which genomic DNA was later extracted.  Only those patients in whom the absence of 
additional major congenital anomalies was confirmed at birth were considered eligible for 
inclusion in this study.  All samples were collected with approval of the respective local 
ethical committee, and in accordance with the Helsinki Declaration of 1975 (as revised in 
1983). 
Targeted Array Design 
An array was designed comprising 15,000 (15K) oligonucleotide probes in an 8x 15K format 
(Oxford Gene Technology [OGT], Oxford, UK).  The approach for the array design is a 
combination of two methods; 1. To target the genomic regions recurrently associated with 
CDH in humans.  2. To target candidate genes from CDH animal models and proposed 
pathways involved in CDH.  (See results section, and supplementary tables S1 & S2). 
Array Comparative Genomic Hybridisation (array CGH) 
Reference genomic DNA samples were derived from healthy males and females.  All patients 
and sex-matched reference samples were labelled with fluorescent Cy-3 and Cy-5 dyes in 
dye-swap experiments.  The CytoSure Genomic DNA Labelling Kit (OGT) was used according 
to the manufacturer’s protocol, with the following modifications; 500ng DNA was labelled  
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instead of 1000ng, and consequently all reagent volumes were halved.  The DNA 
denaturation step was performed at 98°C for 20 minutes, and the DNA digestion step was 
omitted.  The subsequent incubation at 37°C was performed overnight.  For DNA purification 
spin columns provided with the CytoSure Genomic DNA Labelling Kit (OGT) were used 
according to the manufacturer’s protocol.  For concentration of labelled DNA samples, either 
Clean & Concentrator-5 spin-columns (Zymo Research, CA, USA) or Amicon Ultra-0.5 spin 
columns (Millipore, MA, USA) were used according to the manufacturer's protocol.  
Hybridisation mixes were prepared using the Oligo aCGH Hyb kit (Agilent Technologies 
S.A./N.V., Belgium) according to the manufacturer’s protocol.  Hybridisation was performed 
using SureHyb chambers and a rotating oven (Agilent Technologies) at 65°C for 24 hours as 
recommended.  Following hybridisation, arrays were washed manually according to the 
manufacturer’s protocol using Agilent Wash Buffer 1 and Wash Buffer 2, following by rinsing 
and drying using acetonitrile. 
 Arrays were scanned immediately with a DNA Microarray Scanner (Agilent Technologies) at 
3 micron resolution.  The tif images were visually checked for artefacts.  Signal intensities 
were generated using the Feature Extraction software (v.10.5.1. Agilent Technologies).  To 
visualise the data and perform analysis the CytoSure Interpret Software (OGT) was used.  A 
global Lowess normalisation is applied by the software in order to correct for the dye 
incorporation bias. 
Data Analysis  
The CytoSure Interpret software package features a Circular Binary Segmentation (CBS) 
algorithm, where thresholds were set at +/- 0.36 from a Log2 ratio of zero, and at least 5 
flanking probes within a segment.  For a region to be called as aberrant it must be present in 
both datasets within the dye-swap experiment.  To complement the CBS algorithm, a second 
threshold-based method was also applied to the individual probe Log2 ratios.  Data from the 
patient labelled in Cy5 and in Cy3 is combined as follows;  X2 x Y2 = Z (where, X = individual 
probe normalised Log2 ratio for Cy5-labelled patient data, Y = individual probe normalised 
Log2 ratio for Cy3-labelled patient data).  The calling threshold was then set at 5 flanking 
probes where Z > 0.016.   
Therefore, by applying a threshold of 5 probes, we achieve an average resolution for 
detecting imbalances of ~80 kb for target regions, and ~16 kb for target genes. 
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The CytoSure Interpret software package (OGT) was used for interpretation of the CNVs 
detected.  We have previously characterised the CNVs present in our male and female 
control samples at ~200kb resolution provided by the CytoSure Syndrome Plus v2 105K array 
(OGT), as well as created an internal database of common likely benign CNVs.  Data from the 
Toronto Database of Genomic Variants (DGV) (http://projects.tcag.ca/variation/) was also 
used to aid the interpretation of CNVs detected.  Any CNV detected in a patient and also 
within regions in our internal benign CNV database were removed from further investigation.  
Any CNV detected in a patient which were within regions containing at least two reports in 
the DGV of being copy number variable in normal individuals were also excluded from 
further investigation. 
Confirmation of imbalances was achieved by the use of a genome-wide 105K array (CytoSure 
Syndrome Plus v2, OGT), or by FISH.  All genomic coordinates are based upon the NCBI 36 
genome assembly build. 
Results 
A custom array was designed to target genomic loci and genes associated with CDH.  19 
genomic regions were selected covering 225Mb for which there were at least three cases of 
CDH in humans identified from a literature search (including (Holder et al., 2007)).  For the 
target genomic regions the average probe spacing is 1 probe every 20kb.  75 CDH-associated 
genes covering 17Mb were selected following a literature search, complemented by using 
aGeneApart (www.esat.kuleuven.be/ageneapart).  aGeneApart uses a text-based input to 
data-mine the literature and identify genes which display an association.  For our purposes 
the search term “congenital hernia of diaphragm” (LNDB 170403) was used.   Candidate 
genes were selected based upon; single gene disorders associated with CDH in humans, 
genes identified from animal models of CDH, genes whose expression was dysregulated in 
CDH models, and genes involved in cellular pathways proposed to be involved in CDH.  Probe 
coverage included 5kb flanking region for target genes.  Average probe coverage for target 
genes is 55 probes per gene (range 17-95 probes), with average probe spacing of 1 probe 
every 4kb.  Target genomic regions and genes selected for this array are listed in 
supplementary tables S1 and S2, respectively. 
A targeted array comprising 15,000 oligonucleotide probes was designed to provide high 
resolution coverage of genomic regions recurrently associated with non-isolated CDH, as well 
as candidate genes for diaphragm and lung development.  Eighty-eight isolated CDH patients 
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were screened for genomic imbalances through the use of the custom-design targeted array.  
Nine samples (10.23 %) had insufficient quantity of DNA for analysis, or poor quality DNA for 
which the result could not be interpreted.  For the remaining 79 patients, 76 patients (96.2%) 
displayed normal results, i.e. no CNVs, or only benign CNVs were detected.  For three 
patients (3.8%) genomic imbalances were detected; a deletion of chromosome 8p22-p23.3 
in one patient, a duplication of Xq13.1 encompassing the EFNB1 gene in a second patient, 
and mosaicism for trisomy 2 in a third patient. 
Foetus 1 
The mother was referred because of the presence of a left-sided CDH with herniation of the 
liver into the thorax.  The Observed to Expected Lung to Head Ratio (O/E LHR) was 21.8%.  
No other abnormalities were detected except for a missing 12th rib.  Fetoscopic tracheal 
occlusion (FETO) was performed.  The gestational age at the time of diagnosis was 27 weeks.  
The child was delivered at 36 weeks gestation, with birth weight 2300 grams, and deceased 
soon after with all clinical features of pulmonary hypoplasia but no other abnormal features.  
Autopsy was not accepted by the parents, however, a postnatal echocardiography was 
performed for which no cardiac defects were observed.  The array result showed an 
interstitial deletion on chromosome 8p22-p23.3.  This deletion was confirmed by a genome 
wide 105K array (CytoSure Syndrome Plus v2, OGT), which also refined the proximal deletion 
breakpoint.  The deletion was shown to be 14.2Mb in size (958312 – 15160490bp) and is 
shown in figure 1.  
Foetus 2 
The mother was referred at 27 weeks because of the presence of a left-sided CDH and liver 
herniation.  The O/E LHR was 22%.  No other abnormalities were detected.  FETO was 
undertaken.  The male child was delivered at 38 weeks gestation, birth weight 2585 grams, 
with CDH and no other observed abnormalities.  The child died due to pulmonary hypoplasia 
and pulmonary hypertension.  The array result showed a duplication of Xq13.1, including the 
EFNB1 gene.  This duplication was confirmed by a genome wide 105K array (Cytosure 
Syndrome Plus v2, OGT), which also refined the duplication breakpoints.  The duplication is 
340 kb in size (67899816 – 68240036bp) and is displayed in figure 2.  Parental (maternal) 
samples were declined.   
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Figure 1. Chromosome 8p23.3-p22 deletion; Red dataset displays the 15K custom array result for 
patient labelled in Cy5, and blue dataset displays the 105K genome-wide array result for patient 
labelled in Cy3.  The 105K array result determined the telomeric break point of the deletion.  The 
location of the 8p23.1 deletion region is shown at the bottom of the image. 
 
Figure 2. EFNB1 gene duplication on X chromosome;  Red dataset displays the 15K custom array result 
for patient labelled in Cy5, and blue dataset displays the 105K genome-wide array result for patient 
labelled in Cy3.  The 105K array refines the extent of the duplication.  Genes are displayed in the blue 
track, where the black arrow highlights the position of the EFNB1 gene. 
  
75 
 
Foetus 3 
The mother was referred because of the presence of a left-sided CDH, without liver 
herniation, and moderate lung hypoplasia (O/E LHR = 29.8%).  No other abnormalities were 
detected.  Fetoscopic tracheal occlusion (FETO) was performed within the TOTAL trial.  The 
male child died postnatally from pulmonary hypoplasia, with no additional congenital 
malformations observed.  Autopsy was declined.  The array result indicated a high level of 
mosaicism for trisomy 2.  This result was confirmed by a genome wide 105K array (Cytosure 
Syndrome Plus v2, OGT).  The average median signal intensity ratios for probes on 
chromosome 2 for the targeted array and for the genome-wide array were found to be 0.35 
and 0.39 respectively, suggesting 60 - 97% mosaicism.  FISH analysis with a commercially 
available centromeric FISH probe (CEP2 SpectrumOrange VYSIS, Abbott S.A./N.V., Belgium) 
on cultured AF cells determined the level of mosaicism to be ~88%, with 391/445 trisomic 
cells observed.  The array result and the FISH confirmation are displayed in figure 3A & 3B. 
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Figure 3A. Mosaic trisomy 2; Red dataset displays the 15K custom array result for patient labelled in 
Cy5, and blue dataset displays the 105K genome-wide array result for patient labelled in Cy3.  The 
entire chromosome 2 is shown, with the duplication apparent.   
 
Figure 3B. Mosaic Trisomy 2; Displays an image from the confirmatory FISH analysis used to 
determine the level of mosaicism.  A centromeric FISH probe (CEP2 SpectrumOrange VYSIS, Abbott) 
was used, where three or two fluorescent red signals equal a cell with three or two copies of 
chromosome 2 respectively. 
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Discussion 
We designed a targeted array comprising 15,000 oligonucleotide probes.  This array was 
targeted at regions recurrently associated with CDH in humans, and to potential candidate 
genes involved in diaphragm and lung development.  A screen of 79 isolated CDH patients 
using this targeted oligonucleotide microarray revealed 2 causal imbalances and 1 likely 
causal variant.   
The finding of an 8p deletion in one patient adds further evidence to this region being 
associated with CDH.  8p deletions encompassing the 8p23.1 microdeletion region have 
previously been observed in a number of patients with CDH (Pecile et al., 1990; Howe et al., 
1996; Faivre et al., 1998; Borys and Taxy, 2004; Slavotinek et al., 2005; Shimokawa et al., 
2005; Lopez et al., 2006; Baynam et al., 2008; Wat et al., 2009).  In addition, deletions of this 
region are also associated with congenital heart defects (Claeys et al., 1997; Devriendt et al., 
1998; Devriendt et al., 1999).  GATA4 is considered to be the gene responsible for the heart 
abnormalities observed in patients with 8p deletions following the identification of GATA4 
mutations in patients with congenital heart defects (Garg et al., 2003; Okubo et al., 2004; 
Tomita-Mitchell et al., 2007; Rajagopal et al., 2007; Reamon-Buettner and Borlak, 2005; 
Reamon-Buettner et al., 2007).  GATA4 has also been previously proposed as a candidate 
gene for diaphragm defects given the diaphragmatic abnormalities observed in mice 
heterozygous for a deletion of GATA4 exon 2 (Jay et al., 2007).  However, no patients have 
been reported with GATA4 mutations and CDH.  Interestingly, our patient was an apparently 
isolated case of CDH, with no heart defects detected prenatally by ultrasound, or postnatally 
by echocardiography.  To our knowledge there are no reported cases of 8p deletions in 
association with isolated CDH.  However, we cannot fully exclude the presence of a heart 
defect in our patient, and additional phenotypic features of typical 8p23.1 microdeletion 
syndrome may not be apparent at birth. 
The transcription factor COUP-TFII has been shown to interact with FOG2 (Huggins et al., 
2001), which in turn modulates the transcriptional activity of GATA4 (Crispino et al., 2001).  
COUP-TFII and FOG2 are located on 15q26 and 8q23 respectively, regions recurrently 
associated with CDH in humans reviewed in (Holder et al., 2007)).  Furthermore, tissue-
specific ablation of COUP-TFII in mice caused a posterolateral Bochdalek-type CDH (You et 
al., 2005), and FOG2 N-ethyl-N-nitrosourea (ENU) mutant mice displayed diaphragm and 
lung defects (Ackerman et al., 2005).  All of these genes are proposed to be involved in the 
retinoic acid pathway, and their co-expression in the mesenchymal cells of the 
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pleuroperitoneal folds supports the retinoid hypothesis and the mesenchymal hit hypothesis 
which have been proposed as potential mechanisms of abnormal diaphragm development 
(Clugston et al., 2006; Jay et al., 2007; Clugston et al., 2010a).  It is possible that these 
proteins act together to regulate transcription of target genes downstream of the retinoic 
acid pathway involved in normal diaphragm development.  There may be additional genes 
related to diaphragm development present in the deleted region.  However, with no 
evidence supporting other candidate genes in the 8p region as being involved in CDH, more 
research is needed.  The exact mechanism by which 8p deletions cause diaphragm defects is 
unknown, and the influence of GATA4 deletions or mutations on human CDH remains to be 
proven. 
Mutations and deletions of the EFNB1 gene have been linked to craniofrontonasal syndrome 
(CFNS) (Twigg et al., 2004; Wieland et al., 2005; Wieland et al., 2007), in which 
diaphragmatic defects have been observed in a number of patients (Vasudevan et al., 2006).  
CFNS is an X-linked disorder in which the phenotype is of greater severity in heterozygous 
females than in hemizygous males.  The mechanism by which mutations in EFNB1 manifest 
themselves is proposed to occur by cellular interference (Wieacker and Wieland, 2005; 
Twigg et al., 2006; Wieland et al., 2008).  In females, due to random X-inactivation there are 
2 sub-populations of cells, some of which express the wild type and some the mutant EFNB1 
allele, supported by in vitro  evidence from studies of CFNS patient cell lines (Wieland et al., 
2008).  This process is proposed to cause a cellular interference which for EFNB1 interferes 
with tissue boundary formation (Twigg et al., 2004).  Recently, Twigg et al identified somatic 
mosaic mutations in more severely affected CFNS males compared to constitutionally 
affected males (Twigg et al., 2013) further supporting the increased severity in heterozygous 
females with a cellular interference model.  Since our male patient displays a previously 
unreported duplication of Xq13.1 including the EFNB1 gene, we consider this imbalance to 
be an unclassified variant.  Unfortunately, maternal samples were not available to determine 
the inheritance status of this imbalance.  Whilst the syndromic features of CFNS are seen 
with greater severity in affected females, since CDH is observed in both males and females 
with EFNB1 mutations, it is unlikely that the cellular interference model can explain 
abnormal diaphragm development without the presence of somatic mosaic males.  The 
exact function of EFNB1 with respect to diaphragm development is unknown.  EFNB1 acts as 
both a receptor and a ligand in a tissue-specific manner during embryogenesis, and the 
resulting forward and reverse signalling may be important for diaphragm development.  
EFNB1 may display a degree of dosage sensitivity in which duplications, as well as deletions 
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or mutations, affect the function of developing tissues.  EFNB1 has important roles in 
migration of neural crest cells, a pathway proposed to be involved in CDH (Davy et al., 2004; 
Davy and Soriano, 2005; Arvanitis and Davy, 2008).  A single report in the database of 
genomic variants (DGV) finds the region encompassing the EFNB1 gene to be a rare variant 
in normal individuals (frequency <1%) (Shaikh et al., 2009).  However, this finding has not 
been reproduced by other studies of normal individuals and, hence, may be an artefact.  
Furthermore, we have not observed a similar CNV in over 5000 cases meanwhile analysed by 
array CGH in our laboratory.  Duplications of EFNB1 may represent a susceptibility locus for 
CDH, or may be a rare but benign CNV.  Without the identification of additional isolated CDH 
patients with similar duplications, or further imbalances from studies of normal individuals, 
it is difficult to fully establish the clinical significance of this finding. 
Mosaicism for trisomy 2 is a rare finding with only 7 liveborn cases reported thus far 
(Robinson et al., 1997; Sago et al., 1997; Mihci et al., 2009).  In a recent report, Mihci et al 
describe a patient with mosaic trisomy 2 and displaying mental retardation, multiple 
congenital anomalies including diaphragmatic hernia, and dysmorphic features similar to 
Pallister-Killian syndrome (Mihci et al., 2009).  Our patient therefore represents the eighth 
reported case of mosaic trisomy 2 in a liveborn, and the second case with CDH.  The finding 
of CDH in our patient adds further evidence to this abnormality being part of the variable 
spectrum of phenotypic features associated with mosaicism for trisomy 2.  Imbalances on 
chromosome 2 have previously been observed in CDH patients, reviewed by Holder, et al. 
(Holder et al., 2007), although our finding does not make it possible to further confirm these 
specific regions as being causal for CDH.  However, given the rarity of this finding, we 
conclude that whilst CDH does display an association with mosaic trisomy 2, this finding does 
not represent a common cause of diaphragmatic hernia. 
We have taken the approach of only targeting the regions recurrently associated with non-
isolated CDH, as well as targeting CDH-associated genes.  All patients had a karyotype 
performed, as well as FISH analysis for the common aneuploidies (21, 18, 13, X & Y), which 
revealed normal results.  FISH analysis to exclude the presence of isochrosome 12p which 
causes Pallister-Killian syndrome was also performed for the majority of patients revealing 
normal results.  Only 19 patients have had a genome-wide array performed which revealed 
only benign CNVs for these patients.  Therefore, we cannot rule out that submicroscopic 
imbalances outside of our target regions may be present in some patients.  Additional 
research of both isolated and non-isolated CDH patients by array CGH is likely to reveal 
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novel submicroscopic loci associated with CDH, and refine those regions recurrently 
associated with CDH. 
Conclusion 
We identified chromosome abnormalities causal for CDH in one patient with an 8p deletion 
and in one patient mosaic for trisomy 2.  In addition, the duplication of EFNB1 further 
highlights this gene as a potential candidate involved in diaphragm development.  Since a 
number of loci which display strong associations with CDH are below the resolution of 
conventional karyotyping, such as 8p23.1 deletions, 15q26 deletions, and 4p16 deletions 
(Wolf-Hirschhorn syndrome), the continued investigation of isolated CDH patients by high 
resolution microarrays will eventually reveal the true incidence of submicroscopic 
imbalances as a cause of CDH, and whether imbalances in genomic loci associated with 
syndromic CDH are also a cause of isolated CDH.  Gene prioritisation strategies and next-
generation sequencing may also prove to be an effective method of screening a large cohort 
of isolated CDH patients for mutations in the many candidate genes which are associated 
with CDH. 
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Abstract 
Objective: Congenital Diaphragmatic Hernia (CDH) is a foetal abnormality affecting 
diaphragm and lung development with a high mortality rate despite advances in foetal and 
neonatal therapy.  CDH may occur either as an isolated defect or in syndromic form for 
which the prognosis is worse.  Although conventional karyotyping and more recently 
chromosomal microarrays support a substantial role for genetic factors, causal genes 
responsible for isolated CDH remain elusive.  We propose that chromosomal microarray 
analysis will identify CNVs associated with isolated CDH. 
Methods: We perform a prospective genome wide screen for copy number variations using 
chromosomal microarrays on 75 foetuses referred with apparently isolated CDH, six of 
which were later reclassified as non-isolated CDH.   
Results: The results pinpoint haploinsufficiency of NR2F2 as a cause of CDH and 
cardiovascular malformations.  In addition, the 15q25.2 and 16p11.2 recurrent 
microdeletions are associated with isolated CDH.  By using gene prioritisation and network 
analysis we provide strong evidence for several novel dosage sensitive candidate genes 
associated with CDH. 
Conclusions: Chromosomal microarray analysis detects submicroscopic copy number 
variations associated with isolated CDH or CDH with cardiovascular malformations. 
Introduction 
Congenital Diaphragmatic Hernia (CDH) is a congenital abnormality affecting diaphragm and 
lung development with an incidence of 1.7 to 5.7 per 10,000 live-born infants (Kotecha et al., 
2012).  CDH occurs either as an isolated defect or in syndromic form for which the prognosis 
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is worse (Skari et al., 2000).  CDH is associated with variable degrees of pulmonary 
hypoplasia and postnatal pulmonary hypertension which account for the high mortality rate, 
and much of the morbidity observed in survivors.  Survival rate of isolated CDH is in the 
range of 60-70% and better in high-volume centres (Kotecha et al., 2012).   
Animal models have been used to identify many genes involved in diaphragm development 
(Clugston et al., 2006; van Loenhout et al., 2009; Brady et al., 2011).  Some of those genetic 
models are tissue-specific or incorporate hypomorphic alleles which allow investigators to 
study diaphragm development in cases for which complete elimination of gene function 
using traditional knockout mice results in early lethality (Ackerman et al., 2005; You et al., 
2005; Jay et al., 2007; Wat et al., 2012).  Mouse and rat models have also revealed the 
importance of the pleuroperitoneal folds (PPFs) in diaphragm development and how defects 
in this structure can lead to CDH (Greer et al., 2000; Babiuk et al., 2003; Clugston et al., 
2010b; Mayer et al., 2011).  Patterns of gene expression have been studied using 
transcriptome analysis in both normal and teratogenic animal models identifying 
dysregulated genes and pathways (Clugston et al., 2010a; Russell et al., 2012; Dingemann et 
al., 2012).  Among the most important pathways that have been identified are the retinoic 
acid (RA), SHH, WNT and TGFβ signalling pathways as genetic variants within these pathways 
are shown to cause CDH in humans and / or animal models (Kim et al., 2001; Clugston et al., 
2010a; Russell et al., 2012). 
Analogous with those animal models, CDH is a key feature of different human monogenic 
syndromes.  Gene mutations causing syndromic forms of CDH in humans include; STRA6 
[OMIM *610745] (Matthew-Wood syndrome); NIPBL [OMIM *608667] (Cornelia de Lange 
syndrome), WT1 [OMIM *607102] (Denys-Drash syndrome); and LRP2 [OMIM *600073] 
(Donnai-Barrow syndrome).  In addition to single gene mutations, large chromosomal 
imbalances are also a frequent cause of syndromic CDH.  Conventional karyotyping and, 
more recently, genome-wide screening for copy number variations (CNVs) has identified 
many loci scattered throughout the genome that are recurrently deleted or duplicated in 
individuals with CDH.  Those regions most likely harbour one or more genes for which 
diaphragm development is dosage sensitive.  Chromosomal regions commonly identified in 
association with CDH include; 8p23.1 [OMIM %222400], 8q23 [OMIM #610187], 15q26 
[OMIM %142340], and 1q41-42 [OMIM #612530] which is a possible locus for Fryns 
syndrome (Klaassens et al., 2005; Kantarci et al., 2006; Shaffer et al., 2007; Klaassens et al., 
2007; Scott et al., 2007; Wat et al., 2009; Kantarci et al., 2010; Srisupundit et al., 2010; 
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Rosenfeld et al., 2011; Wat et al., 2011).  Those results show that the use of genome wide 
arrays enable the identification of dosage sensitive genes involved in human CDH.  In 
addition to syndromic forms, CDH is often seen as an isolated defect, and those patients are 
most suited to prenatal and/or neonatal therapy to improve lung growth and function (Jani 
et al., 2009; Deprest and De Coppi, 2012).  Despite a large body of evidence that genetic 
variants can cause diaphragmatic hernias in animal models, confirmation of their 
involvement in human isolated CDH is largely lacking.  
We hypothesised that by applying chromosomal microarrays to a prospective study of 
isolated CDH foetuses we would identify pathogenic copy number variations (CNVs) which 
would allow for; (i) identification of novel CNVs and genes linked to CDH; and (ii) 
identification of causal genes by refinement of known CDH loci.  As a European reference 
centre for foetal therapy during the prenatal phase following identification of isolated 
severe CDH, we have acquired detailed phenotype information and have access to a large 
cohort of patients. 
Methods 
Patients 
Pregnant women with foetuses affected by severe isolated CDH were referred to UZ Leuven 
for prenatal assessment and where applicable evaluation for possible Fetoscopic 
Endoluminal Tracheal Occlusion (FETO) during pregnancy.  The presence of any major 
anomaly for which the pathology of this alone would indicate a poor prognosis is classified 
as non-isolated; ‘isolated’ CDH may include minor anomalies which are not a 
contraindication for foetal management or a prognostic factor for outcome or response to 
therapy.  Severity of herniation was determined by measurement of the normalised lung 
area to head circumference ratio (LHR) and sonographic evidence of intra-thoracic 
herniation of the liver as previously described (Jani et al., 2009).  All patients received pre-
test counselling and provided informed consent for chromosomal microarray analysis.  
Samples were received between July 2009 and December 2012.  Approval for this study was 
granted by the KU Leuven / University Hospital Leuven Commission for Medical Ethics 
(S55513).   
Chromosomal Microarray Analysis 
Genome-wide array comparative genomic hybridisation (array CGH) analysis was 
undertaken for all cases on DNA extracted from amniotic fluid (AF), either directly or from 
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cultured cells.  For 1 case an additional foetal blood sample was also analysed (foetus 7, see 
Results section).  Samples were analysed using a 180K chromosomal microarray (Oxford 
Gene Technology, UK) in dye swap experiments with patient DNA labelled with Cy5 
hybridised against a sex-matched commercial reference DNA sample (Megapool Reference 
DNA, Kreatech Diagnostics, The Netherlands) labelled with Cy3, and vice versa.  Analysis and 
visualisation of array results was achieved using the CytoSure Interpret software (Oxford 
Gene Technology, UK), with analysis based upon genome build hg18.  CNVs were firstly 
filtered against an in-house curated database of common polymorphic CNVs.  Classification 
is subsequently aided by tracks for external databases such as the DGV (Database of 
Genomic Variants, http://projects.tcag.ca/variation/), ISCA database (The International 
Standards for Cytogenomic Arrays Consortium, www.iscaconsortium.org) and DECIPHER 
(Database of Chromosomal Imbalance and Phenotype in Humans using Ensembl Resources, 
http://decipher.sanger.ac.uk/).  DNA extracted from parental blood samples was also 
analysed using the same platform to assist with interpretation of pathogenic and/or rare 
CNVs detected in the foetus.   
Confirmation of findings 
Rare CNVs were confirmed by dye-swap analysis using the same chromosomal microarray 
platform, fluorescent in situ hybridisation (FISH), or conventional karyotyping, as 
appropriate. 
Prioritisation of Genes Located Within CNVs & Network Analysis 
Gene prioritisation was performed to prioritise and rank candidate genes within CNV regions 
detected by array analysis.  A training set of genes was curated for CNV gene prioritisation 
which was performed using Endeavour (www.esat.kuleuven.be/endeavour).  Full details of 
the training gene set used and the CNV prioritisation results are provided in online 
supplementary information.  Evidence for involvement of candidate genes in CDH was 
further aided by determining; (i) whether candidate genes are reported as dysregulated in 
animal models and/or human CDH [gene list updated from (Brady et al., 2011)]; (ii) whether 
candidate genes are expressed in the normal developing PPFs and / or developing muscular 
diaphragm [gene lists sourced from (Russell et al., 2012)]; and (iii) whether candidate genes 
interact directly with genes in a CDH gene network.  This CDH gene network was created 
using Ingenuity Pathway Analysis software package (IPA), (Ingenuity Systems, CA, USA).  The 
‘training genes’ were connected where experimental evidence of direct interactions existed 
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in the software database; i.e. predicted interactions were not permitted.  To this ‘CDH gene 
network’, we connected candidate genes from the CNV loci identified in this study, again 
only where direct interactions were supported by experimental evidence in the software 
database.  In more general terms, the ‘training genes’ which are associated with CDH were 
used as ‘baits’ to ‘fish’ for interacting candidate genes within our CNV loci.  Genes located 
within the marker ring X and 13q were not incorporated since these contain too many genes 
and would diffuse the identification of causative genes. 
A network analysis of this CDH gene network was then performed within the IPA software in 
order to identify which biological functions and pathways are enriched for.  The network 
scores are derived from p-values (score = -log p-value) and represent the likelihood that 
focus genes within the network are enriched for by random chance alone.  Similarly, the p-
values associated with a function or a pathway is a measure of the likelihood that the 
association between a set of focus genes in and a given process or pathway is due to random 
chance alone.  The p-values are calculated using the right-tailed Fisher Exact Test.  Full 
details are provided in online supplementary information.  Further details of the 
methodology and the results are provided in the Supporting information. 
Results 
75 consecutive foetuses referred due to severe, and apparently isolated CDH were analysed 
prospectively.  Of those 75 foetuses, a total of 69 foetuses had isolated CDH; 67 of which 
were confirmed clinically as isolated CDH (15 of those by necropsy or MRI virtopsy); for 2 
foetuses no necropsy, MRI virtopsy or postnatal clinical information was available.  Six 
foetuses considered isolated on initial prenatal examination were later shown to be non-
isolated CDH at subsequent examinations; 1 from necropsy or MRI virtopsy, and 5 from 
clinical observation (1 of which was identified postnatally).   
Genomic array analysis revealed de novo CNVs in 9.3% (7/75 foetuses) and rare inherited 
variants which may be involved in CDH in a further 4% (3/75 foetuses).  The full clinical and 
molecular cytogenetic findings are provided in Table 1.  None of those patients presented in 
Table 1 underwent necropsy or MRI virtopsy.  Clinical confirmation of isolated CDH was 
confirmed postnatally in 4 (foetuses 2, 3, 8 and 9).  Two pregnancies were terminated, with 
no necropsy or MRI performed (foetus 5 and foetus 10).  Foetus 1 had a left clubfoot and 
hydrops; foetus 4 had hydrops.  These foetuses were all considered to have isolated CDH.  
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For 2 foetuses (foetus 6 & foetus 7), a coarctation of the aorta was identified and were re-
classified as non-isolated CDH.  
Foetus 7 was referred due to isolated CDH, however, a coarctation of the aorta was later 
identified.  A deletion of 15q26.2, only 1.7Mb in size (94,221,024-95,920,254; build hg18), 
was detected on DNA from uncultured AF.  The mean Log2 signal intensity ratio was -0.6, 
which indicates the presence of a mosaicism where the deletion would be present in ~60% 
of cells.  Chromosomal microarray on DNA from a subsequent (uncultured) foetal blood 
sample revealed an identical result.  Parental array analysis showed no CNV at this locus, 
confirming this deletion originated de novo.  Conventional karyotype on cultured AF 
revealed 46,XX in 2/10 cells and 47,XX,+mar in 8/10 cells.  However, the array analysis did 
not reveal any large regions of additional genomic material, suggesting that the marker 
chromosome consists of heterochromatic material only. This finding thus represents the 
smallest reported deletion of the 15q26 locus in a patient with CDH and cardiovascular 
malformation (CVM) (Figure 1).  The figure also shows the former CDH ‘smallest region of 
overlap’ at 15q26, ~5 Mb in size, identified by FISH and microarray analysis, and the 
positions of the specific deletions which defined this region (Klaassens et al., 2005; Castiglia 
et al., 2005; Slavotinek et al., 2006; Klaassens et al., 2007).  
In foetus 10 with left-sided CDH and a single umbilical artery, array CGH on DNA from 
uncultured AF showed a deletion of the X chromosome, however, a 10Mb region of 
Xp22.2p22.11, and a 15Mb region of Xp11.1q13.1 showed reduced dynamic range of signal 
intensity ratios.  In order to confirm this unusual array finding, FISH analysis was performed 
with probes for the X centromere and the Xp sub-telomere regions (CEPX & TelXpYp) in a 
dual hybridisation, and for probes targeted to the Xp22 and Xq11 regions (RP11-1129A6 & 
RP11-284B18) in a dual hybridisation.  This revealed the presence of 1 signal in 23/50 and 2 
signals in 27/50 cells for the centromeric X chromosome probe, but only a single signal for 
the Xp sub-telomeric probe in the same 50 cells.  Probes for the Xp22 and Xq11 regions both 
displayed a single signal for 40/50 cells counted and 2 signals for 10/50 cells.  The karyotype 
on cultured AF revealed the presence of a 45,X cell line in 20/25 cells and a 46,X,+ring 
chromosome of unidentified origin, in 5/25 cells examined.  The array, karyotype and FISH 
results are displayed in Figure 2.  The final interpretation based upon array and conventional 
cytogenetic investigations was of a ring X chromosome comprised of material from 
Xp22.2p22.11 and the Xp11.1q13.1 centromeric region, present in mosaic form, and lacking 
the X inactivation centre (XIC). 
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 Chr/cyto band size Gain/Loss CDH 
Type 
Additional Features Inherited
/ de novo 
Classification Karyotype result Array Result 
Genome build hg18 
FETO  Outcome 
Foetus 1 1p22.2 102 kb Duplication Bilateral Left clubfoot, hydrops Paternal VOUS 46,XY arr 1p22.2(92,027,785-
92,129,888)x3, pat 
Y Deceased 
Foetus 2 4p15.2-p14 13.487 
Mb 
Duplication Right None De novo Pathogenic 46,XY arr 4p15.2p14(22,819,570-
36,306,519)x3, dn 
N Alive 
Foetus 3 13q12.12 1.37 Mb Duplication Left None Paternal VOUS 46,XX arr 13q12.12(22,439,339-
23,808,774)x3, pat 
N Alive 
Foetus 4 13q14.3-q33.3 57 Mb Mosaic 
Duplication 
Left Hydrops De novo Pathogenic Not performed arr 
13q14.3q33.3(51,620,432-
108,613,709)x3 [30%], dn 
Y Deceased 
Foetus 5 15q25.2 1.592 Mb Deletion Left None De novo Pathogenic Not performed arr 15q25.2(81,011,052-
82,602,711)x1, dn 
N TOP 
Foetus 6 15q25.2 
17p12 
2.434 Mb 
1.344 Mb 
Deletion 
Deletion 
Left Coarctation of the aorta De novo 
De novo 
Pathogenic 
VOUS 
46,XX arr 15q25.2(80,422,638-
82,856,949)x1, dn 
17p12(14,039,023-
15,382,903)x1, dn 
Y Deceased 
Foetus 7 15q26.2 1.699 Mb Deletion Left Coarctation of the aorta De novo Pathogenic 46,XX[2]/47,XX,+MAR[8] arr 15q26.2(94,221,024-
95,920,254)x1 [60%], dn 
N Deceased 
Foetus 8 16p11.2 543 kb Deletion Left None De novo Pathogenic Not performed arr 16p11.2(29,559,861-
30,102,955)x1, dn 
Y Alive 
Foetus 9 17p13.3 713 kb Duplication Left None Maternal VOUS 46,XY arr 17p13.3(1,656-
714,933)x3, mat 
Y Deceased 
Foetus 10 Xp22.2-p22.11 
Xp11.1-q13.1 
10.4 Mb 
15.4 Mb 
Mosaic 
Ring X 
 
Left SUA De novo Pathogenic 46,X,r(X)(::p22.2p22.11::
p11.1q13.1::) [5] / 45,X 
[20] 
arr Xp22.33p22.2(106,314-
12,656,628)x1, dn 
Xp22.2p22.11(12,741,959-
23,093,838)x2 [30%], dn 
Xp22.11p11.21(23,293,215-
56,523,984)x1, dn 
Xp11.1q13.1(56,573,141-
71,997,108)x2 [30%], dn 
Xq13.2q28(72,063,396-
154,899,837)x1 
N TOP 
Table 1.  Molecular cytogenetic results and clinical summary of CDH foetuses with abnormal chromosomal microarray findings.  VOUS=Variant of Uncertain Significance; 
FETO=fetoscopic endoluminal tracheal occlusion; TOP=termination of pregnancy; SUA=single umbilical artery 
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Figure 1.  Refinement of the critical deleted region at 15q26 with a single case of isolated CDH. The 
array result of foetus 7 is displayed in the main window with probes plotted by genomic position on 
the x-axis and signal intensity log ratio on the y-axis. The tracks below display (from top to bottom); (i) 
the previous smallest region of overlap (checkered track); (ii) Patient C and (iii) Patient H from 
Klaassens et al 2007, which allowed for defining the region in shown in (i); and (iv) Patient 2 reported 
by Mosca et al 2011, which was recently used to refine the 15q26 region, however, this case is the 
result of an unbalanced translocation with a 50Mb duplication of 2p. (v) Protein coding genes from 
refseq visualised within the UCSC genome browser are shown below, where NR2F2 and SPATA8 are 
the only genes located within the deleted region in foetus 7. 
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Figure 2.  Cytogenetic analysis of foetus 10.  A. The array result for chromosome X is shown in the 
main window with the deleted region highlighted. Probes are plotted by genomic position on the x-
axis and signal intensity ratio on the y-axis.  The reduced deviation of Log2 signal intensity ratios is 
apparent for the Xp22.2-p22.11 and Xp11.1-q13.1 regions.  B. The karyotype is shown which revealed 
a 46,X, +mar cell line in a proportion of cells examined.  C. FISH result with probes for the Xp22 and 
Xq11 regions (RP11-1129A6 & RP11-284B18, respectively) revealed 2 signals for both probes in a 
proportion of cells examined (left arrows = Xp22, right arrows = Xq11).  D. FISH result with probes for 
the X centromere and the Xp sub-telomere regions (CEPX & TelXpYp) revealed the presence of 2 
signals for the centromeric X chromosome probe, but only a single signal for the Xp sub-telomeric 
probe in a proportion of cells examined (left arrow = TelXpYp, right arrows = CEPX). 
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Foetuses 5 and 6 both have de novo deletions of 15q25.2, 1.59Mb and 2.43Mb in size, 
respectively.  These deletions overlap the 15q25.2 microdeletion syndrome locus in which 
CDH has been observed, as well as cognitive deficits and Diamond--Blackfan anaemia (Wat 
et al., 2010).  Foetus 5 had isolated left-sided CDH; foetus 6 was referred due to isolated left-
sided CDH, though a coarctation of the aorta was detected later in pregnancy.  Foetus 6 also 
has a de novo duplication of 17p12, 1.34Mb in size (Charcot-Marie-Tooth disease Type 1A 
locus).  
A de novo deletion of 16p11.2, 543kb in size, was detected in foetus 8 with isolated left-
sided CDH on DNA from uncultured AF.  This coincides with the recurrent 16p11.2 
microdeletion syndrome [OMIM #611913], in which 2 cases of CDH were recently reported 
(Wat et al., 2011).  This locus is however more often associated with autism spectrum 
disorder and schizophrenia (Itsara et al., 2009; Sahoo et al., 2011).  
A de novo duplication of 4p15.2-p14, 13.5Mb in size, was detected in foetus 2 with isolated 
right-sided CDH on DNA from uncultured AF.  Given the size, de novo nature, gene content, 
and lack of reports in normal individuals this CNV is likely to be pathogenic.   
Aside from de novo events, we also detect rare inherited variants whose pathogenicity is 
uncertain.  Given the lack of reports of similar CNVs in normal individuals, these may 
represent risk loci for CDH.  These include; a 102kb paternally inherited duplication of 
1p22.2 which partially overlaps the TGFBR3 gene, detected in foetus 1 with bilateral CDH; a 
paternally inherited duplication of 13q12.12, 1.37Mb in size, in foetus 3 with left-side CDH; 
and, a maternally inherited 713kb duplication of 17p13.3 in foetus 9 with left-side CDH. 
Gene Prioritisation 
We performed gene prioritisation using the Endeavour application (Tranchevent et al., 
2008).  Full details of these ‘training genes’ is provided in online supplementary information, 
along with the ranked gene prioritisation results of each CNV loci.  Using the ‘training genes’, 
we curated a ‘CDH gene network’ using the Ingenuity Pathway Analysis software application.  
This curated ‘CDH gene network’ is displayed in Figure 3, and shows ; (i) the presence of 
training genes in CNVs identified in this study and previous studies of CDH, e.g. NR2F2, 
GATA4, ZFPM2, and EFNB1; and (ii) the presence of genes in CNVs identified in this study 
which interact directly with the CDH gene network, e,g RBPJ, and BNC1.  
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Figure 3. CDH gene network.   A protein interaction network was generated using Ingenuity Pathway 
Analysis (IPA) and curated from; (i) a ‘training gene set’ (labelled in normal font); (ii) Genes within CNV 
loci identified in this study which connect directly to the ‘training gene set’ (labelled in bold italic font, 
in boxes).  NR2F2 and EFNB1 are in both the ‘training gene set’ and present within CNVs identified in 
this study. 
 
A consequence of the creation of this CDH gene network is the identification of novel 
candidate genes with likely involvement in CDH, but hitherto not yet identified.  These 
include the RBPJ gene, present in the duplicated 4p15.2-p14 region in foetus 2, which is 
shown to interact with genes from the training gene set in the CDH gene network and is also 
ranked 1st by gene prioritisation of this CNV (online supplementary information). 
Enrichment analysis was performed using the IPA software of the final CDH gene network 
shown in figure 3, which revealed significant enrichment for biological networks and genes 
known to be involved in; respiratory system development and function; cardiovascular 
system development and function, skeletal and muscular system development and function.  
These findings are concordant with observations in humans and animal models.  Significant 
enrichment for genes involved in canonical biochemical pathways included; Regulation of 
the Epithelial-Mesenchymal Transition (EMT) Pathway; FGF Signalling; Axonal Guidance 
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Signalling; Human Embryonic Stem Cell Pluripotency; Wnt/β-catenin Signalling; and RAR 
Activation.  These findings support candidate pathways such as the RA pathway as being 
involved in CDH, but also highlight pathways and genes involved with the EMT pathway, FGF 
signalling and Wnt/β-catenin signalling as potential candidates for involvement in human 
CDH.  Full details of the enriched networks, and the top 20 enriched canonical pathways and 
the top 20 biological functions are given in online supplementary information.   
Discussion 
Whereas it was well known that specific microscopically visible chromosomal imbalances are 
associated with syndromic forms of CDH, our study shows that submicroscopic CNVs 
underlie a significant fraction of isolated forms as well.  The identification of rare and novel 
CNVs has enabled the identification of dosage sensitive genes involved in CDH with RBPJ 
representing a novel candidate.  We confirm the association of candidate genes such as 
NR2F2 with CDH and cardiovascular malformations.  In addition, we add further evidence for 
some genes known to cause syndromic forms of CDH, such as EFNB1, to also be associated 
with isolated CDH.  This study adds to the growing body of evidence that CDH is a genetically 
heterogeneous disorder which can be caused by genetic variants in different developmental 
pathways. 
Haploinsufficiency of NR2F2 causes CDH and cardiovascular malformations (CVMs) 
This study identifies the smallest reported deletion of the 15q26 region in a case of CDH and 
coarctation of the aorta.  This refines the minimal deleted region at 15q26 to a region 1.7Mb 
in size containing only 2 protein coding genes; NR2F2 (also known as Coup-tfII) [OMIM 
*107773]; and SPATA8 (Figure 1), and thus excludes IGF1R and ARRDC4 from the previously 
defined minimal deleted CDH region at 15q26.  The NR2F2 gene has been considered the 
prime CDH candidate gene at 15q26 since tissue-specific Coup-tfII null mice were shown to 
develop CDH (You et al., 2005).  Surprisingly, mutation analysis has not revealed pathogenic 
NR2F2 variants confidently linked to CDH (Slavotinek et al., 2006; Scott et al., 2007).  Little 
information is available for the SPATA8 (spermatogenesis associated 8) gene, but this gene is 
unlikely to play a role given its identification as a testis specific expressed gene (Nie and 
Xiang, 2006).  A recent study reported to have refined the critical region at 15q26 to a region 
which did not contain NR2F2 (Mosca et al., 2011).  However, the case which allowed for this 
refinement also had a large (50 Mb) trisomy for 2p16.3p25.3, and we suspect that the 2p 
duplication represents the cause of the CDH given previous reports of trisomy 2p in the 
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literature, including our previous study which found mosaicism for trisomy 2 in one isolated 
CDH foetus (Srisupundit et al., 2010; Pober, 2007; Holder et al., 2007).  NR2F2 interacts with 
ZFPM2 (FOG2) (Huggins et al., 2001), which is also an interacting partner of GATA4 (Crispino 
et al., 2001), to regulate retinoic acid receptor / retinoid X receptor (RAR / RXR) dimerization 
and thus retinoic acid dependent gene transcription.  ZFPM2 and GATA4 have both been 
implicated in CDH pathogenesis in humans and genetic mouse models (Ackerman et al., 
2005; Wat et al., 2011; Jay et al., 2007; Yu et al., 2013), as well as with CVMs (Zhou et al., 
2009; Crispino et al., 2001; Rajagopal et al., 2007).  NR2F2 has also been linked to 
cardiovascular development from studies in mouse models (Wu et al., 2013; Lin et al., 2012; 
Huggins et al., 2001; Pereira et al., 1999), and is proposed as a cause of CVMs in syndromic 
patients with deletion of 15q26 (Nakamura et al., 2011; Tumer et al., 2004; Rump et al., 
2008; Davidsson et al., 2008; Poot et al., 2007).  Our finding thus pinpoints haploinsufficiency 
of NR2F2 as a cause of diaphragm and cardiovascular abnormalities in humans. 
EFNB1 Overexpression causes CDH 
The EFNB1 gene is located on the X chromosome and mutations or deletions are associated 
with craniofrontonasal syndrome (CFNS) [OMIM #304110](Twigg et al., 2004; Wieland et al., 
2007).  CDH has previously been observed in both males & females affected with CFNS and 
EFNB1 mutations (Vasudevan et al., 2006; Hogue et al., 2010).  However, reports of EFNB1 
duplications are rare (Srisupundit et al., 2010; Petit et al., 2011; Babbs et al., 2011).  Here, 
we present a mosaic ring X chromosome in a female foetus with CDH.  Another foetus of a 
mosaic ring X chromosome identified by conventional karyotyping in association with CDH 
has been described  (Nowaczyk et al., 1998).  We have previously reported a male foetus 
with isolated CDH and a duplication containing only the EFNB1 gene, which we proposed as 
the likely cause (Srisupundit et al., 2010).  A second male with isolated CDH and duplication 
of Xq13.1 including EFNB1 has since been reported (Petit et al., 2011).  Taken together, this 
evidence adds further support for a dosage sensitive role of EFNB1 in diaphragm 
development and thus represents the likely cause of CDH in this foetus.  We conclude that 
that duplications of Xq13.1 in males, or the presence of this region on active marker X 
chromosomes in 45,X / 46,X, +mar(X) females, not subject to random X-inactivation or 
lacking the XIC, predisposes to CDH. 
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15q25.2 recurrent microdeletion is associated with CDH 
We identified 2 cases of CDH with 15q25.2 deletions.  Due to low copy repeats (LCRs) in this 
region, the 15q25 locus was predicted to be a hotspot for recurrent genomic 
rearrangements via non-allelic homologous recombination (NAHR) (Itsara et al., 2009).  
Whilst reports of the recurrent 15q25.2 microdeletion remain limited, there is mounting 
evidence that recurrent deletions of the 15q25.2 locus are associated with a significant risk 
of congenital diaphragmatic hernia.  A recent report provides an update on patients and 
phenotypic features associated with deletions of this region (Doelken et al., 2013).  Adding 
our findings to this data reveals that 6/8 reported cases of 15q25.2 recurrent microdeletions 
present with CDH, providing further evidence that isolated CDH represents one of the major 
features of the 15q25.2 recurrent microdeletion syndrome (Mefford et al., 2007; Wat et al., 
2010; Yu et al., 2012).  Candidate genes in this region include BNC1 and BTBD1.  BNC1 is 
involved in cell proliferation (Tseng, 1998; Boldrup et al., 2012), and defective cell 
proliferation & migration in the pleuroperitoneal folds of the developing diaphragm have 
been proposed to underlie CDH (Clugston et al., 2010b).  Given the musculature of the 
diaphragm, BTBD1 is an interesting candidate involved in myoblast growth and 
differentiation (Pisani et al., 2004; Pisani et al., 2007).   
16p11.2 deletions can cause isolated CDH 
Deletions of 16p11.2 are a risk factor for autism.  This deletion was recently reported in 2/45 
cases of CDH (Wat et al., 2011).  Here, we also identified a 16p11.2 deletion in a patient with 
CDH adding further evidence that 16p11.2 deletions may pose a risk of CDH.  This combined 
total of 3/120 CDH cases with 16p11.2 deletions detected by array in this study and that of 
Wat et al (Wat et al., 2011), compared with the reported incidence of 6/22,246 in normal 
individuals (Rosenfeld et al., 2013), is significantly higher than expected by chance alone (p < 
0.0001; one-tailed Chi-square test with Yates correction).  Plausible candidate genes include 
the TBX6 gene which is important for specification of paraxial mesoderm structures 
(Yasuhiko et al., 2006; Yasuhiko et al., 2008; Nowotschin et al., 2012) and also interacts with 
MESP2 which is associated with spondylocostal dysostosis (SCD) (Whittock et al., 2004).  A 
link to SCD and diaphragm abnormalities has been reported (Day and Fryer, 2003; Lam et al., 
1999; Rodriguez et al., 2004), with some individuals affected with SCD and CDH having 
mutations in DLL3 (Bulman et al., 2000).   Both MESP2 and DLL3 are involved in Notch 
signalling, as is the LFNG gene which has also been associated with SCD (Sparrow et al., 
2006). 
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Novel CNVs Associated with CDH & New Candidate Genes 
We identify novel CNVs which may be responsible for CDH pathogenesis.  These CNVs range 
in size from 13.5Mb to 100kb, encompassing 100’s of genes to a single gene, and include 
both de novo and inherited CNVs.   
A 13.5Mb de novo duplication of 4p15.2-p14 identified in a foetus with CDH contains the 
RBPJ gene which represents a novel CDH candidate.  RBPJ is a mediator of Notch signalling 
and knockout mouse embryos develop severe vascular defects, as well as defective somite 
generation and heart looping morphogenesis (Krebs et al., 2004).  RBPJ dependent notch 
signalling has also been shown to be a crucial regulator of mesenchymal progenitor cell 
proliferation and differentiation during skeletal development (Dong et al., 2010).  RBPJ 
mutations have been linked to Adams-Oliver syndrome in humans (AOS3, OMIM #614814).   
The PPARGC1A gene is also present in the duplicated region of 4p15.2-p14.  PPARGC1A is a 
co-activator of PPARG, which is known to form heterodimers with retinoid X receptors 
(RXRs) to regulate gene transcription.  PPARG has recently been shown to be downregulated 
in the nitrofen-induced hypoplastic lungs of the CDH rodent (Gosemann et al., 2012), and 
the authors propose that downregulation of PPARG and the associated upregulation of MCP-
1 may impair lung maturation by disrupting surfactant production and alveolar maturation 
by interference with epithelial-mesenchymal interactions.  In contrast, other studies have 
suggested that overexpression of PPARGC1A and PPARG are predicted to have protective 
effects on skeletal muscle atrophy and lung development (Kang and Li, 2012; Wang et al., 
2009).  PPARGC1A may thus represent a novel dosage sensitive gene involved in 
development or severity of CDH. 
An inherited partial duplication of the TGFBR3 gene was observed in foetus 1 referred due to 
apparently isolated CDH, but with clubfoot and hydrops subsequently identified.  TGFBR3 
plays an essential role in coronary vasculogenesis (Compton et al., 2007), and is important 
for BMP-induced epithelial-mesenchymal transition (EMT) (Kirkbride et al., 2008), factors 
which may be relevant for PPF and diaphragm development, since it is proposed that a 
mesenchymal cell defect in the PPFs underlies subsequent CDH development – the 
mesenchymal hit hypothesis (Jay et al., 2007; Clugston et al., 2008; Jesudason, 2006; 
Clugston et al., 2010b). 
  
96 
 
Conclusion 
Mounting evidence from array studies supports genetic variation as being a significant cause 
of CDH.  We show that 9% (and as much as 13%) of isolated CDH patients, or those with CDH 
associated with cardiovascular malformations, harbour pathogenic submicroscopic CNVs 
associated with CDH.  This diagnostic yield is higher than the ~6% rate which is observed in 
recent studies for the routine diagnostic use chromosomal microarrays for pregnancies with 
ultrasound anomalies (Wapner et al., 2012; Shaffer et al., 2012).  We therefore advocate the 
use of chromosomal microarrays for CNV detection in the prenatal diagnosis of foetuses 
with isolated or non-isolated CDH.  Despite the reduced penetrance of CDH, arrays have 
proven to be a powerful approach in identifying genes underlying both isolated and 
syndromic cases of CDH.  Further use of chromosomal microarrays for the investigation of 
isolated CDH patients will continue to identify loci and genes which are involved in CDH.  The 
combination of array analysis along with clinical outcome and long term follow up of 
survivors will allow for the determination of which submicroscopic CNVs are associated with 
a poor outcome. 
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Chapter 5.  Exome Sequencing to Identify the Genetic Cause of CDH 
Adapted from; 
Exome sequencing identifies ZFPM2 as a cause of familial isolated Congenital 
Diaphragmatic Hernia and possibly cardiovascular malformations.   
(Manuscript under review, European Journal of Medical Genetics).  
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Introduction 
Congenital Diaphragmatic Hernia (CDH) is a congenital abnormality affecting diaphragm and 
lung development with an incidence of 1.7 to 5.7 per 10,000 live-born infants (Kotecha et al., 
2012).  CDH occurs either as an isolated defect or in syndromic form for which the prognosis 
is worse.  CDH is associated with variable degrees of pulmonary hypoplasia and postnatal 
pulmonary hypertension which account for the high mortality rate, and much of the 
morbidity observed in survivors.  Survival rate of isolated CDH is in the range of 60-70% and 
better in high-volume centres (Kotecha et al., 2012).   
The generation of genetic mouse models with diaphragm defects has identified a number of 
genes which cause CDH, although some models are either tissue-specific or produce 
hypomorphic alleles (Jay et al., 2007; Ackerman et al., 2005; Wat et al., 2012; You et al., 
2005).  RNA expression analysis and immunohistochemistry analysis in normal and 
teratogenic animal models (Clugston et al., 2010; Russell et al., 2012; Dingemann et al., 
2012) has also confirmed gene expression and protein localisation of numerous candidate 
CDH genes during normal and/or abnormal diaphragm development.  Most recently, 
defective development of the pleuroperitoneal folds (PPFs) is proposed as an underlying 
cause of subsequent CDH development.  From those studies and through applying network 
analysis of interacting genes/proteins, some of the most important pathways that have been 
identified are the retinoic acid (RA), SHH, WNT and TGFβ signalling pathways (Holder et al., 
2007; Kantarci and Donahoe, 2007; van Loenhout et al., 2009; Brady et al., 2010; Russell et 
al., 2012).   
Analogous with those animal models, CDH is a key feature of numerous genetic syndromes 
in humans.  An OMIM search for ‘diaphragmatic hernia’ returns > 200 genetic syndromes, 
genomic loci or genes linked to human CDH.  Some of those more frequently associated with 
CDH are given in Table 1.   
Mutation analysis has been performed on cohorts of isolated and non-isolated CDH patients 
for a limited number of candidate CDH genes, summarized in Table 2.  Surprisingly however, 
these studies have identified only a small number of variants in those genes which are likely 
causal for isolated CDH.  One potential reason for the failure to detect causative mutations 
in such retrospective targeted gene sequencing studies is the high genetic heterogeneity 
which underlies CDH. 
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Syndromes and genomic loci associated 
with CDH in humans 
OMIM 
Syndrome/Locus 
Causal or Candidate 
CDH gene(s) 
OMIM 
Gene 
Trisomy 18  unknown n/a 
Tetrasomy 12p 
Pallister Killian syndrome 
#601803 unknown n/a 
15q26 deletion %142340 [DIH1] NR2F2 *107773 
8p23.1 deletion %222400 [DIH2] GATA4 
SOX7 
*600576 
*612202 
8q23 #610187 [DIH3] ZFPM2 *603693 
4p16.3 deletion 
Wolf-Hirschhorn syndrome 
#194190 FGFR3 
FGFRL1 
*134934 
*605830 
15q25.2 deletion  unknown  
22q11.2 deletion/duplication #188400 / #608363 TBX1 *602054 
Matthew Wood syndrome 
15q24 microdeletion 
#601186 STRA6 *610745 
Denys-Drash syndrome #194080 WT1 *607102 
Donnai Barrow syndrome #222448 LRP2 *600073 
Cornelia de Lange syndrome #122470 / #300590 NIPBL 
SMC1A 
*608667 
*300040 
Craniofrontonasal syndrome #304110 EFNB1 *300035 
Fryns Syndrome  
(Possible locus at 1q41-42) 
%229850 
(#612530) 
 
(DISP1) 
 
(*607502) 
Table 1.  Examples of syndromes and genomic loci associated with CDH in humans, with estimates of 
CDH frequencies and respective candidate genes.  Adapted from Holder, and Adapted from Brady 
review and custom array design. 
locus Gene(s) No. of patients  
(no. with variants) 
Mutations Study 
8q23 ZFPM2 (Fog2) 30 (1) p.R112X (de novo, het) (Ackerman et 
al., 2005) 
8q23 
4q12 
FOG2 
PDGFRA 
96 (2) 
96 (1) 
p.M703L; p.T843A (het) 
p.L967V (het) 
(parents unavailable) 
(Bleyl et al., 
2007) 
15q26 SIAT8B, CHD2, 
MCTP2, NR2F2, 
ARRDC4, RGMA 
>100 (0) No pathogenic variants (Slavotinek et 
al., 2006) 
15q26 NR2F2 73 (0) No pathogenic variants (Scott et al., 
2007) 
1q41-42 DISP1 
HLX 
179 (1) 
179 (1) 
p.A1471G (de novo, het) 
p.F9L (mat, het) 
(Kantarci et 
al., 2010) 
4p16.3 FGFRL1 54 (0) No pathogenic variants (Lopez 
Jimenez et 
al., 2010) 
8p23.1 GATA4 (exome seq) 
GATA4 
1 (1) 
96 (1) 
p.R252W (pat, het) 
p.R283H (de novo, het) 
(Yu et al., 
2013) 
11p13 WT1 27 (0) No pathogenic variants (Nordenskjold 
et al., 1996) 
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Table 2.  Presents the results from sequencing analysis of candidate CDH genes in mixed cohorts of 
isolated and non-isolated CDH patients.  Genes investigated, numbers of CDH patients studied, and 
any novel or rare mutations discovered are listed.  Those mutations in red italics are of uncertain 
pathogenicity. 
 
Exome sequencing is an attractive approach to the study of CDH, in the absence of any 
pathogenic structural rearrangement identified by cytogenetic or microarray analysis, 
because this would enable the interrogation of those candidate CDH genes identified by CNV 
analysis and from animal studies, as well as all known genes for causative mutations.  One 
potential reason for the failure to detect causative mutations in such retrospective targeted 
gene sequencing studies is the high genetic heterogeneity which underlies CDH.  A large 
degree of genetic heterogeneity is observed in syndromic cases of CDH, with many 
monogenic disorders having an association (Slavotinek, 2007), as well as large structural 
rearrangements and CNVs (Holder et al., 2007).  More recently, we and others have 
demonstrated that submicroscopic CNVs are a cause of isolated CDH (Srisupundit et al., 
2010; Wat et al., 2011), (Chapter 4), also caused by genomic loci scattered throughout the 
genome.  The large number of genes associated with syndromic forms of CDH and the many 
genomic loci which share an association with both isolated and non-isolated forms, and the 
large number of candidate genes which have not been proven in humans, make exome 
sequencing an attractive approach.  A similar approach has been successfully applied to 
larger patient cohorts for genetically heterogeneous disorders with large numbers of 
candidate genes including intellectual disability (ID) (de Ligt et al., 2012; Rauch et al., 2012) 
and congenital heart disease (Zaidi et al., 2013), identifying causal mutations in known or 
novel genes in a significant proportion of individuals studied.  For ID and heart disease, the 
search was mainly for identification of highly penetrant de novo events.  However, exome 
sequence analysis for causative variants responsible for CDH may be more challenging due 
to variable penetrance and / or expressivity of the phenotype. 
We hypothesised that by applying exome sequencing to the study of CDH we would identify 
pathogenic variants, thus identifying (novel) genes linked to CDH in humans. 
Methods 
Chromosomal Microarray Analysis 
Chromosomal microarray analysis was performed using the CytoSure Syndrome Plus 180k 
array (Oxford Gene Technology - OGT, Oxford, UK) for all affected individuals to exclude any 
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pathogenic CNV(s) as the cause, as previously described in Chapter 3 & 4 (Brady et al., 
2013a; Brady et al., 2013b). 
Targeted enrichment and exome sequencing 
Genomic DNA was sheared by sonication, and whole genome sequencing libraries were 
prepared using the TruSeq DNA Library Preparation Kit (Illumina) in which platform-specific 
adaptors and unique DNA indexes were ligated.  The gel-free method was performed with 
no size selection of fragments.  DNA sequencing libraries were subsequently enriched with 
the SeqCap EZ Human Exome Library v2.0 or v3.0 (Roche, NimbleGen), and 2 × 100-bp 
paired-end reads were generated on a HiSeq2000 (Illumina) with 3 or 4 exome-seq samples 
pooled per lane of a sequencing flow-cell.  Sheared DNA, whole genome libraries and 
enriched exome-seq libraries were validated using DNA-1000 chips on the BioAnalyser 
(Agilent), and library concentrations were determined using the dsDNA BR Assay on the 
Qubit (Invitrogen). 
Mapping and variant calling 
The paired-end sequence reads were aligned to the human genome (hg19) with the 
Burrows-Wheeler Aligner (BWA; version 0.5.9 – 0.6.2) (Li and Durbin, 2009) using default 
settings, and the read trimming parameter was set to 15.  SAMtools (version 0.1.12a) (Li et 
al., 2009) was used for converting (SAM/BAM), sorting and indexing alignments. The quality 
metrics for mapping were calculated with Picard tools (version 1.38 – 1.78).  Duplicate reads 
were marked with Picard tools and excluded from downstream analysis.  The GATK 
framework (version 1.0.4974 – 2.4.9) (McKenna et al., 2010) was used for performing the 
local realignment, base call recalibration and SNP calling.  Indels were called with Dindel 
(version 1.01) (Albers et al., 2011) using default parameters.  Variants were annotated with 
ANNOVAR (version 2011 – version 2013) (Wang et al., 2010), which provides information 
including dbSNP (dbSNP132 – dbSNP137), and 1000 Genomes data (release May 2011 – 
release April 2012).  The current analysis pipeline includes annotation for the ESP6500 panel 
(NHLBI GO Exome Sequencing Project (ESP), Seattle, WA), 
(http://evs.gs.washington.edu/EVS/).  The current exome variant server (EVS) data release 
(ESP6500SI-v2) is taken from 6503 samples drawn from multiple ESP cohorts and represents 
all of the ESP exome variant data.  Functional predictions for the amino-acid changes 
according to different models is also provided (SIFT, Polyphen2, LRT and MutationTaster) 
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were retrieved from dbNSFP (database of human nonsynonymous SNPs and their functional 
predictions) (Liu et al., 2011). 
Variant Filtering  
Variant files annotated by the GATK analysis pipeline were filtered against provided 
annotations in Excel, and using the web application ‘Annotate-it’ (Sifrim et al., 2012) 
(http://www.annotate-it.org/).  Details of filters applied by each method and the number of 
variants remaining after filtering are provided in the results section.  Annotate-it provides 
details at the gene level for pathways and biological processes associated with the 
respective gene function.  Additionally, annotate-it provides text-based genotype-phenotype 
associations (according to HPO and LDDB terms) from ‘A Gene Apart’ and respective p-
values for this association.  Variants of interest were also checked against the Exome Variant 
Server, (NHLBI GO Exome Sequencing Project (ESP), Seattle, WA), 
(http://evs.gs.washington.edu/EVS/).  The current in-house analysis pipeline now provides 
annotation for the ESP 6500 dataset in the variant files.   
Variant confirmation 
Primers were designed using Primer3 software (http://frodo.wi.mit.edu/), and SpanPrimers 
(http://medgen.ua.ac.be/~gvandeweyer/SpanPrimers/index.php).  PCR products were 
purified with ExoSAP-IT (GE Healthcare) and sequenced using BigDye Terminator v3.1 
chemistry (Life Technologies) on a 3730 DNA Analyzer (Life Technologies).  Sequence traces 
were aligned to the reference sequence using Sequence Scanner v1.0 software (Applied 
Biosystems) and CLC Main Workbench v6 (CLC Bio).  
X-Inactivation Analysis 
The methylation status of the X-linked androgen receptor (AR) gene was assessed by gene 
methylation assay, as previously described (Allen et al., 1992; Froyen et al., 2007).  The 
resulting products were separated on an ABI 3730 (Applied Biosystems) and peak positions 
and peak intensity areas were further processed using Excel to calculate the percentage 
inactivation of both alleles. 
Patients 
Written, informed consent was provided for exome sequencing by patients prior to analysis.  
Details of the phenotypes are described below, per family, and the family pedigrees are 
shown in Figure 2. 
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Family 1 
The parents (II.1 and II.2) have a total of 4 pregnancies; the family pedigree is shown in 
Figure 2.  The first child (III.1) is a healthy male; the second pregnancy (III.2) was a female 
foetus, with TOP at 5 months due to apparently isolated CDH; the third pregnancy (III.3) was 
a male foetus, with TOP at 5 months due to apparently isolated CDH, confirmed at autopsy 
examination; the fourth pregnancy (III.4) led to a male child, with a cardiac defect [total 
anomalous pulmonary venous return (TAPVR)] detected neonatally, with subsequent 
corrective surgery, and no current health problems.  Upon a later X-ray, this child was shown 
to have a right-sided anterior diaphragm eventration, which has no apparent effects on 
respiration or health.  Exome sequencing was undertaken for both parents (II.1 and II.2) and 
for the 2 foetuses affected with isolated CDH (III.2 and III.3). 
Family 2 
From the first relationship of the mother (I.2), with partner (I.3), two healthy daughters were 
born (II.5 and II.6).  From her current relationship there were two affected male foetuses 
(II.1 and II.2) and two healthy daughters (II.3 and II.4), see pedigree, Figure 2.  Patient II.1 
was born with microphthalmia and coloboma of the retina, a left-sided posterolateral 
diaphragmatic hernia, and an atrial septal defect (ASD).  He was deceased at day 0, with 
confirmation of the clinical findings by pathology examination.  Patient II.2 had multiple 
anomalies that were detected at 28 weeks of gestation and manifest as bilateral 
microphthalmia with dens intra-ocular tissue, a large thoraco-lumbar spina bifida and 
hydronephrosis of the left kidney.  He was born at 38 weeks of gestation, with hypospadias 
and disarrayed toes detected postnatally, and he was deceased after 10 days due to 
respiratory insufficiency.  No post-mortem examination was performed.  A potential 
diagnosis of MCOPS9 or Matthew Wood syndrome [OMIM #601186] was made, but 
mutation analysis of the STRA6 gene was negative for any causal variants in patient II.2 
(performed at the Institute for Human Genetics, Erlangen, Nurnberg, Germany).  Exome 
sequencing was undertaken for both affected foetuses (II.1 and II.2) and the parents (I.1 and 
I.2). 
Family 3 
The index is a foetus, the first pregnancy of consanguineous parents (first cousins, once 
removed), of North-African descent.  Pregnancy was terminated at a gestational age of 16 
weeks because of a diaphragmatic hernia and associated malformations.  At autopsy, facial 
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dysmorphism was observed (figure 1a & b); a broad nose, hypertelorism, anteversion of the 
nostrils and low set, dysplastic ears.  There was a hygroma colli and mild axillary pterygia, a 
cleft palate, and small penis with hypospadias.  The left foot (figure 1c) was abnormal with 
oligodactyly (absence of rays 3-5), and hypoplasia of the remaining toes; the first toe had no 
nail and lacked a proximal phalanx, the second ray lacked a nail, and the middle phalanx was 
missing.  Attached to the left heel, there was a synovial cyst (figure 1a and c).  The right foot 
appeared normal.   Internal examination confirmed the bilateral postero-lateral 
diaphragmatic hernia.  There were cardiovascular anomalies, a muscular VSD, overriding 
aorta, hypoplastic pulmonary trunk, an aberrant retro-esophageal right subclavia (lusoria).  
There was gut malrotation, cryptorchidism, and the kidneys revealed segmental renal 
dysplasia.  Images of the foetus are shown in Figure 1 (A-C).  The affected foetus (II.1) and 
both parents (I.1 and I.2) underwent exome sequencing. 
 
Figure 1. Images of the affected foetus. A. Full body view, from right. B. Frontal view showing head 
and chest. C. Close-up of left foot. 
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Pedigrees 
Figure 2.  Pedigrees for Family 1; Family 2; and Family 3.   
 
  Family 1. 
 
Family 2. 
 
 
 
 
 
 
Family 3.         
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Results 
Exome Sequencing Quality Metrics 
The tables below (Table 3; Table 4; and Table5) provide quality metrics for a number of key 
parameters provided by Picard metrics (http://picard.sourceforge.net/index.shtml).  The 
associated graphs, shown in Figure 3, provide % target bases covered at 2x, 10x, 20x, and 
30x coverage. 
Patient 
Total Reads 
(number) 
Aligned 
Reads 
(number) 
Aligned 
Reads (%) 
Mean 
Coverage of 
Target Region 
Target Fold 
Enrichment 
Targets with 
Zero 
Coverage (%) 
III.2 60329403 59631806 98.8 72 38 2.2 
III.3 55295963 54638871 98.8 65 38 2.2 
II.1 76908967 75873223 98.7 91 39 1.8 
II.2 67560828 66679281 98.7 77 37 2.1 
Table 3; Exome Sequencing Quality Metrics for Family 1. 
 
Patient 
Total Reads 
(number) 
Aligned 
Reads 
(number) 
Aligned 
Reads (%) 
Mean 
Coverage of 
Target Region 
Target Fold 
Enrichment 
Targets with 
Zero 
Coverage (%) 
I.2 52744438 50996671 96.7 39 22 13 
I.1 64301594 60844058 94.6 42 20 11 
II.1 65003977 62669610 96.4 43 20 11 
II.2 59010896 56759670 96.2 36 19 10 
Table 4; Exome Sequencing Quality Metrics for Family 2. 
 
Patient 
Total Reads 
(number) 
Aligned 
Reads 
(number) 
Aligned 
Reads (%) 
Mean 
Coverage of 
Target Region 
Target Fold 
Enrichment 
Targets with 
Zero 
Coverage (%) 
I.1 82405961 82083567 99.6 50 21 2.1 
I.2 79009381 78746637 99.7 49 21 2.4 
II.1 85315952 85012247 99.6 52 21 2.2 
Table 5; Exome Sequencing Quality Metrics for Family 3. 
Tables 3, 4, 5. The tables above provide metric details for; Total Read number; Aligned Reads number; 
% Reads Aligned; Mean Target Coverage; Target Fold Enrichment; % Targets with Zero Coverage.  
Details are provided per individual and displayed by family. 
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Family 1.  
 
Family 2. 
 
Family 3. 
 
Figure 3.  The graphs above provide values for the percentage of target bases covered at 2x, 
10x, 20x, and 30x coverage.  Values are provided per individual and displayed by family. 
 
  
122 
 
Results:  Family 1 
Retrospective chromosomal microarray analysis of fetal material from both affected 
foetuses revealed no pathogenic CNVs.  With two affected foetuses with isolated CDH a 
familial cause was suspected.  We therefore applied exome sequencing in the two affected 
foetuses (III.2 and III.3) and the parents (II.1 and II.2) to search for inherited variants which 
could explain the cause of recurrent CDH in this family. 
Exome-seq and Variant Filtering Strategy. 
Variant filtering using Excel for a possible recessive cause (i.e. homozygous or compound 
heterozygote variants in the affected individuals) identified no obviously pathogenic 
candidate variants when filtering against dbSNP.  However, when filtered against variants 
present in the 1000genomes database rather than dbSNP, a candidate pathogenic variant 
was identified in both affected individuals (III.2 and III.3).  Details of the parameters used are 
provided in Table 6 and Table 7. Functional predictions were used to filter for damaging non-
synonymous variants. Variant filtering identified a stop (nonsense) mutation in exon 4 of 
ZFPM2 [NM_012082: ENST00000407775: c.C334T: p.Arg112*].  Since this mutation creates a 
premature stop codon the identification of this variant was aided by manual filtering of stop-
gain or –loss, and splice site mutations against a list of candidate CDH genes.  ‘Annotate-it’ 
(Sifrim et al., 2012) was also used for variant filtering to search for compound heterozygote 
variants, but did not reveal any apparently plausible candidate variants.  Using criteria to 
search for rare variants in both affected individuals and inherited from one of the parents, 
the same ZFPM2 p.Arg112* variant was identified by Annotate-it.  Again, identification of 
the candidate variant was aided by filtering against a list of candidate CDH genes.  The ability 
to combine filtering strategies in annotate-it across multiple samples created far more 
manageable candidate variant lists from which to identify the potential pathogenic variant.  
The candidate variant details are provided in Table 8.   
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   III.2 III.3 
  Total number of 
Variants 
41836 40100 
 Quality Filter Depth > 10 
Q (phred) > 30 
31733 31035 
 Variant Type Non-synonymous total 
Not dbSNP 
Not 1000g 
Rare Variant <1%  
<1% or absent 
1000g 
10756 
761 
1184 
252 
(1436 combined) 
10698 
677 
1106 
243 
(1349 
combined) 
 Stop Gain Total 
Not dbSNP 
130 
12 
103 
10 
 Stop Loss Total 
Not dbSNP 
24 
1 
26 
0 
 Exonic Splicing Total 
Not dbSNP 
395 
14 
389 
17 
Table 6.  Excel Variant Filtering 
 
  Rare Paternal 
Variants 
Rare Maternal Variants Compound 
Heterozygote 
Included 
Samples 
 III.2, III.3, II.1(pat) 
In at least 3 samples 
III.2, III.3, II.2(mat) III.2, III.3 
compound 
heterozygote 
Excluded 
Samples 
 II.2(mat) II.1(pat) None 
Filter Included 
Samples 
 Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
Filter Excluded 
Samples 
 Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
None 
 Variant Type Nonsense 
Splice Site 
Non-synonymous 
Synonymous 
UTR 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
dbSNP  Not used Not used Not used 
1000genomes Population 
Frequency 
< 1% < 1% < 1% 
200 Danish 
Exomes 
 Not used Not used Not used 
Prediction 
Criteria 
SIFT 
Polyphen2 
LRT 
Mutation Taster 
NO [YES] NO [YES] NO [YES] 
Total number 
of Variants 
 58 [5] 63 [4] 11 [0] 
Table 7.  Annotate-it Variant Filtering 
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 III.2 III.3 II.1 
(Father) 
II.2 
(Mother) 
Chromosome 8 8 8 8 
Position 106573623 106573623 106573623 106573623 
Gene Name ZFPM2 ZFPM2 ZFPM2 ZFPM2 
Depth 40 26 28 32 
Reference Allele C C C C 
Number of reads with Ref. allele [freq.] 25 [0.62] 15 [0.57] 28 [1.0] 11 [0.34] 
Alternate Allele T  T - T 
Number of reads with Alt. allele [freq.] 15 [0.37] 11 [0.42] - 21 [0.65] 
Mutation Type Nonsense Nonsense - Nonsense 
Refseq accession ID NM_012082 NM_012082 - NM_012082 
Mutation DNA c.C334T c.C334T - c.C334T 
Mutation Protein p.Arg112*  p.Arg112*  - p.Arg112* 
Functional Predictions; 
- SIFT 
- Polyphen2 
- LRT 
- Mutation Taster 
None None - None 
Confirmed by Sanger Seq Yes Yes Yes Yes 
dbSNP132 – dbSNP137 rs121908602 
probable 
pathogenic 
allele 
rs121908602 
probable 
pathogenic 
allele 
 rs121908602 
probable 
pathogenic 
allele 
Table 8.  Variant Details for Main Candidate 
In order to exclude germline mosaicism as a contributory factor, de novo variants were 
searched for.  This did not reveal any apparent de novo events which were shared by both 
affected individuals.  To exclude that a second causal variant in ZFPM2 was removed by the 
variant filtering process or had no read coverage, the .bam files were manually checked in a 
genome browser for each exon of ZFPM2 for each individual.  All exons of ZFPM2 are 
covered sufficiently (>15x coverage) with no additional mutation(s) observed, except for the 
first 9 and 12 bases of exon 1, covered at 5x and 4x respectively in the 2 affected individuals.  
None of those reads contained any ZFPM2 variant in those bases with low coverage in any 
individual.  The full list of rare variants for both affected individuals is provided in 
supplementary tables S3 and S4 (depth>10; Q>30; population frequency <0.03; and coding). 
Familial Analysis 
Mutation analysis for the p.Arg112* mutation by conventional Sanger sequencing confirmed 
the presence of the mutation in both siblings (III.2 and III.3) and the mother (II.2).  In 
addition, other family members (III.4, I.1, and I.2) were subsequently tested for the presence 
of this variant, shown in Figure 4.   The sibling with a TAPVR (III.4), who was also shown to 
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have a mild diaphragmatic eventration, was confirmed to have inherited the same maternal 
p.Arg112* mutation.  Images of the diaphragm eventration which was visible on X-ray after 
surgical correction of the TAPVR are shown in Figure 5.  In order to determine if the variant 
had occurred de novo in the mother (II.2) those grandparents (I.1 and I.2) were tested which 
revealed the variant was inherited from the maternal grandfather (I.1).  The maternal sister 
(II.3) was subsequently tested, which was also positive for the same variant.  The mother of 
the affected foetuses (II.2), her father (I.1) and her sister (II.3) all carry the ZFPM2 p.Arg112* 
variant, but are all asymptomatic with no diaphragm or heart abnormalities reported in any 
of these individuals.  Individuals III.1, II.4, and foetus III.5 were not tested. 
 
Figure 4.  Family 1 Pedigree;  Individuals II.1, II.2, III.2, and III.3 underwent exome-sequencing which 
revealed the R112X mutation in the ZFPM2 gene in both affected individuals (III.2 and III.3) as well the 
asymptomatic mother (II.2).  Further analysis of additional family members revealed that the sibling 
III.4, affected with a TAPVR also shares the mutation which is likely to be responsible for the heart 
defect.  The grandfather (I.1), and the maternal sister (II.3), both of whom are asymptomatic also 
carry the mutation.  Individuals III.1, II.4, and foetus III.5 were not tested (n.t.).  WT = wild type allele 
(II.1 and I.2). 
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Figure 5. Shows the diaphragm eventration observed on X-ray in the sibling affected with a total 
anomalous pulmonary venous return (TAPVR) who was shown to also carry the p.Arg112* ZFPM2 
mutation. The left image shows the frontal view and the right image shows the view from the patients 
left side. The anterior right sided diaphragm eventration is highlighted with the white arrow heads. 
 
Discussion:  Family 1  
We undertook exome sequencing in a familial case of isolated CDH which identified a 
heterozygous nonsense mutation (p.Arg112*) in the ZFPM2 (or FOG2) gene in 2 foetuses 
affected with isolated CDH.  The ZFPM2 p.Arg112* mutation has a dbSNP entry 
(rs121908602) and is therefore removed when filtering against dbSNP variants (from 
dbSNP132 onwards).  In dbSNP this ‘SNP’ is annotated as a pathogenic allele, albeit observed 
in only one individual in association with a diaphragmatic eventration (Ackerman et al., 
2005).  The ZFPM2 gene has been previously investigated for a role in CDH following 
identification of diaphragm and primary lung abnormalities in an ENU-derived mouse model 
(Ackerman et al., 2005).  The authors subsequently sequenced the ZFPM2 gene in 30 
(deceased) CDH patients and reported a heterozygous nonsense mutation, shown to have 
occurred de novo, in a patient who died at birth with severe pulmonary hypoplasia and a 
posterior diaphragmatic eventration (Ackerman et al., 2005).  Interestingly, it is the exact 
same p.Arg112* variant which we identify in this study.  Bleyl et al sequenced the ZFPM2 
gene in an additional 96 individuals with CDH and identified novel sequence alterations 
predicting p.M703L and p.T843A in two patients with isolated CDH.  However, due to the 
lack of parental DNA samples the authors were not able to determine if the sequence 
alterations were de novo (Bleyl et al., 2007).  In order to determine the potential functional 
effects of those mutations, we manually checked the Exome Variant Server (EVS) database 
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for their presence in normal individuals, and SIFT and PolyPhen-2 functionally damaging 
predictions were calculated.  The M703L mutation is not present in the EVS database, is 
predicted tolerated by SIFT, and identified as possibly damaging (HumDiv) or probably 
damaging (HumVar) by Polyphen-2.  The T843A mutation is also not present in the EVS 
database, is also predicted tolerated by SIFT, and possibly damaging (HumDiv) or benign 
(HumVar) by Polyphen-2.  ZFPM2 mutation analysis alone is thus somewhat inconclusive as a 
cause of isolated CDH, with only a single deleterious de novo mutation so far associated with 
a diaphragmatic eventration (Ackerman et al., 2005). 
Evidence from chromosomal microarray analysis of CDH patients however does add further 
support for pathogenicity.  Chromosomal microarray analysis revealed submicroscopic copy 
number variations (CNVs) causing (partial) deletion of ZFPM2 considered causal for CDH, but 
which were transmitted from an apparently unaffected parent (Wat et al., 2011).  The 
authors propose that haploinsufficiency of ZFPM2 can cause dominantly inherited isolated 
diaphragmatic defects with incomplete penetrance.  Kuechler et al have previously 
described 5 patients with overlapping deletions of 8q22q23 (Kuechler et al., 2011).  In 2 of 
these patients the ZFPM2 was partially deleted; one had CDH and the other had a hiatal 
hernia.  There are no nonsense, splicing or frameshift mutations in ZFPM2 reported in the 
exome variant server database, and no CNVs exist in the database of genomic variants (DGV) 
of whole gene deletions of ZFPM2 in normal individuals. 
Taken together, the previous finding of the identical mutation in a foetus with diaphragmatic 
eventration, evidence from the ZFPM2 (Fog2) ENU mouse model of CDH and pulmonary 
hypoplasia, and supporting evidence from chromosomal microarray analysis in patients with 
CDH, this variant is likely to be the cause of the isolated CDH (and diaphragm eventration) in 
those affected in this family.  This finding thus represents the first inherited ZFPM2 mutation 
associated with recurrent isolated CDH in a single family and adds further evidence for 
haploinsufficiency of ZFPM2 as a cause of CDH.  The presence in one family member (III.4), 
with a heart defect and mild diaphragm eventration, as well as further family members who 
are apparently asymptomatic (I.1, II.2, and II.3) reinforces the considerable complexity 
associated with CDH penetrance.  This mutation displays apparent autosomal dominant 
inheritance with variable penetrance. 
The previous observations of heart defects in association with ZFPM2 variants suggests that 
the p.Arg112* variant present in individual III.4 may also be responsible for the TAPVR in this 
child.  Heterozygous missense mutations of the ZFPM2 gene have been reported in patients 
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with sporadic tetralogy of Fallot (TOF) (Pizzuti et al., 2003).  Similar to Tetralogy of Fallot 
(TOF), double outlet right ventricle (DORV) is a conotruncal heart defect (CTD) and is 
anatomically characterized by a malposition of the great arteries.  Sequencing of ZFPM2 has 
also revealed novel rare variants in patients with sporadic DORV, TOF, and/or transposition 
of the great arteries (Tan et al., 2012).  To date, there is no definitive correlation with TAPVR, 
but it is plausible that this is not incidental.  Interestingly, Yu et al recently applied whole 
exome sequencing (WES) to identify a paternally inherited novel missense GATA4 variant 
(c.754C>T; p.R252W) in a familial case of CDH which was also associated with incomplete 
penetrance.  Detailed phenotypic characterization of additional family members by MRI of 
the chest and abdomen revealed asymptomatic defects in the diaphragm of the two 
"unaffected" missense variant carriers (Yu et al., 2012).   
ZFPM2 interacts with GATA4 and both are considered essential for diaphragm development 
as well as pulmonary development and heart development from multiple studies in animal 
models (Molkentin et al., 1997; Crispino et al., 2001; Ackerman et al., 2005; Ackerman et al., 
2007; Zhou et al., 2009; Jay et al., 2007).  The RA pathway is illustrated in Figure 1.2.4, 
(Chapter 1, this thesis), including the involvement of ZFPM2 (Fog2), GATA4 and NR2F2 in 
regulation of RA dependent gene transcription.  SUMO modifications are post-translational 
processes which regulate the biological activity of many proteins by the addition of a small 
ubiquitin-related modifier (SUMO) protein to target lysine residues.  It has been shown 
recently that the biological activity of ZFPM2 is dependent on intact SUMOylation sites, with 
ZFPM2 (Fog2) SUMO mutants displaying stronger transcriptional repression and more 
efficient interaction with GATA4 (Perdomo et al., 2012).  Since SUMOylation is a dynamic 
and reversible process, it provides a potential mechanism for rapid fine-tuning of ZFPM2 
activity, which if affected may increase the risk of CDH development in susceptible 
individuals. 
Genetic counseling in this family is challenging; there are at least three persons in this family 
who are carriers of this mutation and who have no manifestations.  This is known for other 
dominant conditions and thus probably points to additional genetic and / or environmental 
influences, for example, variants inherited from the other parent or epigenetic factors.  To 
explore the potential presence of modifier variants in genes implicated to interact with 
ZFPM2, exome sequences were searched for rare paternal variants, including ZFPM2 
interacting genes involved in RA pathway; NR2F2 and GATA4.  This manual search revealed 
no candidate variant identifiable as a ‘second-hit’ inherited from the father.  The finding of 3 
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asymptomatic family members clearly demonstrates that haploinsufficiency of ZFPM2 alone 
is not necessary, but can be sufficient to cause CDH in combination with as yet unidentified 
(epi-)genetic and/or environmental influences. 
 
Results:  Family 2 
Chromosomal microarray analysis of fetal material from both affected foetuses revealed no 
pathogenic CNVs.  A clinical diagnosis of Matthew-Wood syndrome was excluded in the 
second affected child by mutation analysis of the STRA6 gene by conventional Sanger 
sequencing.  Given the high likelihood of a recessive or X-linked mode of inheritance as the 
cause of the severe phenotypic features, we applied exome sequencing in the 2 affected 
foetuses (II.1 and II.2), as well as both parents (I.1 and I.2). 
Exome-seq and Variant Filtering Strategy 
Variants were filtered on quality parameters, variant type and against the annotated 
population databases using Excel and annotate-it as shown in Table 9 and Table 10.  Filtering 
was performed in Excel for the two affected individuals (II.1 and II.2) for possible 
mechanisms of inheritance (i.e. homozygous or compound heterozygote variants, or 
possible X-linked inheritance).  Variant filtering was aided by filtering against variants 
present in dbSNP, the 1000 genomes database, and by using functional predictions 
(provided from SIFT, Polyphen2, and Mutation Taster).  A shortlist of only around 30 non-
synonymous variants remained in each affected individual (II.1 and II.2) which contained a 
strong candidate variant; a missense mutation in the PORCN gene [NM_203474: 
ENST00000326194: c.G470A:p.G157D.  Annotate-it was used for variant filtering to search 
for compound heterozygote variants, but of 11 compound heterozygote variants shared by 
both affected individuals, none were predicted functionally damaging.  Using criteria to 
search for rare variants in both affected individuals and inherited from one of the parents, 
the PORCN G157D variant was identified as a strong candidate.  Annotate-it provides text-
based genotype-phenotype associations (according to HPO and LDDB terms) from ‘A Gene 
Apart’ and respective p-values for this association.  Both anophthalmia (p-value (1.348 E-05) 
and congenital hernia of diaphragm (p-value 7.655 E-03) are listed in association with the 
candidate variant in PORCN thus aiding the candidate variant identification process in this 
situation.  The details for the candidate variant are shown in Table 11. 
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   II.1 II.2 
  Total number of Variants 52226 52169 
 Quality Filter Depth > 10 
Q (phred) > 30 
31361 30538 
 Variant Type Non-synonymous total 
Not dbSNP 
Not 1000g 
Rare Variant <1% 1000g 
1000g combined 
dbSNP & 1000g 
 
SIFT 
PolyPhen 
Mutation Taster 
Predictions combined 
10696 
660 
1084 
241 
(1325 combined) 
412 
 
160 
60 
77 
(28 combined) 
10449 
670 
1106 
242 
(1348 combined) 
438 
 
147 
61 
69 
(32 combined) 
 Stop Gain Total 
Not dbSNP 
111 112 
18 
 Stop Loss Total 
Not dbSNP 
27 25 
0 
 Exonic Splicing Total 
Not dbSNP 
404 380 
10 
Table 9.  Excel Variant Filtering 
 
 
  Rare Paternal 
Variants 
Rare Maternal Variants Compound 
Heterozygote 
Included Samples  II.1, II.2, I.1(pat) 
In at least 3 samples 
II.1, II.2, I.2(mat) II.1, II.2 
Genes must be 
compound 
heterozygote 
Excluded Samples  I.2(mat) I.1(pat) None 
Filter Included Samples  Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
Filter Excluded Samples  Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
None 
 Variant Type Nonsense 
Splice Site 
Non-synonymous 
Synonymous 
UTR 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
dbSNP  Not used Not used Not used 
1000genomes Population 
Frequency 
< 1% < 1% < 1% 
200 Danish Exomes  Not used Not used Not used 
Prediction Criteria 
All 4 used / None used 
SIFT 
Polyphen2 
LRT 
Mutation Taster 
NO [YES] NO [YES] NO [YES] 
Total number of Variants  49 [5] 60 [7] 11 [0] 
Table 10.  Annotate-it Variant Filtering 
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 II.1 II.2 I.1 (Father) I.2 (Mother) 
Chromosome X X X X 
Position 48370810 48370810 48370810 48370810 
Gene Name PORCN PORCN PORCN PORCN 
Depth 57 37 37 73 
Reference Allele G G G G 
Number of reads with Ref. 
allele [freq.] 
0 [0] 0 [0] 37 [1.0] 42 [0.57] 
Alternate Allele A A - A 
Number of reads with Alt. 
allele [freq.] 
57 [1.0] 37 [1.0] - 31 [0.42] 
Mutation Type nonsynonymous nonsynonymous - nonsynonymous 
Refseq accession ID NM_203474 NM_203474 - NM_203474 
Mutation DNA c.G470A c.G470A - c.G470A 
Mutation Protein p.G157D p.G157D - p.G157D 
Functional Prediction 
- SIFT 
- Polyphen2 
- LRT 
- Mutation Taster 
 
Damaging 
Probably Damaging 
Deleterious 
Disease Causing 
 
Damaging 
Probably Damaging 
Deleterious 
Disease Causing 
-  
Damaging 
Probably 
Damaging 
Deleterious 
Disease Causing 
Confirmed by Sanger Seq Yes Yes Yes Yes 
Table 11.  Variant Details for Main Candidate 
Familial Analysis & X-inactivation analysis. 
Mutations in PORCN are associated with Goltz-Gorlin syndrome Focal Dermal Hypoplasia 
(FDH; OMIM #305600), an X-linked dominant disorder in which heterozygous females are 
expected to be affected.  Conventional Sanger sequencing of the PORCN gene confirmed the 
presence of the PORCN G157D mutation in the mother (I.2) and both affected males (II.1 
and II.2).  Analysis of the 4 daughters revealed the same mutation to be present in II.3 and 
II.4, but not in II.5 and II.6.  We therefore investigated the X-inactivation status in genomic 
DNA from the mother (I.2) and the 4 daughters from both relationships (II.3 and II.4; and II.5 
and II.6).  This revealed extreme skewing of X-inactivation (90%/10%) in the heterozygous 
mother; and levels of 88%/12% and 70%/30% in the 2 heterozygous daughters (II.3 and II.4, 
respectively) for the same maternally inherited X chromosome.  One of the heterozygous 
female carriers, initially considered unaffected (II.4), displayed aplasia cutis on the scalp, 
shown in Figure 6.  The 2 daughters who do not carry the mutation (II.5 and II.6) showed 
random X-inactivation with levels of 54%/46% and 67%/33%, respectively and inheritance of 
the alternate maternal X chromosome.  The pedigree is shown in Figure 7, including the 
results of the X-inactivation analysis. 
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Figure 6. Cutis aplasia of the scalp in female II.4. 
 
 
Figure 7.  Family 2 Pedigree;  Individuals I.1, II.2, II.1, and II.2 underwent exome-sequencing which 
revealed the G157D mutation in the PORCN gene in both affected individuals (III.2 and III.3) as well 
the asymptomatic mother (I.2) who was shown to have 90% skewing of X-inactivation.  Further 
analysis of additional family members revealed that the two female siblings II.3 and II.4 also carry the 
mutation, with 88% and 70% skewing of X-inactivation, respectively.  The two females from the 
previous relationship (II.5 and II.6) have not inherited the mutation and demonstrate 54% and 67% 
skewing of X-inactivation, respectively.  Individual I.3 was not tested. 
Discussion:  Family 2 
We describe the first case of non-mosaic males affected with syndromic microphthalmia due 
to a non-synonymous mutation in the PORCN gene.  The 2 foetuses were affected with 
multiple congenital anomalies including; microphthalmia, CDH and an ASD (II.1); and 
bilateral microphthalmia and spina bifida (II.2).  To our knowledge, there are 4 previous 
cases reported of a PORCN mutation in association with syndromic CDH; a female foetus 
with multiple congenital anomalies including CDH, limb anomalies, microphthalmia, and lung 
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anomalies; a female with phenotypic features consistent with FDH and Pentalogy of Cantrell, 
including an anterior diaphragmatic hernia; and 2 unrelated female foetuses born to 
affected mothers who displayed ectopia cordis, diaphragmatic hernia and abdominal wall 
defects (Maas et al., 2009; Smigiel et al., 2011; Dias et al., 2011).  Our finding thus adds 
further support for PORCN mutations as a cause of syndromic CDH and not a coincidental 
association. 
Mutations in PORCN were first reported as a cause of Focal Dermal Hypoplasia in 2007 
(Wang et al., 2007; Grzeschik et al., 2007), and Froyen et al later identified PORCN mutations 
and deletions in a cohort of patients with a clinical diagnosis of FDH (Froyen et al., 2009).  
FDH is characterized by phenotypic features including; longitudinal striation of the long 
bones, the combination of split hand with syndactyly and absence of rays (also termed 
‘lobster-claw hand’), as well as atrophy and linear pigmentation of the skin, herniation of fat 
through dermal defects, and multiple papillomas of the mucous membranes or skin. Oral 
anomalies, in addition to lip papillomas, include hypoplastic teeth, and ocular anomalies 
including coloboma of iris and choroid, strabismus, and microphthalmia have also been 
reported.  Mental retardation occurs in many of the patients.  Recently, a ‘mutation update’ 
for PORCN reported a number of new cases and reviewed those reported to date (Lombardi 
et al., 2011).   
Interestingly, FDH is observed in heterozygous females, whereas the few reports in affected 
males are limited to cases of somatic mosaic.  FDH due to PORCN mutations are thus an X-
linked dominant condition which, until now, were considered to result in in utero lethality in 
males.  Our finding thus represents the first report of affected non-mosaic males, adding 
evidence for PORCN mutations in males as a cause of phenotypic features including eye 
anomalies, diaphragm defects, spina bifida, cardiac defects, kidney defects and syndactyly / 
polydactyly.  This is in contrast to some of the characteristic phenotypic features more 
commonly seen in females affected with Goltz-Gorlin syndrome or focal dermal hypoplasia.  
The possible clinical diagnosis of Matthew-Wood syndrome (MWS) / Microphthalmia, 
Syndromic 9 (MCOPS9) (OMIM #601186) due to overlap of some phenotypic features may 
suggest that some male foetuses without a genetic diagnosis of MWS due to STRA6 
mutation, may have mutation of PORCN.      
PORCN (Porcupine) is involved in the trafficking of Wnt proteins between the ER and Golgi, 
as shown in Figure 8, adapted from reviewed in (Clements, 2009).  Defective PORCN impairs 
transfer of Wnt proteins through the cell leading to reduced Wnt secretion affecting 
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downstream pathways reliant on Wnt signalling.  The mutation observed likely encodes a 
hypomorphic allele with reduced function.  Wnt signalling is essential for many aspects of 
embryonic development and this explains the constellation of congenital anomalies in 
multiple organs.  A conditional mouse model of PORCN was used to study its requirement in 
Wnt signaling and embryonic development (Barrott et al., 2011).  Consistent with the 
female-specific inheritance pattern of FDH, Porcn hemizygous male embryos arrest during 
early embryogenesis and fail to generate mesoderm, a phenotype previously associated with 
loss of Wnt activity. Heterozygous Porcn mutant females exhibit a spectrum of limb, skin, 
and body patterning abnormalities resembling those observed in human patients with FDH.  
In a conditional mouse model of PORCN loss of function defects were observed in 
ectodermal and mesenchymal derived structures (Liu et al., 2012).  It has been proposed 
that CDH originates from a defect in the mesenchymal cells of the developing 
pleuroperitoneal folds (PPFs) and this provides a plausible mechanism for the development 
of CDH seen in one of our patients.  
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Figure 8.  Provides an overview of the role of PORCN in the trafficking of WNT proteins through the ER 
to the golgi.  WNT proteins are glycosylated and lipid modified by PORCN (Porcupine) in the ER, where 
they are subsequently escorted through the Golgi to the plasma membrane for secretion by Wntless.  
Defective PORCN results in reduced WNT secretion. 
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Results:  Family 3 
Chromosomal microarray analysis did not reveal any pathogenic CNVs in the fetus referred 
due to MCA including CDH.  Due to the consanguineous relationship of the parents a genetic 
cause was suspected and we undertook exome sequencing in the parent-fetus trio (I.1, I.2, 
and II.1).  We assumed a homozygous recessive mutation as the likely cause given the 
consanguineous relationship.   
Variant filtering was performed with two approaches; using excel, and using annotate-it 
(Sifrim et al., 2012).  Annotated variant files for the affected individual (II.2) were filtered in 
Excel on quality parameters, variant type, and by dbSNP137 and/or the ESP6500 annotation.  
Variant frequency was also used to identify homozygous mutations.  Of 3 splice variants 
remaining after variant filtering, a homozygous splice variant was identified in the affected 
patient as a plausible candidate; PIGN (NM_012327:exon17:c.1574+1G>A, 
NM_176787:exon18:c.1574+1G>A).  Checking the variant files of both parents revealed that 
they both carry the heterozygous form.  Details of variant filtering are given in table 12.   
Annotate-it was also used to identify candidate variants assuming a homozygous recessive 
or de novo cause.  The variant filtering strategy using annotate-it is provided in Table 13.  No 
likely candidate variants were identified assuming a de novo mutation as the possible cause.  
Searching for a homozygous recessive mutation as the cause revealed a candidate splice 
variant in the PIGN gene present in homozygous form in the affected foetus (II.1) and 
present in heterozygous state in both parents (I.1 and I.2).  The splice mutation identified as 
a possible candidate has been observed once in the exome variant server database (var.freq. 
0.000083) in heterozygous form, but is seen in homozygous state in our patient.  Details of 
the candidate variant are shown in Table 14, and the pedigree in Figure 9. 
 
Figure 9.  Family 3 Pedigree;  All individuals I.1, II.2, and II.1 
underwent exome-sequencing which revealed the c.1574+1G>A 
splice mutation in the PIGN gene in all individuals, present in 
homozygous form in the affected foetus (II.1) and heterozygous 
form in the parents (I.1 and I.2). 
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   II.1 
  Total number of Variants 81698 
 Quality Filter Depth > 10 
Q (phred) > 30 
46200 
 Variant Type Non-synonymous total 
Not dbSNP137 
Rare Variant <1% ESP6500 
dbSNP137 & ESP6500 
var freq. >0.8 
SIFT 
PolyPhen 
Mutation Taster 
Predictions combined 
11829 
259 
431 
30 
3 
 
 
 Stop Gain Total 
Not dbSNP137 
171 
 Stop Loss Total 
Not dbSNP137 
66 
 Exonic Splicing Total 
Not dbSNP137 
Rare Variant <1% ESP6500 
var freq. >0.8 
7144 
671 
26 
3 
 Frameshift substitution total 114 
Table 12.  Excel Variant Filtering 
 
  Consanguineous 
Homozygous Recessive Variant 
De novo 
Included Samples  II.1, I.1, I.2  
In at least 3 samples 
II.1 
Excluded Samples  None I.1, I.2 
Filter Included Samples  Min. Depth: 10 
Var. Freq.: 30-100% 
Min. Depth: 10 
Var. Freq.: 30-100% 
Filter Excluded Samples  None Min. Depth: 10 
Var. Freq.: 30-100% 
 Variant Type Nonsense 
Splice Site 
Non-synonymous 
Synonymous 
UTR 
Yes 
Yes 
Yes 
No 
No 
Yes 
Yes 
Yes 
No 
No 
dbSNP  Not used Not used 
1000genomes Population Frequency < 1% < 1% 
200 Danish Exomes  Not used Not used 
Prediction Criteria SIFT 
Polyphen2 
LRT 
Mutation Taster 
NO [YES] NO [YES] 
Total number of Variants  48 [0] 32 [0] 
Table 13.  Annotate-it Variant Filtering 
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 Affected Father Mother 
Chromosome 18 18 18 
Position 59777066 59777066 59777066 
Gene Name PIGN PIGN PIGN 
Depth 15 16 15 
Reference Allele C C C 
Number of reads with 
Ref. allele [freq.] 
0 [0] 6 [0.37] 10 [0.66] 
Alternate Allele T T T 
Number of reads with 
Alt. allele [freq.] 
15 [1.0] 10 [0.62] 5 [0.33] 
Mutation Type Splicing Splicing Splicing 
Refseq accession ID NM_012327:exon17; 
NM_176787:exon18 
NM_012327:exon17; 
NM_176787:exon18 
NM_012327:exon17; 
NM_176787:exon18 
Mutation DNA c.1574+1G>A c.1574+1G>A c.1574+1G>A 
Mutation RNA NM_012327:exon17 
Exon skipped 
NM_012327:exon17 
Exon skipped 
NM_012327:exon17 
Exon skipped 
Mutation Protein Predicted frameshift 
and truncated protein 
Predicted frameshift 
and truncated protein 
Predicted frameshift 
and truncated protein 
Functional Prediction 
- SIFT 
- Polyphen2 
- LRT 
- Mutation 
Taster 
None None None 
Confirmed by Sanger 
Seq 
Yes Yes Yes 
EVS: Number [freq.] Homozygous form not 
observed 
1/12029 [0.000083] 1/12029 [0.000083] 
Table 14.  Variant Details for Main Candidate 
In order to determine the consequences of the PIGN splice site mutation exon junction 
primers were designed spanning exons 15/16 and exons 18/19 (NM_012327).  cDNA was 
reverse transcribed from mRNA isolated from cultured foetal skin fibroblasts from the 
affected patient.  Exon junction PCR on the cDNA sample demonstrated a PCR product of 
~310bp in size consistent with skipping of exon 17 as shown in Figure 10.   
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Exon-Junction PCR 
 
 
In order to confirm this interpretation and to check for the potential involvement of a cryptic 
splice site, this PCR product was sequenced by conventional Sanger sequencing which 
confirmed this interpretation of skipping of exon 17.  This novel splicing event is predicted to 
cause a frameshift due to the aberrant splicing of exons 16 and 18 which would be predicted 
to lead to premature truncation of the protein, as shown in Figure 11. 
Predicted effect on Protein 
=================== Exon 16 =============================   =================== 
VSLCKELIHLALKGLSYYHTYDRFFLGVNVVIGFVGWISYASLLIIKSHSNLIKGVSKEVK KPSHLLPCSFVAIGILVAFFL 
VSLCKELIHLALKGLSYYHTYDRFFLGVNVVIGFVGWISYASLLIIKSHSNLIKGVSKEVK ---------------------------------- 
 
=Exon 17 ================ ============Exon 18=========== 
LIQACPWTYYVYGLLPLPIWYAVLR  EFQVIQDLVVSVLTYPLSHFVGYLLAFTLGIEVL 
------------------------------------------- ISSYSGPCCISVDLSSEPFCWVPVSLYPGNX 
Figure 11.  Displays part of the amino acid sequence for the PIGN surrounding the splice site 
mutation.  The location of exon 16, 17 and 18 is shown on the top row; the normal amino acid 
sequence is displayed on the middle row; and the predicted amino acid sequence generated by the 
splice site mutation on the bottom row.  The mutation is predicted to cause a frameshift due to exon 
skipping of exon 17, and the splicing of exons 16 and 18, leading to a premature stop codon after 30 
novel amino acids translated from the splicing of exon 16 and 18. 
  
Figure 10.  Agarose gel image of the PCR 
products obtained from exon junction RT-PCR in 
the patient and a control sample.  Lane 1 = 
Ladder; Lane 2 = Patient sample; Lane 3 = 
Control sample.  The Control sample shows a 
PCR product of ~450bp, consistent with the 
expected product size.  The patient sample 
shows a PCR product of ~310bp, consistent with 
exon skipping of exon 17. 
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Discussion:  Family 3 
Using exome sequencing we identify a homozygous splice mutation in the PIGN gene in a 
foetus from consanguineous parents, affected with multiple malformations including 
bilateral diaphragmatic hernia.  Recently nonsynonymous PIGN mutations in humans were 
identified as a cause of multiple congenital anomalies-hypotonia-seizures syndrome [OMIM 
#614080] in a large consanguineous family with multiple affected individuals (Maydan et al., 
2011).  CDH was not described in any of the affected individuals.  Our report of a second 
consanguineous family with a mutation in PIGN thus adds to the phenotypic spectrum 
observed with pathogenic autosomal recessive PIGN variants.  This suggests that complete 
loss-of-function nonsense, or splicing mutations, in PIGN can cause severe multiple 
congenital anomalies, including CDH, which are likely to be lethal in the embryonic or 
neonatal phase.  The present case shows phenotypic overlap with the foetuses with a 
suspected diagnosis of Fryns syndrome reported by Ramsing et al (Ramsing et al., 2000), 
including; diaphragmatic hernia, oligodactyly, and cardiac defects.  This raises the possibility 
that some cases with MCA including CDH, which may be clinically classified as Fryns 
syndrome (or-Fryns-like), may be due to autosomal recessive mutations in PIGN, or other 
genes involved in the GPI-anchor biosynthesis pathway.  In our case the homozygous splice 
site mutation predicting a truncated protein is likely responsible for the increased severity of 
the phenotypic features in comparison to the previous report of nonsynonymous mutations 
which may produce hypomorphic alleles.  However, further reports are necessary to 
determine the full phenotypic spectrum associated with different types of variants in PIGN. 
PIGN is involved in GPI anchor biosynthesis.  Glycosylphosphatidylinositol (GPI) anchors 
allow the attached protein to anchor to the outer leaflet of the cell membrane, and perform 
a diverse set of functions including roles in signal transduction, cell adhesion and antigen 
presentation.  GPI anchors are assembled stepwise on phosphatidylinositol (PI) in the ER 
membrane, as shown in Figure 12.  PIGN encodes one of the ethanolamine phosphate (EtNP) 
transferases and has been demonstrated to be essential for the addition of the first EtNP 
unit to the first mannose unit (Hong et al., 2005; Hong et al., 1999; Yada et al., 2001).  A 
number of the genes involved in GPI anchor synthesis have recently been identified as 
causing phenotypes in humans, many by exome sequencing analysis, including; PIGA 
(OMIM*311770), PIGL (OMIM*605947), PIGM (OMIM*610273), PIGN (OMIM*606097), 
PIGO (OMIM*614730), PIGT (OMIM*610272), and PIGV (OMIM*610274), summarized in 
Table 15.  Mutations in many of these genes share overlapping features of MR/ID, seizures, 
cardiac defects, skeletal defects, and dysmorphic features.  The defective GPI anchor caused 
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by mutations in these genes results in the subsequent mis-localisation of GPI anchored 
proteins.  While there is some degree of overlap between these different syndromes, there 
is clearly phenotypic variability between those features depending on which step in the GPI 
anchor synthesis pathway is affected. 
 
Figure 12.  Shows a schematic representation of GPI anchor biosynthesis. PIGA transfers 
phosphatidylinositol (PI) to the cytoplasmic face of the ER, where PIGL undertakes de-N-acetylation of 
N-acetylglucosaminylphosphatidylinositol (GlcNAc-PI).  GlcN-PI is flipped to the ER lumen, where 
PIGW adds an acyl chain (a) to inositol (GlcN-aPI).  PIGM is a mannosyltransferase that adds the first 
mannose (Man) to the core GPI, followed by addition of a second mannose by PIGV.  PIGN 
(highlighted) encodes an ethanolamine phosphate transferase, which adds the ethanolamine 
phosphate (EtNP) to the first mannose on the GPI anchor. PIGB adds a third mannose, to which PIGO 
adds an EtNP, and PIGF adds EtNP to the second mannose.  Several PIG genes are involved in 
anchoring of the entire sugar-lipid unit to proteins with the appropriate C-terminal amino acid 
sequence using a multi-subunit transamidase complex.  A de-acylase finally removes the acyl chain 
generated by PIG-W. 
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Gene Function Phenotypic Features OMIM syndrome Method Reference 
PIGA GlcNAc-PI 
synthesis 
Cleft palate, seizures, 
contractures, brain 
structural malformations, 
early death 
#300868 
Multiple congenital 
anomalies-hypotonia-
seizures syndrome 2 
Exome (Johnston 
et al., 
2012) 
PIGL GlcNAc-PI de-
N-acetylase 
Coloboma, congenital 
heart disease, 
ichthyosiform 
dermatosis, intellectual 
disability, hearing loss 
#280000 
CHIME syndrome 
Exome (Ng et al., 
2012) 
PIGM Mannosyl 
transferase 
venous thrombosis and 
seizures 
#610293 
Glycosylphosphatidyl-
inositol deficiency 
Mapping (Almeida 
et al., 
2006) 
PIGN GPI 
ethanolamine 
phosphate 
transferase 
Hypotonia, psychomotor 
delay, seizures, 
dysmorphic features, 
anomalies in cardiac, 
urinary, and 
gastrointestinal systems. 
#614080 
Multiple congenital 
anomalies-hypotonia-
seizures syndrome 1 
Mapping (Maydan 
et al., 
2011) 
PIGO GPI 
ethanolamine 
phosphate 
transferase 
moderate to severe 
psychomotor 
developmental delay, 
facial dysmorphism, 
brachytelephalangy, 
hyperphosphatasia. 
Additional features 
include cardiac septal 
defects and seizures 
#614749 
Hyperphosphatasia 
with mental 
retardation syndrome 2 
Exome (Krawitz 
et al., 
2012) 
PIGT Catalysis of 
protein 
attachment 
distinct facial features, 
intellectual disability, 
hypotonia and seizures,  
in combination with 
abnormal skeletal, 
endocrine, and 
ophthalmologic findings 
No OMIM entry 
A novel autosomal 
recessive intellectual 
disability syndrome 
Exome (Kvarnung 
et al., 
2013) 
PIGV Mannosyl 
transferase 
mental retardation, 
various neurologic 
abnormalities such as 
seizures and hypotonia, 
and hyperphosphatemia.  
Additional features 
include facial 
dysmorphism and 
brachytelephalangy 
#239300 
Hyperphosphatasia 
with mental 
retardation syndrome 1 
Exome (Krawitz 
et al., 
2010; 
Horn et 
al., 2011) 
 
Table 15.  Lists the genes involved in GPI anchor synthesis in which pathogenic mutations have been 
found in humans, along with the associated phenotypic features, and reference to the OMIM listed 
syndrome.  Adapted and updated from (Freeze, 2013). 
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A recent study investigated the effect of two mouse models, the Pign (gonzo mutant) and 
the Pgap1 (beaker mutant), on Cripto signalling in forebrain development as a model of 
holoprosencephaly (McKean and Niswander, 2012).  Cripto is a GPI anchored protein, and is 
an obligate Nodal co-factor involved in TGFβ signalling.  Defects in Cripto (mouse) and the 
human ortholog TDGF1 have previously been associated with forebrain defects, and Cripto is 
thus considered a key GPI anchored protein which causes an HPE-like phenotype (McKean 
and Niswander, 2012).  Interestingly the authors demonstrate that TGFβ signalling is 
reduced both in vitro and in vivo in these models.  TGF-β1 null mice develop apparently 
normally, but soon die from aggressive pulmonary or gut inflammation due to a failure to 
negatively modulate the immune system (McLennan et al., 2000).  Disruption of TGF-β 
signaling in TAB1 null mice results in lethal cardiovascular and lung abnormalities (Komatsu 
et al., 2002).  Abnormal diaphragm morphology has also been reported in a Tgfb1 mouse 
model; the diaphragm showed inflammation and necrosis which were severe enough to 
interfere with normal respiration (Shull et al., 1992). 
Conclusion 
We demonstrate that exome sequencing can identify pathogenic variants associated with 
both syndromic and isolated CDH where a familial origin is suspected due to multiple 
affected individuals or consanguinity.  In cases of isolated-CDH, with no prior family history, 
the recurrence risk for future pregnancies is often quoted as 1-2%.  However, the application 
of exome sequencing (following a normal chromosomal microarray analysis) may identify 
deleterious mutations which thus allow for a more accurate prediction of recurrence risk, 
which may be up to 50% for CDH or other congenital anomalies in some families.   
We add further evidence for association of ZFPM2 with CDH by identification of a 
heterozygous nonsense mutation in ZFPM2 as a cause of familial isolated CDH in 2 affected 
siblings.  This mutation displays variable phenotypic expression being present in a third 
sibling with a mild diaphragmatic eventration and a TAPVR.  The same variant is seen in the 
mother and 2 additional family members, all of whom are asymptomatic, thus highlighting 
that ZFPM2 haploinsufficiency is associated with reduced penetrance.  Our finding adds 
further evidence for ZFPM2 having a role in diaphragm and cardiovascular development, 
defects in which are associated with an autosomal dominant effect, but with reduced 
penetrance and variable expression.  We add evidence for PORCN mutations in males as a 
cause of multiple congenital anomalies including microphthalmia and CDH by the 
identification of a non-synonymous mutation in PORCN as a cause of Focal Dermal 
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Hypoplasia (FDH) in 2 male foetuses.  This represents the first report of PORCN mutations in 
affected non-mosaic males, highlighting a spectrum of phenotypic features including 
microphthalmia, CDH, neural tube defects, and cardiac anomalies.  The mutation is inherited 
from the mother who showed extreme skewing of X-inactivation.  Two female siblings 
carried the same mutation, one of whom displays mild features of FDH.  We also identified a 
homozygous splice site mutation in PIGN in a foetus with multiple congenital anomalies 
including bilateral CDH.  Our finding expands the phenotypic spectrum associated with 
homozygous loss of function mutations in PIGN, and adds further support for defective GPI 
anchor biosynthesis as a cause of developmental abnormalities.   
Our findings demonstrate that exome sequencing is a valuable approach for the 
identification of a genetic cause for isolated and non-isolated CDH due to inherited 
mutations.  However, conventional methods of variant filtering remain challenging for 
disorders which display reduced penetrance and variable expression between individuals, 
particularly in small family pedigrees with perhaps only a single affected individual. 
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Chapter 6. Gene Expression Analysis of CDH Patients 
Adapted from; 
Gene Expression Profiling by RNA-Sequencing of Amniotic Fluid Cells Distinguishes 
Different Classes of Isolated CDH Foetuses. (Manuscript in preparation) 
P. Brady 1, J. Van Houdt 1, P. DeKoninck 2, J. Deprest 2, K. Devriendt 1, J. R. Vermeesch 1. 
1 Centre for Human Genetics, KU Leuven, University Hospital Leuven, Belgium. 
2 Department of Development and Regeneration, Unit Pregnancy, Foetus and Newborn, KU 
Leuven, and Department Obstetrics and Gynaecology, University Hospital Leuven, Belgium. 
 
Introduction 
Congenital diaphragmatic hernia (CDH) occurs with an incidence of 1.7 to 5.7 per 10,000 
live-born infants (Kotecha et al., 2012), and is associated with pulmonary hypoplasia and 
postnatal pulmonary hypertension which account for the high mortality and much of the 
morbidity in survivors. CDH is observed in association with additional anomalies in ~40% of 
cases, i.e. syndromic or non-isolated CDH, for which the prognosis is worse (Skari et al., 
2000).   For the remainder, CDH occurs as an isolated defect and it is those patients who are 
most suited to prenatal or neonatal therapy.   
Currently, a number of clinical observations and biometrics in both the prenatal and 
neonatal phase are used as biomarkers of isolated CDH severity and certain predictors of 
outcome.  Predictions based on the lung area to head circumference ratio, and the liver 
position, are among the best studied.  Jani et al showed that significant predictors of survival 
were the observed to expected lung to head ratio (O/E LHR), gestational age at delivery, and 
the side of CDH (i.e. left or right; with ~85% occurring on the left) (Jani et al., 2007).  Jani et 
al later investigated the value of the O/E LHR and liver position as predictors of neonatal 
morbidity in survivors with isolated CDH (Jani et al., 2009).  The O/E LHR provided significant 
prediction of the need for prosthetic patch repair, duration of assisted ventilation, need for 
supplemental oxygen at 28 days, and incidence of feeding problems.  An additional 
independent prenatal predictor of the need for patch repair was herniation of the liver into 
the thorax. 
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This information is highly relevant in the counselling of patients, assisting with decision for 
either; prenatal intervention by fetoscopic endoluminal tracheal occlusion (FETO) which 
aims to reverse pulmonary hypoplasia for the most severe cases; expectant management 
and neonatal therapy; or the option for termination of pregnancy (Deprest et al., 2009).  
Deprest et al proposed four categories of classification for isolated left-side CDH based upon 
the observed to expected lung to head ratio (O/E LHR), and also taking into account liver 
position (extreme; severe; moderate; and mild) (Deprest et al., 2009); (i) foetuses with an 
O/E LHR <15% have extreme pulmonary hypoplasia and (virtually) no survivors are reported; 
(ii) foetuses with an O/E LHR between 15 and 25% have severe pulmonary hypoplasia and 
their predicted survival is ~20%, those with the liver down doing better than those with liver 
into the thorax; (iii) foetuses with an O/E LHR between 26% and 35%, and those with an O/E 
LHR between 36 and 45% but with the liver up, have moderate pulmonary hypoplasia and 
have an expected survival rate between 30% and 60%, depending on the size of the lung; 
and (iv) foetuses with an O/E LHR 36 and 45% with the liver down, and those with an O/E 
LHR >45%, have mild pulmonary hypoplasia and they are very likely to survive (>75%). 
Recently, Done et al investigated neonatal morbidity in fetuses with severe isolated CDH 
treated with FETO versus those managed expectantly (Done et al., 2013).  Early neonatal 
morbidity indicators including the need for patch repair, duration of mechanical ventilation 
and supplemental oxygen, age at full enteral feeding and incidence of pulmonary 
hypertension were investigated.  Gestational age at delivery was predictive of the duration 
of assisted ventilation, number of days on supplemental oxygen, and age at full enteral 
feeding.  Delivery after 34 weeks gestation was correlated with neonatal morbidity of FETO 
cases comparable to that of expectantly managed cases with moderate hypoplasia (Done et 
al., 2013). 
Studies of chromosomal abnormalities and the identification of single gene disorders in the 
group of non-isolated or syndromic CDH patients shows there is a strong genetic 
component, with as much as 20-30% having an identifiable genetic cause (Howe et al., 1996; 
Enns et al., 1998; Witters et al., 2001; Holder et al., 2007; Scott et al., 2007; Wat et al., 2011; 
Yu et al., 2012).  However, large chromosomal abnormalities are not frequently seen in 
association with isolated CDH, and causative genes for isolated cases remain elusive.  We 
have recently shown that chromosomal microarray analysis identified pathogenic 
submicroscopic copy number variations (CNVs) in ~10% of foetuses with moderate-severe 
isolated CDH (Brady et al., 2013), and we also identified ZFPM2 as a cause of familial isolated 
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CDH (Brady et al., manuscript submitted).  However, for the vast majority of isolated CDH 
patients a genetic cause remains unidentified by chromosomal microarray analysis and 
exome sequencing has not yet been applied to cohorts of sporadic cases of isolated CDH. 
Clinically, it would be useful to timely identify good responders and poor responders to the 
currently available foetal therapy, and the genetic factors influencing this response.  The 
identification of genetic biomarkers from amniotic fluid (AF), or even from maternal blood or 
plasma, offers the possibility of a more personalised foetal therapy.  We sought to explore 
whether gene expression analysis in AF cells of CDH foetuses using RNA-Sequencing could 
identify dysregulated genes and biological pathways which could be correlated with, and are 
thus predictive biomarkers, of factors such as severity, response to FETO therapy, or 
neonatal outcome.   
Methods 
Patients 
Retrospective samples were obtained from 23 male foetuses with moderate to severe 
isolated CDH, and with normal karyotype and/or chromosomal microarray.  These included 
14 fetuses with left-sided CDH, and 9 fetuses with right-sided CDH.  In order to minimize the 
effects of different gestational ages, samples were selected in the range of 25-29 weeks, and 
prior to FETO (where performed).  Cultured amniotic fluid (AF) cells were obtained from 
frozen cell cultures.  As a control, AF samples of normal foetuses from twin-twin transfusion 
pregnancies from the same gestational age range were selected (n=8). 
RNA Isolation 
Total RNA was isolated from cultured AF cells with the RNeasy mini kit (Qiagen) according to 
the manufacturer’s recommendation.  Briefly, samples were washed twice in PBS and the 
final cell pellet was resuspended in 600µl Buffer RLT, using a syringe for lysis and 
homogenization.  The same volume of 70% EthOH was added to the lysate which was passed 
through a single spin column.  Following 3 wash steps, total RNA was eluted in 55µl RNase 
free water.  RNA concentration was measured using the Nanodrop 1000 spectrophotometer 
(Thermo Scientific).  RNA integrity was assessed using the RNA 6000 Nano Kit and the 
Bioanalyser (Agilent Technologies) according to the manufacturer’s recommendations. 
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RNA-Seq Library Preparation & Sequencing 
mRNA isolation, cDNA conversion and sequencing library preparation was performed using 
the TruSeq RNA library preparation kit (Illumina) according to the manufacturer’s 
recommendations for the low throughput manual protocol, with the gel-free method, and 
the following modifications; fragmentation time was reduced from 8 minutes to 6 minutes; 
the enrichment PCR step was reduced from 15 to 12 cycles.  2µg total RNA was used as 
initial input material. 
Library concentrations were measured using the Qubit fluorometer (Life Technologies).  
Library quality and size range was assessed using the Bioanalyser (Agilent Technologies) with 
the DNA 1000 Kit (Agilent Technologies) according to the manufacturer’s recommendations.  
Conversion to molar concentrations was calculated suing the cynosura calculator; 
(http://www.cynosura.org/molbiol/scripts/01_07.html), with final concentrations of 2nM 
provided for sequencing on the HiSeq 2000 (Illumina).  Samples were indexed during library 
preparation and subsequently pooled 12 per lane of a sequencing flow cell. 
Bioinformatics Analysis 
After demultiplexing and quality filtering, fastq files were imported into Array Studio 
(OmicSoft) and mapped against the ensembl GRCh37 reference human genome and 
transcriptome (ensembl release 66) using default parameters for single short read data.  
Expression values were calculated per gene; normalized to ‘reads per kilobase per million 
reads’ (RPKM) values as previously described (Mortazavi et al., 2008).  This measurement 
has been criticised, but is widely used for analysis of RNA-Seq data (Wagner et al., 2013; 
Wagner et al., 2012).  An advantage of RNA-Seq analysis compared to expression arrays is 
there is no background signal noise, so a low number of sequencing reads theoretically 
equates to gene expression.  However, it has been proposed that RNA-Seq identifies one 
group comprised of very low abundance and putatively non-functional mRNAs, and another 
group of highly expressed mRNAs with active chromatin marks at their promoters 
(Hebenstreit et al., 2011).  In order to address this, we apply a cutoff of 1RPKM to distinguish 
between ‘noisy’ or ‘leaky’ transcription and ‘true’ mRNA expression levels for comparison 
between samples. 
In order to proceed with conventional expression analysis methodologies developed for 
expression array data we Log2 transform the RPKM values for downstream clustering 
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analysis by principal component analysis (PCA) and by hierarchical clustering, and for the 
subsequent calculation of fold changes by statistical inference analysis. 
Pathway Analysis 
Pathway analysis was performed using the Ingenuity Pathway Analysis (IPA) software 
application (Ingenuity Systems, CA, USA). 
Generation of Networks and Calculation of p-values and Scores using the IPA Software. 
(i) Network Algorithm and Network Scores; 
The IPA software applies an algorithm for generating networks from uploaded gene sets 
(gene lists, or with associated expression values) by mapping each gene identifier to its 
corresponding gene object in the IPA Knowledge Base (comprising data from multiple 
curated evidence sources).  These focus genes are then overlaid onto a global molecular 
network developed from information contained in the Knowledge Base.  Networks of these 
focus genes are then algorithmically generated based on their connectivity.  Each individual 
IPA network has a maximum of 35 focus genes and is assigned a significance score (based on 
the p-value) representing the likelihood that the focus genes within the network are 
enriched for by random chance alone.  A high number of focus genes within a dataset leads 
to a higher network score, where the score is equal to –log(p-value), such that a score of 3 or 
higher corresponds to a p-value of 10E-3 and higher. 
(ii) Calculating and Interpreting the p-values for Biological Function and Canonical 
Pathways in IPA; 
The p-value associated with a function or a pathway in Global Functional Analysis (GFA) and 
Global Canonical Pathways (GCP) is a measure of the likelihood that the association between 
a set of focus genes in and a given process or pathway is due to random chance alone.  In 
general, p-values less than 0.05 indicate a statistically significant, non-random association.  
The p-value is calculated using the right-tailed Fisher Exact Test. 
In this method, the p-value for a given process annotation is calculated by considering (i) the 
number of focus genes that participate in that process, and (ii) the total number of genes 
that are known to be associated with that process in the selected reference set (in this case 
all information in the IPA Knowledge Base).  The more focus genes which are involved, the 
more likely the association is not due to random chance alone and the more significant the 
p-value.  In this way, the larger the total number of genes known to be associated with the 
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process, the greater the likelihood that an association is due to random chance, and the p-
value accordingly becomes less significant.  The p-value thus identifies statistically significant 
over-representation of focus genes in a given process.  Over-represented functional or 
pathway processes are processes which have more focus genes than expected by chance 
using the right-tailed Fisher Exact Test. 
(iii) Downstream Effects Analysis, Upstream Regulator Analysis and Mechanistic 
Network Analysis; 
The IPA Downstream Effects Analysis predicts increases or decreases in downstream 
biological activities occurring in the tissues or cells under study.  Using the directional 
expression changes of the genes in the respective dataset, IPA computes the likely effect 
(increase of decrease) on diseases and cell biological processes.  The IPA Upstream Regulator 
Analysis predicts upstream regulators using the directional expression changes of the 
underlying data.  Mechanistic Networks Analysis takes this analysis further by 
computationally generating plausible directional networks from these regulators. 
Results 
PCA, Hierarchical Clustering Analysis and Identification of Sub-Classes for Fold Change 
Calculation 
At least 10 million reads were obtained for all samples (range 12-28 million reads), with 89-
92% of reads mapping uniquely to the reference human genome / transcriptome.  
Normalised expression values per gene (RPKM values) were filtered; genes with <1 RPKM in 
all samples were excluded from further analysis (for reasoning, see methods), leaving 10,792 
protein coding genes.  The RPKM values for these 10,792 genes were subsequently log2 
transformed.  Correlation analysis identified one control sample to be a clear outlier, which 
was removed from subsequent analysis.  Unsupervised hierarchical clustering and PCA on 
the remaining 7 control samples and 23 CDH samples was performed.  This could not clearly 
identify any clustering of, controls vs CDH, nor left vs right CDH.  No batch effect could be 
identified due to factors including cell culture batches, RNA isolation batches, library 
preparation batch, or total number of reads obtained. 
Statistical inference analysis was performed using the general linear model function in Array 
Studio to generate fold changes and FDR values (false discovery rate; BH; Benjamin-
Hochberg corrected p-values).  Group analysis comparing all 23 CDH patients vs 7 controls 
revealed no significant fold changes with cutoff of fold change +-2, and FDR <0.01.  Similarly, 
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analysis comparing 14 left-sided CDH vs controls, and 9 right-sided CDH vs controls revealed 
no significant fold changes using the same cutoffs. 
In order to further stratify the CDH group into potential subtypes with similar molecular 
profiles, comparison was made to the control group per individual CDH patient (assuming 
equal variance of expression as for the control group for the respective gene).  By applying a 
cutoff p-value of <0.1, >4000 genes showed a fold change of >2, or <-2.  PCA and 
unsupervised hierarchical clustering were performed on this subset of 4226 genes which 
show an apparent fold change in any CDH sample vs the control group.  This allowed for the 
identification of several homogenous subgroups, 2 of which contained at least 5 CDH cases, 
and one group which contained only 2 cases and was not further analysed.  An additional 2 
control samples were identified as outliers from the remaining control samples, and were 
removed from subsequent analysis, leaving 5 control samples with more homogeneous 
expression profiles.  Inference analysis was then repeated on the 10,792 genes from above, 
but comparing the 2 defined CDH groups against the newly defined control group.  Those 
groups herein referred to as group2 and group7, showed significantly dysregulated gene 
expression, and are shown in the PCA plot in Figure 6.1.  Group2 contains 6 isolated CDH 
cases; 2 with left-sided CDH and 4 with right-sided CDH, 5 of which survived and 1 foetus 
deceased neonatally (right-sided CDH).  Group7 contains 5 isolated CDH cases; 4 with left-
sided CDH and 1 with right-sided CDH, 4 of which survived and 1 deceased neonatally (right-
sided CDH). 
Only 32 genes were dysregulated with a fold change +-2, and FDR 0.01, in group2.  Using the 
same fold change +-2, but FDR of 0.05, 101 genes were dysregulated.  This list of 101 genes 
was used for the subsequent downstream pathway analysis.  In contrast, in group7, 250 
genes were found to be dysregulated with fold change +-2, and FDR 0.01.  Using the same 
fold change +-2, but FDR of 0.05, 374 genes were dysregulated.  We used this list of 374 
genes for the downstream pathway analysis.  These 2 groups share in common 35 
dysregulated genes; however the direction of expression change between these two groups 
is not the same for many of these genes.  The details of the top 10 upregulated and top 10 
downregulated genes are listed in Tables 6.1, and Table 6.2, below.  The details for genes in 
common between group2 and group7 are given in Table 6.3.  Figure 6.2 displays a heatmap 
generated by unsupervised hierarchical clustering of the 440 total genes which were 
significantly differentially expressed in group 7 and/or group 2 in comparison to the control 
group.   
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Figure 6.1.  PCA for subgroup 2 (6 isolated CDH), subgroup 7 (5 isolated CDH), and 5 control samples.  
Subgroup 7 separates from the control group (as well as subgroup 2) on the first component (Comp1; 
x-axis), and subgroup 2 separates from the control group on the second component (Comp2; y-axis). 
 
 Ensembl Gene ID Gene Name Chr Start End Fold Change FDR (BH) 
Downregulated ENSG00000108753 HNF1B 17 36,046,434 36,105,237 -6.6739 0.001 
 ENSG00000171234 UGT2B7 4 69,917,081 69,978,705 -6.2276 0.0027 
 ENSG00000132182 NUP210 3 13,357,737 13,461,809 -4.9789 0.001 
 ENSG00000106003 LFNG 7 2,552,163 2,568,811 -4.5124 0.0039 
 ENSG00000126878 AIF1L 9 133,971,863 133,998,539 -4.3895 0.0029 
 ENSG00000075891 PAX2 10 102,495,360 102,589,698 -4.3415 0.0016 
 ENSG00000085563 ABCB1 7 87,132,948 87,342,611 -4.1651 0.0106 
 ENSG00000146038 DCDC2 6 24,171,984 24,358,280 -3.8992 0.0055 
 ENSG00000197635 DPP4 2 162,848,751 162,931,052 -3.8738 0.0241 
 ENSG00000156510 HKDC1 10 70,980,059 71,027,315 -3.7977 0.0029 
Upregulated ENSG00000112769 LAMA4 6 112,429,963 112,576,141 2.7279 0.026 
 ENSG00000170801 HTRA3 4 8,271,492 8,308,838 2.7359 0.0237 
 ENSG00000113083 LOX 5 121,398,890 121,414,206 2.7761 0.0116 
 ENSG00000049323 LTBP1 2 33,172,039 33,624,576 2.786 0.0404 
 ENSG00000143867 OSR1 2 19,551,246 19,558,414 2.8778 0.0188 
 ENSG00000185112 FAM43A 3 194,406,622 194,409,762 2.9923 0.0119 
 ENSG00000147027 TMEM47 X 34,645,181 34,675,405 3.1498 0.0132 
 ENSG00000157404 KIT 4 55,524,085 55,606,881 3.6289 0.0088 
 ENSG00000108821 COL1A1 17 48,260,650 48,278,993 3.6542 0.0149 
 ENSG00000168542 COL3A1 2 189,839,046 189,877,472 4.8514 0.0498 
Table 6.1. Group2;  Top 10 Downregulated & Top 10 Upregulated genes in dataset. 
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 Ensembl Gene ID Gene Name Chr Start End Fold Change FDR (BH) 
Downregulated ENSG00000117152 RGS4 1 163,038,565 163,046,592 -13.5477 0.0003 
 ENSG00000168542 COL3A1 2 189,839,046 189,877,472 -12.674 0.0026 
 ENSG00000164161 HHIP 4 145,567,173 145,666,423 -10.7118 0.0007 
 ENSG00000140937 CDH11 16 64,977,656 65,160,015 -9.1247 0.0006 
 ENSG00000169851 PCDH7 4 30,722,037 31,144,728 -9.1034 2.33E-05 
 ENSG00000166923 GREM1 15 33,010,175 33,026,870 -8.9563 0.001 
 ENSG00000166033 HTRA1 10 124,221,041 124,274,424 -8.7589 0.0007 
 ENSG00000115165 CYTIP 2 158,271,131 158,345,473 -8.2579 0.0003 
 ENSG00000138650 PCDH10 4 134,070,470 134,129,356 -6.9348 0.004 
 ENSG00000172572 PDE3A 12 20,522,179 20,837,315 -6.4175 7.58E-05 
Upregulated ENSG00000121858 TNFSF10 3 172,223,298 172,241,297 6.6386 0.0012 
 ENSG00000013297 CLDN11 3 170,136,653 170,578,169 6.7213 0.0338 
 ENSG00000137203 TFAP2A 6 10,393,419 10,419,892 6.8867 0.0043 
 ENSG00000232810 TNF 6 31,543,344 31,546,113 7.0349 2.33E-05 
 ENSG00000166920 C15orf48 15 45,722,727 45,740,959 7.4503 0.0002 
 ENSG00000184292 TACSTD2 1 59,041,099 59,043,166 7.6042 0.0016 
 ENSG00000163235 TGFA 2 70,674,412 70,781,325 7.9543 0.0002 
 ENSG00000198910 L1CAM X 153,126,969 153,174,677 9.1634 0.003 
 ENSG00000169429 IL8 4 74,606,223 74,609,433 9.7168 0.016 
 ENSG00000136244 IL6 7 22,765,503 22,771,621 16.5099 0.0012 
Table 6.2. Group7;  Top 10 Downregulated & Top 10 Upregulated genes in dataset. 
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Ensembl Gene ID Gene 
Name 
Chr Start End Group 2 
Fold 
Change 
Group 2 
FDR (BH) 
Group 7 
Fold 
Change 
Group 7 
FDR (BH) 
ENSG00000253368 TRNP1 1 27,320,198 27,327,147 -2.5157 0.0143 2.0957 0.0267 
ENSG00000158769 F11R 1 160,965,001 161,008,784 -2.3126 0.0152 2.4089 0.0064 
ENSG00000196352 CD55 1 207,494,853 207,534,311 2.0724 0.0088 -2.3361 0.0013 
ENSG00000136542 GALNT5 2 158,114,110 158,170,723 2.3666 0.0125 -4.0596 0.0002 
ENSG00000197635 DPP4 2 162,848,751 162,931,052 -3.8738 0.0241 3.4487 0.0247 
ENSG00000168542 COL3A1 2 189,839,046 189,877,472 4.8514 0.0498 -12.674 0.0026 
ENSG00000183671 GPR1 2 207,040,040 207,082,771 2.3228 0.0237 -2.3854 0.0129 
ENSG00000121858 TNFSF10 3 172,223,298 172,241,297 -3.1276 0.0363 6.6386 0.0012 
ENSG00000185112 FAM43A 3 194,406,622 194,409,762 2.9923 0.0119 -3.2698 0.0036 
ENSG00000157404 KIT 4 55,524,085 55,606,881 3.6289 0.0088 -3.3632 0.0054 
ENSG00000038427 VCAN 5 82,767,284 82,878,122 -2.1506 0.0325 2.046 0.0335 
ENSG00000113083 LOX 5 121,398,890 121,414,206 2.7761 0.0116 -4.4381 0.0004 
ENSG00000160867 FGFR4 5 176,513,887 176,525,145 -2.3548 0.0099 2.0665 0.0129 
ENSG00000146038 DCDC2 6 24,171,984 24,358,280 -3.8992 0.0055 2.6771 0.0174 
ENSG00000106003 LFNG 7 2,552,163 2,568,811 -4.5124 0.0039 2.994 0.0131 
ENSG00000086300 SNX10 7 26,331,541 26,413,949 -2.2183 0.0185 2.3581 0.0068 
ENSG00000178445 GLDC 9 6,532,464 6,645,650 -2.9214 0.0371 2.7221 0.0405 
ENSG00000151892 GFRA1 10 117,816,444 118,033,126 -3.5518 0.0072 3.2869 0.0048 
ENSG00000165868 HSPA12A 10 118,430,703 118,502,085 -3.5456 0.0039 2.2208 0.0274 
ENSG00000136052 SLC41A2 12 105,196,331 105,352,522 -2.0701 0.027 2.1182 0.0158 
ENSG00000136153 LMO7 13 76,194,570 76,434,004 2.2247 0.0208 -2.2179 0.0128 
ENSG00000100557 C14orf105 14 57,936,019 57,960,585 -3.2144 0.0056 2.0351 0.045 
ENSG00000166145 SPINT1 15 41,136,216 41,150,405 -2.0184 0.0155 2.5389 0.0013 
ENSG00000166147 FBN1 15 48,700,503 48,938,046 2.0706 0.0099 2.8223 0.0004 
ENSG00000169594 BNC1 15 83,924,655 83,953,466 -2.8191 0.0183 2.4581 0.0231 
ENSG00000153822 KCNJ16 17 68,071,426 68,131,744 -3.0141 0.0394 3.7244 0.0126 
ENSG00000154864 PIEZO2 18 10,670,238 11,148,761 2.5537 0.0401 -3.307 0.0085 
ENSG00000053747 LAMA3 18 21,269,562 21,535,030 -2.0468 0.0374 2.0982 0.0248 
ENSG00000074181 NOTCH3 19 15,270,445 15,311,792 2.676 0.0447 -3.4295 0.0116 
ENSG00000127528 KLF2 19 16,435,651 16,438,337 2.4707 0.0279 -2.54 0.0168 
ENSG00000105699 LSR 19 35,739,559 35,758,865 -2.5724 0.0056 3.2561 0.0005 
ENSG00000101017 CD40 20 44,746,911 44,758,502 -2.0112 0.0291 2.7626 0.002 
ENSG00000188064 WNT7B 22 46,316,242 46,373,009 -2.3267 0.0149 2.0155 0.0234 
ENSG00000198947 DMD X 31,132,808 33,357,558 2.1093 0.0413 -3.7068 0.001 
ENSG00000147027 TMEM47 X 34,645,181 34,675,405 3.1498 0.0132 2.4763 0.0268 
Table 6.3. Genes dysregulated in both group2 & group7.  Note that the expression change is in the 
opposite direction for many of the genes listed. Only FBN1 and TMEM47 show common upregulation 
in both groups. 
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Figure 6.2.  Heatmap displaying Log2 transformed RPKM expression values per sample.  Only group 2, group 7, and controls are shown.  Data is displayed for the 440 genes 
significantly dysregulated in group 2 and/or group 7. 
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A number of genes which are associated with, or are candidates for, CDH or lung 
development are identified as dysregulated in group7 and / or group 2.  Interestingly, 
COL3A1 is downregulated in group7 (fold change -12.674, FDR 0.0026).  Mutations in 
COL3A1 are associated with Ehlers Danlos syndrome in humans [OMIM #130050], in which 
CDH has been observed (Lin et al., 2006).  LFNG is dysregulated in both groups (group7 fold 
change 2.994, FDR 0.0131; group2 fold change -4.5124, FDR 0.0039).  LFNG is expressed in 
the pulmonary epithelium, and KO mice exhibit defects in impaired myofibroblast 
differentiation and alveogenesis [Xu et al. (2009)].  WNT7B is dysregulated in both groups 
(group7 fold change 2.0155, FDR 0.0234; group2 fold change -2.3267, FDR 0.0149) and was 
reported to be downregulated in the nitrofen induced rodent (Takayasu et al., 2007).  
Furthermore, the effects of Wnt7b on lung development were examined using a conditional 
Wnt7b-null mouse (Rajagopal et al., 2008), which revealed Wnt7b-null lungs were 
hypoplastic, yet displayed largely normal patterning and cell differentiation.  In contrast to 
results from hypomorphic Wnt7b models, decreased replication of both developing 
epithelium and mesenchyme were seen, without abnormalities of vascular smooth muscle 
development.  BNC1 is dysregulated in both groups (group7 fold change 2.4581, FDR 0.0231; 
group2 fold change -2.8191, FDR 0.0183).  The BNC1 gene is in the 15q25.2 microdeletion 
region which has been recently associated with CDH, including in 2 cases we have identified 
(Chapter 4) (Wat et al., 2010).  Taken together, this provides support for potential 
involvement of BNC1 in some cases of CDH pathogenesis.  PDE3A was also found to be 
significantly downregulated in group7 (fold change -6.4175, FDR 7.72E-08).  This is of 
potential interest given the investigation of sildenafil as a possible therapeutic treatment for 
CDH, via inhibition of PDE5A.  PDE3A is also a target of sildenafil.  Sildenafil has recently been 
shown to improve pulmonary vascular development in a rodent CDH model and in humans 
with CDH (Luong et al., 2011; Stultz et al., 2013).  A number of genes dysregulated in group 7 
are also observed to be associated with diaphragm abnormalities in mouse models (Tables 
1.2.1 & 1.2.2, Chapter 1, this thesis).  Downregulated genes include; LOX (fold change -
4.4381, FDR 0.0004); DMD (fold change -3.7068, FDR 0.001); TCF21 (fold change -2.6663, 
FDR 0.0049); and TGFB1 (fold change -2.0195, FDR 0.0044).  Upregulated genes include; 
PTPRD (fold change 2.3708, FDR 0.0405); and FBN1 (fold change 2.8223, FDR 0.0004).   
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Network & Pathway Analysis 
Downstream Effects Analysis 
Pathway analysis was performed of the dysregulated gene lists for each group individually 
using the IPA software application (Ingenuity Pathway Analysis, Ingenuity Systems, CA, USA).  
From this pathway analysis, predictions are also given for activation and inhibition of specific 
biological functions based upon the direction of expression change observed (see 
methodology).  Table 6.4 provides details of the biological functions for group2 which are 
predicted to be increased or decreased.  Interestingly, lung development is predicted 
enriched for with a p-value of 7.76E-05, but an activation z-score of only -0.962, which may 
suggest decreased lung development, but without clear significance.  Nine molecules are 
annotated as involved in lung development and are significantly dysregulated in group2; 
COL3A1, FBN1, FGFR4, KLF2, LFNG, LOX, NOTCH3, PDGFB, WNT7B.  Additionally, molecules 
significantly dysregulated in group2 and involved in CDH are FBN1 and LOX, although these 
genes are both upregulated. 
From the pathway analysis performed using IPA on the dysregulated gene sets, Table 6.5 
provides details of the biological functions which are predicted to be increased or decreased 
for group7 also.  Interestingly, respiratory development (23 genes, p-value 1.39E-06, 
activation Z-score 2.896) and lung development (22 genes, p-value 5.95E-07, activation Z-
score 2.722) are the functions predicted activated with highest significance.  Epithelial-
mesenchymal transition (EMT) (11 genes, p-value 2.76E-05, activation Z-score -2.530) and 
inflammation of lung (23 genes, p-value 1.10E-05, activation Z-score -2.444) are the 
functions predicted inhibited with highest significance.  Vascularisation is also predicted to 
be decreased, with 18 genes whose expression change is consistent with decreased 
vascularization. 
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Functions 
Annotation 
p-Value Predicted 
Activation 
State 
Activation 
z-score 
Molecules # 
Molecules 
hypoplasia of 
organ 
4.48E-03 Increased* 1.964 HS6ST2, LOX, LSR, PAX2, RASSF2, RPS6KA5, 
WNT7B 
7 
organismal death 5.79E-06 Increased* 1.860 AMOT, CD40, COL1A1, COL3A1, DMD, E2F8, 
FBN1, FGFR4, GFRA1, GUCY1B3, HIPK2, 
HNF1B, KIT, KLF2, KRT19, LAMA3, LAMA4, 
LFNG, LMO7, LOX, LSR, LTBP1, MLLT3, NES, 
NRK, OSR1, PAX2, PDGFB, PROS1, RASSF2, 
RPS6KA5, SPINT1, TNFSF10, UGT8, WNT7B 
35 
Growth Failure 7.54E-04 Increased* 1.772 AMOT, CREB3L1, E2F8, FGFR4, GUCY1B3, 
HIPK2, KLF2, NOTCH3, PDGFB, RASSF2, 
SPINT1, UGT8 
12 
vasculogenesis 1.97E-03 Decreased -2.049 AMOT, CD40, COL1A1, F11R, HAS3, HS6ST2, 
KIT, KLF2, LOX, LTBP1, PDGFB, TNFSF10 
12 
proliferation of 
endothelial cells 
8.00E-03 Decreased -2.184 F11R, HAS3, KIT, KLF2, PDGFB, TNFSF10 6 
proliferation of 
cells 
2.03E-05 Decreased -2.844 ABCB1, AKR1C1/AKR1C2, BNC1, CD40, CD55, 
COL1A1, CYP2S1, DPP4, E2F8, F11R, FBN1, 
FGFR4, GFRA1, GLDC, HAS3, HIPK2, HNF1B, 
HS6ST2, KCNJ16, KIT, KLF2, KRT19, LAMA3, 
LAMA4, LITAF, LOX, LTBP1, MLLT3, NES, 
NOTCH3, OSR1, PAX2, PDGFB, PTPN3, 
RPS6KA5, RTKN2, TNFSF10, TPD52, TYMS, 
VCAN, WNT7B 
41 
Table 6.4. Group 2;  Biological functions which are predicted to be decreased or increased based upon 
the observed dysregulation in expression.  We list those functions with Z-score >2, or<-2.   
*No functions were predicted activated with a Z-score >2, so we list the top 3 activated functions and 
the respective Z-scores obtained.  
 
Functions 
Annotation 
p-Value Predicted 
Activation 
State 
Activation 
z-score 
Molecules # Molecules 
respiratory system 
development 
1.39E-06 Increased 2.896 BMP4, CDKN1C, COL3A1, CTGF, FBN1, 
FGF1, FGFR4, FOXA1, GREM1, IL6, ITGB6, 
KLF2, LFNG, LOX, NOTCH3, PCSK5, TCF21, 
TGFB1, TGFBR2, THBS1, TLR4, TNF, WNT7B 
23 
lung development 5.95E-07 Increased 2.722 BMP4, CDKN1C, COL3A1, CTGF, FBN1, 
FGF1, FGFR4, FOXA1, GREM1, IL6, ITGB6, 
KLF2, LFNG, LOX, NOTCH3, TCF21, TGFB1, 
TGFBR2, THBS1, TLR4, TNF, WNT7B 
22 
infiltration of cells 4.87E-11 Increased 2.516 ADAM8, AKR1B1, CD40, CFH, CTGF, 
CXCL16, CXCL2, CXCL5, F2R, F2RL1, F3, FST, 
HAVCR1, HMOX1, IL32, IL6, IL8, IRF6, 
ITGA4, KITLG, LDLR, MCAM, NFKBIA, 
NFKBIZ, PLA2G4A, PLAT, PPT2, STC1, 
TGFB1, TGFBR2, THBS1, TLR4, TNF 
33 
infiltration by 
neutrophils 
3.53E-08 Increased 2.428 ADAM8, CFH, CTGF, CXCL2, CXCL5, F2RL1, 
HAVCR1, HMOX1, IL6, IL8, IRF6, NFKBIA, 
PLAT, TGFBR2, TLR4, TNF 
16 
cell movement of 
neutrophils 
1.18E-06 Increased 2.283 ADAM8, CFH, CTGF, CXCL2, CXCL5, EDNRA, 
F2RL1, HAVCR1, HMOX1, IL6, IL8, IRF6, 
ITGA4, LYN, NFKBIA, PLAT, TGFB1, TGFBR2, 
TLR4, TNF, VEGFC 
21 
activation of 
phagocytes 
1.04E-06 Increased 2.248 CD40, CFH, CLEC4E, CXCL5, DPP4, F2RL1, 
HAVCR1, HMOX1, IL6, IL8, IRF6, ITGB6, KIT, 
KITLG, LYN, RAPGEF3, SCN9A, TGFB1, 
22 
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THBS1, TLR4, TNF, TNFSF10 
quantity of neurons 1.11E-05 Increased 2.220 BMP4, CCND2, DLX2, EMX2, FST, GDNF, 
GFRA1, HOXB3, INHBA, JAG1, KCNIP3, 
L1CAM, LFNG, NEFH, NEFM, NR2F1, 
TFAP2A, TGFA, WNT7B 
19 
infiltration of blood 
cells 
8.67E-10 Increased 2.189 ADAM8, AKR1B1, CFH, CTGF, CXCL16, 
CXCL2, CXCL5, F2R, F2RL1, F3, HAVCR1, 
HMOX1, IL6, IL8, IRF6, ITGA4, KITLG, LDLR, 
MCAM, NFKBIA, NFKBIZ, PLA2G4A, PLAT, 
PPT2, STC1, TGFB1, TGFBR2, THBS1, TLR4, 
TNF 
30 
function of blood 
cells 
3.75E-05 Increased 2.105 ANPEP, CD40, CHST2, CLEC4E, CTSS, F11R, 
F3, GJA1, GPR68, HAVCR1, ICA1, IFI30, IL6, 
IL8, KCNN4, KIT, KLF2, LPAR2, LYN, MALT1, 
NFKBIA, NFKBIZ, PLA2G4A, PLAT, PTGS1, 
SEPT5, SPNS2, TGFB1, TLR4, TNF, TNFSF10 
31 
infiltration of 
granulocytes 
6.69E-07 Increased 2.086 ADAM8, CFH, CTGF, CXCL2, CXCL5, F2R, 
F2RL1, HAVCR1, HMOX1, IL6, IL8, IRF6, 
NFKBIA, PLAT, TGFBR2, TLR4, TNF 
17 
cell spreading 1.95E-09 Increased 2.054 CD40, CDKN2A, EFNA1, EFNB1, EGF, FBN1, 
IL8, ITGA11, ITGA4, ITGB6, KITLG, L1CAM, 
LAMA3, LYN, MAP2, PAK3, PMP22, POSTN, 
RAPGEF3, SDC1, SYNM, THBS1, TNF 
23 
infiltration of 
leukocytes 
3.44E-09 Increased 2.051 ADAM8, CFH, CTGF, CXCL16, CXCL2, CXCL5, 
F2R, F2RL1, F3, HAVCR1, HMOX1, IL6, IL8, 
IRF6, ITGA4, KITLG, LDLR, MCAM, NFKBIA, 
NFKBIZ, PLA2G4A, PLAT, PPT2, STC1, 
TGFB1, TGFBR2, THBS1, TLR4, TNF 
29 
activation of 
antigen presenting 
cells 
1.19E-05 Increased 2.044 CD40, CLEC4E, CTSS, CXCL5, F2RL1, 
HAVCR1, IL6, IL8, ITGB6, LYN, RAPGEF3, 
SCN9A, TGFB1, THBS1, TLR4, TNF, TNFSF10 
17 
activation of 
dendritic cells 
3.28E-05 Increased 2.035 CD40, F2RL1, IL6, IL8, LYN, SCN9A, TGFB1, 
TLR4, TNF, TNFSF10 
10 
invasion of cells 9.92E-17 Increased 2.000 ADAM8, ADAMTS15, ANPEP, BMP4, CDK14, 
CDKN2A, CTGF, CTSS, DPP4, EGF, ELF3, 
EPCAM, F2R, F3, FGFR4, FOXA1, FST, GDNF, 
GFRA1, GJA1, HAS2, HMOX1, IL6, IL8, 
INHBA, ITGA4, ITGB4, ITGB6, JUP, KITLG, 
L1CAM, LAMA3, LYN, MCAM, MMP15, 
MMP16, NFKBIA, PAK3, PLAT, POSTN, 
RGS4, SDC1, SDC2, SOD2, TFAP2A, TGFA, 
TGFB1, TGFBR2, THBS1, TNF, TNFSF10, 
UNC5C, VEGFC 
53 
accumulation of 
extracellular matrix 
3.41E-06 Decreased -2.000 ADAMTS5, CTGF, EDNRA, GREM1, TGFB1 5 
neuritogenesis 1.53E-06 Decreased -2.072 ATP8A2, DLX2, DNER, DPYSL3, EDNRA, 
EFNA1, EFNB1, GDNF, GFRA1, GJA1, IL6, 
KCNJ2, L1CAM, LAMA1, LOX, LYN, NEFH, 
NEFM, NFIA, NFKBIA, PALM, PDGFRB, PLAT, 
PMP22, SDC2, STX3, TGFB1, TNF, WNT7B 
29 
vascularization 7.01E-07 Decreased -2.150 ANPEP, CD40, CTGF, EFNA1, EFNB1, EGF, 
FGF1, INHBA, ITGA4, KIT, PLA2G4A, STC1, 
TGFA, TGFB1, TGFBR2, THBS1, TNF, VEGFC 
18 
neovascularization 
of organ 
3.88E-07 Decreased -2.157 ANPEP, CTGF, EGF, FGF1, INHBA, KIT, 
PLA2G4A, TGFA, THBS1, TNF, VEGFC 
11 
glomerulosclerosis 4.03E-05 Decreased -2.157 GDNF, HAVCR1, HMOX1, ITGB4, KCNN4, 
LYN, MTSS1, PDGFRB, STC1, TGFB1, TLR4 
11 
formation of plasma 
membrane 
projections 
5.68E-07 Decreased -2.237 ATP8A2, DLX2, DNER, DPYSL3, EDNRA, 
EFNA1, EFNB1, EGF, GDNF, GFRA1, GJA1, 
IL6, KCNJ2, KITLG, L1CAM, LAMA1, LOX, 
LYN, MAP2, NEFH, NEFM, NFIA, NFKBIA, 
32 
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PALM, PDGFRB, PLAT, PMP22, SDC2, STX3, 
TGFB1, TNF, WNT7B 
neovascularization 2.37E-08 Decreased -2.286 ANPEP, CD40, CTGF, EFNA1, EGF, FGF1, 
INHBA, ITGA4, KIT, PLA2G4A, TGFA, TGFB1, 
TGFBR2, THBS1, TNF, VEGFC 
16 
Neurodegeneration 1.66E-05 Decreased -2.351 FBXO2, FGF1, GDNF, GPR37, IL6, NEFH, 
PLAT, PPT2, SEPT5, SOD2, TGFA, TGFB1, 
TGFBR2, TLR4, TNF 
15 
inflammation of 
lung 
1.10E-05 Decreased -2.444 CDH11, CTSS, EDNRA, ELF3, F2RL1, FBN1, 
HMOX1, IL6, IL8, INSIG1, ITGB6, KIT, LDLR, 
LPAR2, LYN, PDGFRB, PLA2G4A, PLAT, 
PTGS1, TGFB1, THBS1, TLR4, TNF 
23 
epithelial-
mesenchymal 
transition 
2.76E-05 Decreased -2.530 EFNA1, EGF, ESRP2, FGF1, HAS2, JAG1, 
NFKBIA, POSTN, TGFB1, TGFBR2, TNF 
11 
Table 6.5. Group 7;  Biological functions which are predicted to be decreased or increased based upon 
the observed dysregulation in expression.  We list those functions with Z-score >2, or<-2.   
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Upstream Regulator and Mechanistic Network Analysis  
The mechanistic network analysis for group7 predicts TGFB1 inhibition and TNF activation as 
being largely responsible for the majority of the downstream dysregulation observed.  The 
highest p-values observed for predicted upstream regulators which were concordant with 
the observed dysregulation in gene expression from group 7 were; TNF (p-value 7.99E-22), 
predicted activated; and, TGFB1 (p-value 3.31E-17), predicted inhibited.  TGFB1 is predicted 
to be inhibited (activation Z-score -1.774; p-value 3.31E-17), and shows a fold change of -
2.02 (FDR 0.0044).  CTGF is predicted to be inhibited in group7 (activation Z-score -2.000; p-
value 1.69E-02), and shows a fold change of -3.54 (FDR 2.00E-04).  MYOCD is predicted to be 
inhibited in group 7 (activation Z-score -1.925; p-value 8.63E-03), and is downregulated (fold 
change -2.9819, FDR 0.0038).  Tumor necrosis factor (TNF) is a multifunctional 
proinflammatory cytokine which is predicted activated in group 7 (activation Z-score 3.358; 
p-value 7.99E-22), and is observed to be upregulated (fold change 7.0349, FDR 2.33E-05).  
IL6 is predicted activated, but without clear significance, in group 7 (activation Z-score 0.673; 
p-value 6.23E-07), and is upregulated (fold change 16.5099, FDR 0.0012).  IL8 is also 
upregulated (fold change 9.7168, FDR 0.016).  It is clear from the network displayed in Figure 
6.3 that TGFB1 downregulation is generally causing a downstream inhibitory effect, and that 
conversely the upregulation of TNF is causing activation of many downstream target genes. 
Figure 6.3 (following page).  A ‘mechanistic network’ analysis was performed using IPA (Ingenuity 
Systems).  Significantly dysregulated genes which were predicted to be activated or inhibited (Z-scores 
<-2, >2) were selected and added to the same network.  The network displayed shows the 
downstream effects of a number of key genes including; TGFB1, TNF, CTGF, IL6, IL8, and MYOCD.  The 
orange arrows indicate predicted activation and a concordant upregulation in expression of the target 
gene.  The blue arrows indicate predicted inhibition and a concordant downregulation of the target 
gene.  The yellow arrows indicate discordance for the expected to observed expression change.  
Molecules in red are upregulated, those in green are downregulated, with the colour intensity 
reflecting the size of the fold change. 
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Discussion 
Amniotic fluid (AF) cells are an available source of foetal material during pregnancy and we 
identify different classes of expression profiles in foetuses affected with isolated CDH.  
Goumy et al previously studied foetal skin fibroblasts from CDH foetuses as a model to 
investigate CDH (Goumy et al., 2010).  However, these foetal samples are not so readily 
available.  The authors used targeted expression analysis in CDH patients which revealed 
altered levels of RARs, RALDH2, and CYP26 in two of seven foetuses investigated.  We do not 
observe any dysregulation in key genes involved in the RA pathway and considered to be 
involved in CDH pathogenesis such as STRA6, RARs, NR2F2, GATA4, or ZFPM2.  However, we 
do observe downregulation of NR2F1 in group 7 (fold change -5.4386, FDR 0.0003) which like 
NR2F2 is a member of the steroid/thyroid hormone receptor superfamily.  NR2F1 & 2 share 
similar characteristics interacting with other members of the steroid/thyroid hormone 
receptor superfamily such as TR, RAR, RXR and VDR, which play important roles in regulation 
of gene expression during development, differentiation and homeostasis.  NR2F1 and 2 are 
orphan members of this superfamily of nuclear receptors and have been shown to 
negatively regulate the ability of these nuclear receptors to regulate target gene 
transcription.  Two different mechanisms are proposed to regulate this repression; NR2F1 & 
2 bind to AGGTCA direct repeats, including response elements for TR, RAR, RXR and VDR, 
which permits competition for binding to response elements; and NR2F1 & 2 heterodimerise 
with RXRs, which are essential cofactors for binding of RARs, TRs and VDR to their respective 
response elements.  Detection of COUP-TF transcripts during mouse development reveal 
discrete spatial and temporal expression domains consistent with COUP-TFs being involved 
in regulation of gene expression during embryogenesis.  Some of these expression domains 
co-localize with those of TR, RAR, and RXR.  The simultaneous expression of these genes 
raise the possibility that NR2F1 & 2 act as negative regulatory factors during development 
and differentiation (Zhou et al., 1999; Qiu et al., 1997; Pereira et al., 1995; Qiu et al., 1994). 
From our network analysis of gene expression changes in group 7, we observe that TGFB1 is 
predicted to be inhibited (activation Z-score -1.774; p-value 3.31E-17), and shows a fold 
change of -2.02 (FDR 0.0044).  TGF-β1 null mice develop apparently normally, but soon die 
from aggressive pulmonary or gut inflammation due to a failure to negatively modulate the 
immune system (McLennan et al., 2000).  Disruption of TGF-β signalling in TAB1 null mice 
results in lethal cardiovascular and lung abnormalities (Komatsu et al., 2002).  Abnormal 
diaphragm morphology has also been reported in a Tgfb1 mouse model; the diaphragm 
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showed inflammation and necrosis which were severe enough to interfere with normal 
respiration (Shull et al., 1992).  CTGF is predicted to be inhibited in group 7 (activation Z-
score -2.000; p-value 1.69E-02), and shows a fold change of -3.54 (FDR 2.00E-04).  CTGF is 
upregulated in group2 (fold change 1.8746, FDR 0.0317).  Expression array analysis identified 
CTGF as a novel gene downregulated in the nitrofen rodent model of CDH (Mesas-Burgos et 
al., 2010b).  CTGF was shown to be upregulated in the hyperplastic lungs of a rodent model 
following tracheal ligation (Mesas-Burgos et al., 2009).  The same group subsequently 
investigated the expression pattern of CTGF during lung development (Mesas-Burgos et al., 
2010a) demonstrating reduced CTGF protein levels in the nitrofen rodent model of CDH.  
Interestingly, the reduced pulmonary gene expression of CTGF observed in the nitrofen CDH 
rodent model was reversed after prenatal RA treatment, which may support lung growth by 
promoting alveologenesis in the nitrofen-induced CDH model (Ruttenstock et al., 2011b).  
MYOCD is predicted to be inhibited in group 7 (activation Z-score -1.925; p-value 8.63E-03), 
and is downregulated (fold change -2.9819, FDR 0.0038).  Recently, it was shown that 
knockdown of MYOCD was sufficient to induce vascular smooth muscle cell proliferation 
(Pfisterer et al., 2012). 
From our analysis, we identify 2 classes of isolated CDH foetuses based upon the expression 
profiles of cultured AF cells.  However, these expression profiles do not confidently correlate 
with clinical features including; left-sided CDH vs right-sided CDH; severity of herniation; or 
clinical outcome, Table 6.6. 
Table 6.6 (following page). Clinical information concerning those isolated CDH patients analysed in 
this study. Groups refer to those classes of foetuses with similar expression profiles, where 
information for group 2 and group 7 is presented and discussed in the text.  Group 1 contains only 2 
foetuses and was not analysed further.  Groups 4, 5, and 6 showed similar expression profiles to the 
control group.  Group 8 contains 2 outliers from those in group 7. 
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groups CDH 
type 
Sex GA 
at AF 
sample 
OE 
LHR 
LHR FETO 
y/n 
Increase in 
OE LHR / % 
Increase in 
LHR / % 
MRI OE 
TFLV 
LIVER 
up/down 
Poly 
hydramnios 
GA at 
delivery 
Neonatal 
death <1d 
Neonatal 
death <7d 
Survival till 
discharge 
PH 
refractory 
to NO 
1 left M 27  0.7 y  71 30 up y 38.6 n y n  
1 left M 29  0.99 y  62 37 up y      
2 right M 29 27.2 0.7 y 338 386 19 up y  n n y n 
2 right M 26 28.7  y 205  26 up n 31.7 n n n y 
2 left M 27  0.81 y  260  up n  n n y  
2 left M 27 21.9  y 169  31 up y 37.0 n n y n 
2 right UNK 28  0.93 y  115 33 up n 37.4 n n y n 
2 right M 29 29.7  y 190  16 up y  n n y  
4 right UNK 29  0.62 y    up y 34.7 y y n  
5 left M 29 20  y 85  25 up n 31.9 n n y n 
5 left M 28 8.3  y 8  7 up y 36.6 y y n  
6 right UNK 27 22  y 123  13 up n 36.6 n n y n 
6 right M 28 34  y 97  29 up n 37.7 n n y n 
6 right UNK 27 20.6  y   35 down n 29.0 y y n  
6 left M 26  0.74 y  130  up n 35.0 y y n  
6 left M 26  0.5 y  438  up y 36.4     
7 left M 25 22 0.8 y 209 263 19 up y 31.4 n n y n 
7 left M 28 20 0.79 y 80 103 14 up y 32.1 n n y n 
7 left M 25 32.3  n   38 up n 38.4 n n y n 
7 left M 27  0.8 y  94 22 up n  y y n  
7 right UNK 28 45 1.2 y 62 75 38 up y 36.7 y y n y 
8 left M 28 33  y 37  24 up n 32.9 y y n  
8 left M 27 32  n   29 up n 35.7 y y N  
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The expression changes we observe are suggestive of disruption to a common underlying 
genetic network, or perhaps a similar biological response to disease for each group.  While 
these changes may not correlate with a predictive clinical feature this information suggests 
that for one group (group7) of isolated CDH patients, representing 20-25% of patients in this 
study, downregulation of TGFB1, CTGF, and MYOCD, as well as upregulation of TNF and IL6, 
may be important factors contributing to the diaphragm and / or lung pathogenesis.  It is 
uncertain whether the changes seen are related to the causes of CDH, or are merely the 
effects of the herniation and the hypoplastic lungs and associated anomalies.  However, 
there exist 2 molecular subtypes which may suggest a common underlying genetic defect or 
similar progression of disease for these groups.   
The largest list of significantly dysregulated genes was identified from group 7, which can be 
summarized as having; increased activation of genes and pathways linked to respiratory 
development; and inhibition of genes and pathways associated with epithelial-mesenchymal 
transition (EMT), and with vascularization.  Furthermore, decreased expression of TGFB1, 
and increased expression of TNF, can explain a large proportion of the downstream 
dysregulation in gene expression observed.  While a lower number of genes are observed to 
be significantly dysregulated in group2, this group is characterized by inhibition genes and 
pathways involved in cell proliferation, proliferation of endothelial cells, and vasculogenesis, 
and by activation of genes and pathways involved in hypoplasia of organ, organismal death, 
and growth failure.  The finding of commonly dysregulated genes between 2 molecular 
subtypes identified, but with the opposing direction of expression change, points towards to 
dosage sensitive genes which may cause, or be a response to, the progression of CDH and 
the associated lung hypoplasia. 
Currently, tracheal occlusion during pregnancy is the only fetal intervention for moderate-
severe cases of isolated CDH (Dekoninck et al., 2011).  While this is effective in treating the 
pulmonary hypoplasia in the prenatal phase, the pulmonary hypertension observed after 
birth is still a major factor contributing to the mortality and morbidity in survivors (Danzer et 
al., 2008).  Therapeutic studies using steroids in lamb models of CDH have demonstrated 
improvements in pulmonary vascular remodeling (Davey et al., 2007; Davey et al., 2006b; 
Davey et al., 2006a).  In a rodent model of CDH reduced VEGFR1 and VEGFR2 expression was 
observed, which were subsequently increased by the use of steroids in conjunction with 
tracheal occlusion (Schmidt et al., 2010).  Targeted therapies already proposed to combat 
pulmonary hypertension may also prove beneficial to block key prenatal inflammatory 
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signals which may benefit a subset of foetuses with CDH thus complementing the current 
foetal therapy (O'Callaghan et al., 2011).  This is of potential interest given the apparent pro-
inflammatory response observed in group 7, with upregulation of TNF, IL6 and IL8.  
Increased levels of TNFα, IL6, and IL1 have been previously described in patients with 
primary pulmonary hypertension (Humbert et al., 1995; Soon et al., 2010).  Interestingly, 
Schaible et al have reported increased concentrations of cytokines in newborns with CDH 
including; TNFα, IFNα, IL3, IL6, IL7, IL8, IL10, CCL3, and CCL4).  The authors propose that CDH 
is associated with a pulmonary inflammatory response immediately after birth (Schaible et 
al., 2011).   
Vuletin et al assessed the potential of prenatal predictors of postnatal severe pulmonary 
artery hypertension (PAH) in isolated left congenital diaphragmatic hernia (CDH), defining a 
new prenatal pulmonary hypertension index (PPHI) (Vuletin et al., 2010).  Patients with 
systemic/suprasystemic and subsystemic pulmonary hypertension at 3 weeks of age were 
identified.  Diameters of the right pulmonary artery, left pulmonary artery (LPA(d)), aorta, 
and the length of vermis of the cerebellum were obtained from prenatal magnetic 
resonance imaging to calculate the PPHI [=(LPA(d)/length of vermis of the cerebellum) x 10] 
and the modified McGoon index (MGI) [=(diameter of the right pulmonary artery + 
LPA(d))/diameter of aorta].  PPHI and MGI were compared with LHR, percent predicted lung 
volume, and total lung volume for pulmonary hypertension and survival.  The PPHI and MGI 
had a significant, negative correlation with pulmonary hypertension.  The PPHI and MGI 
were significantly lower in the systemic/suprasystemic PAH group compared with the 
subsystemic PAH group, with no significant differences between the groups comparing the 
LHR, percent predicted lung volume, and total lung volume.  The authors conclude that both 
PPHI and MGI accurately predict the severity of postnatal PAH in isolated left CDH (Vuletin et 
al., 2010). 
Inflammatory markers can also be an indication of intra-amniotic infections such as 
chorioamnionitis (inflammation of the fetal membranes due to a bacterial infection).  It has 
been demonstrated in a mouse model that inflammatory mediators can cause dysfunction of 
the amniotic barrier by disruption of amniotic tight junctions (TJs) (Kobayashi et al., 2010).  
Injection of IL6 into the amniotic cavity induced disruption of amniotic tight junctions by 
decreasing claudin3 and claudin4 levels at the apical junction, and injection of TNFα 
weakened the amniotic barrier by inducing apoptosis of amniotic epithelial cells.  
Intrauterine inflammation has also been associated to preterm delivery, which may be of 
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relevance given the high degree of preterm premature rupture of membranes (PPROM) 
following prenatal therapy by FETO which impacts gestational age at delivery and 
complicates balloon removal prior to birth (Deprest et al., 2011).  Significantly higher levels 
of pro-inflammatory cytokines including TNFα, IL6 and IL8 have been reported in association 
with preterm delivery (Veleminsky, Jr. et al., 2008; Zhang et al., 2000; La Sala et al., 2012), 
though there is some discordance between different studies (Puchner et al., 2012; 
Weissenbacher et al., 2013). 
Previous studies of the origin of amniotic fluid derived cells are limited mainly to 
morphological and culture characteristics (Gosden, 1983; Tyden et al., 1981).  Given that 
cells derived from AF are a mixture of different cell types we cannot fully exclude that the 
changes we observe are not differences in gene expression per se but represent differences 
in the cellular composition.  Culture of cells is also a factor which may influence gene 
expression.  Recently, several groups have focused on global gene expression analysis of cell-
free RNA in AF supernatant including for studies of trisomies 21 and 18 (Hui et al., 2012b; 
Hui et al., 2013; Hui et al., 2012a; Koide et al., 2011).  This may represent an alternative 
source of foetal material for investigation.  However, based upon our analyses and limited 
prior observations of apparent inflammatory responses in CDH patients which may 
contribute to severity of pulmonary hypertension, we propose that a follow up study at the 
protein level using AF supernatant or cord blood in a large cohort of foetuses affected with 
isolated CDH may provide more conclusive evidence to identify potential therapeutic targets 
in a subset of patients.   
We do not identify dysregulation of key genes involved in the retinoic acid (RA) pathway.  
While much data has been generated by targeted gene expression analysis in models of CDH 
(reviewed in (Brady et al., 2010), there is little from unbiased genome-wide analyses.  Many 
studies have utilized the nitrofen CDH rodent model, with a number of these also 
demonstrating ‘rescue’ of the defect by supplementary RA (Montedonico et al., 2006; 
Montedonico et al., 2008; Doi et al., 2009; Ruttenstock et al., 2012; Schmidt et al., 2012; 
Pederiva et al., 2012; Doi et al., 2011b; Ruttenstock et al., 2011b; Doi et al., 2011a; 
Ruttenstock et al., 2011c; Ruttenstock et al., 2011a; Doi et al., 2010c; Doi et al., 2010b; Doi et 
al., 2010a; Ruttenstock et al., 2010).  The molecular relevance of the nitrofen model to the 
human situation is questionable, and the dietary supplementation with RA is also 
controversial, particularly in the absence of an identifiable defect within this pathway.  
Interestingly, Beurskens et al reported that CDH is strongly associated with low retinol and 
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RBP levels in newborns, independent of maternal retinol status, supporting the retinoid 
hypothesis (Beurskens et al., 2010).  More recently, the same group reported that reduced 
dietary vitamin A intake during pregnancy was significantly associated with an increased risk 
of CDH in the offspring (Beurskens et al., 2013).  These studies have been conducted on 
small sample cohorts and further investigation in larger study populations is still necessary.  
Altered levels of RA due to common variants in genes involved in the retinoid signalling 
pathway have also been shown (El et al., 2010; Manolescu et al., 2010).   
In light of our results using an unbiased approach and observations from several recent 
targeted studies which have also found upregulation of inflammatory molecules, it would be 
of interest to examine protein levels in AF supernatant in a larger cohort of moderate-severe 
isolated CDH patients to determine if this can confirm a subset of foetuses with a pro-
inflammatory response which may represent a novel therapeutic target complementing the 
current FETO therapy. 
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Chapter 7.  Conclusions & Future Perspectives 
7.1 Prenatal Diagnosis 
7.1.1. Chromosomal Microarrays for Prenatal Diagnosis 
The general consensus is growing that chromosomal microarrays can be implemented in the 
prenatal setting as the first tier test (Shaffer et al., 2012; Wapner et al., 2012b; Hillman et al., 
2013; Callaway et al., 2013; Brady et al., 2013b).  Those arrays do provide a higher diagnostic 
yield, detecting submicroscopic CNVs undetectable by conventional karyotyping, as well as 
larger genomic imbalances, and within a faster timeframe.  In the first part of this thesis 
(Chapter 3) we demonstrated the added value of chromosomal microarray analysis for 
prenatal diagnosis in the presence of ultrasound abnormalities.  Our findings demonstrated 
an increase in the diagnostic yield of pathogenic CNVs of 6.5 % in comparison to 
conventional karyotype alone, with 2.6 % of those CNVs detected being submicroscopic and 
completely undetectable by karyotype.  A meta-analysis of prenatal microarray studies 
reported an increased diagnostic yield of chromosomal microarrays over karyotyping of 10% 
(8-13%, 95% confidence interval) in the presence of ultrasound anomalies (Hillman et al., 
2013).  More recently, a literature review of prenatal microarray studies estimated a 7% 
increase in the diagnostic yield in the presence of ultrasound anomalies (Callaway et al., 
2013).  The largest prospective studies in recent years report increased detection rates of 
pathogenic CNVs of between 6-8% in the presence of ultrasound anomalies (Shaffer et al., 
2012; Breman et al., 2012; Wapner et al., 2012b).  We summarise the findings of these and 
other recent prenatal array studies in Table 7.1.1 (Wapner et al., 2012b; Shaffer et al., 2012; 
Breman et al., 2012; Lee et al., 2012; Fiorentino et al., 2011; Armengol et al., 2012; Park et 
al., 2011; Hillman et al., 2011).  Using the results from these studies the increased detection 
rate of pathogenic CNVs above karyotyping alone is calculated to be ~2.1% regardless of 
referral indication, rising to ~5.3% where the referral was due to abnormal ultrasound 
findings.  Arrays increased the detection rate by 0.5-1.7% for lower-risk referral indications 
such as advanced age or abnormal biochemical screen, with no abnormal ultrasound 
findings and a normal karyotype.  Lee et al also estimated the baseline risk of a pathogenic 
submicroscopic CNV to be ~0.52% (Lee et al., 2012).     
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Total No. of cases Overall Detection 
Rate
1 
Detection Rate Above karyotyping VOUS Clinically significant but 
unrelated to phenotype 
Study 
Abnormal 
US 
AMA, high-risk 
biochemical screening 
Any 
indication 
4282
2
 
4340 total, 58 
mosaic excluded 
11.7 
(8.7%)
3 
(0.5%)
4 
6.0% 1.7% AMA 
1.6% screening 
2.5% 1.5% 1.3%
5
 normal karyotype 
3.6% abnormal US 
0.8% normal US 
(Wapner et al., 
2012b) 
3876
2 
NR 6.5% 
(7.6%)
6 
NR 5.3% 
(6.5%)
6 
4.2% 
(0.39%)
7 
1.3% (Shaffer et al., 
2012) 
1075
2 
7.6% total 
(4.2 % excluding known 
abnormals) 
NR NR 1.7% 1.6% NR (Breman et al., 
2012) 
3171 2.7% NR NR 1.1% 0.6% 
(0.2%)
7 
0.52%
8
 (Lee et al., 2012) 
1037 3.3% NR NR 0.9% 0% NR (Fiorentino et al., 
2011) 
906 6.2% 3.5% 1.1% AMA 
0.4% screening 
1.7% Anxiety 
1.6% 1.9% NR (Armengol et al., 
2012) 
4073 1.8% NR NR 0.27% NR NR (Park et al., 2011) 
751
9 
NR 5.2% NR 3.6% 1.1% NR (Hillman et al., 
2011) 
AVERAGE TOTALS  5.30%  2.12% 1.56% 
(0.96%)
10 
  
Table 7.1.1.  Summarises the results from the most recent chromosomal microarray studies applied for prenatal diagnosis. 
US = ultrasound; AMA = advanced maternal age; VOUS = variant of uncertain significance; NR = not reported. 
1
 Including karyotypically visible abnormalities for some studies; 
2
 Number of ‘unbiased’ cases used for calculations; 
3
 Automosomal or sex chromosome aneuploidies; 
4
 
Unbalanced rearrangements or marker chromosomes; 
5
 Recurrent CNVs associated with autism and neurocognitive alterations; 
6
 Detection rates for oligonucleotide-based 
arrays only; 
7
 Percentage of VOUS occurring de novo; 
8
 Baseline risk calculation for pathogenic CNV in pregnancies with no sonographic anomalies; 
9
 10 studies included, 8 
studies used for meta-analysis; 
10
 Using de novo VOUS values for calculation. 
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Furthermore, arrays provide the ability to detect a number of microdeletion / 
microduplication syndromes, some of which may cause severe childhood developmental 
disorders but may not show any foetal abnormality by classic ultrasound techniques.  In the 
absence of ultrasound abnormalities, chromosomal microarrays were reported to increase 
the detection rate above karyotyping by 1.7% in cases of advanced maternal age, and 1.6% 
for those with abnormal biochemical screen (Wapner et al., 2012b).  Another study reported 
rates of 1.1% for advanced maternal age, 0.4% from abnormal biochemical screening, and 
1.7% for referral due to maternal anxiety (Armengol et al., 2012).  The National Institute of 
Child Health and Human Development study (NICHD, USA) reported clinically significant 
findings unrelated to the initial referral reason in 1.3% with normal karyotype, 3.6% with 
abnormal ultrasound features, and 0.8% where ultrasound findings were normal.  Shaffer et 
al report a similar rate of 1.3% (Shaffer et al., 2012), and Lee et al estimate the baseline risk 
at 0.52% (Lee et al., 2012).  Given these findings the use of chromosomal microarrays as the 
first tier test for all invasive prenatal referrals seems warranted. 
In the future, routine prenatal screening by chromosomal microarray analysis will most likely 
be offered to any pregnant women who undergo an invasive procedure given the faster 
reporting time and the mainstream use of arrays for postnatal diagnosis.  In Belgium, 
chromosomal microarray analysis has recently been recommended as the primary prenatal 
diagnostic test following invasive sampling (see the Belgian Society of Human Genetics 
(BeSHG) Summary Guidelines for Prenatal Chromosomal Microarray Analysis and Genetic 
Counselling for further reference); 
[http://www.beshg.be/download/annex_2_summary_of_array_and_prenatal_guidelines_20
130502.pdf]. 
Ethical concerns have long been hampering the routine introduction of chromosomal 
microarrays for prenatal diagnosis (Novelli et al., 2013; McGillivray et al., 2012; Beaudet, 
2010).  There was (and still is) concern about how to deal with unsought for findings, late 
onset disorders, CNVs with variable expressivity and/or penetrance, and variants with only 
mild phenotypic anomalies.  Variants of uncertain significance encompass a spectrum of 
findings which can in most cases be sub-classified as likely pathogenic, likely benign or truly 
of unknown significance based upon factors such as size, gene content, inheritance status, 
and the presence of overlapping CNVs in low numbers of patients or controls (Vermeesch et 
al., 2012).  Current experience estimates the number of cases where difficulties in 
counselling arise due to the detection of VOUS and risk factors are limited to 1-2% (Shaffer 
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et al., 2012; Wapner et al., 2012b; Hillman et al., 2013; Brady et al., 2013b).  Nevertheless, 
more research and consensus guidelines in this area would help both clinicians and families.   
The penetrance risks for a number of recurrent CNVs have been estimated based upon the 
frequencies in patients and controls (Kaminsky et al., 2011; Cooper et al., 2011; Rosenfeld et 
al., 2013).  However, while it is possible to calculate a population-based risk, it is impossible 
in the prenatal setting to predict the phenotypic outcome in the future individual.  Thus, in 
the prenatal setting and in the absence of phenotypic anomalies, classification of a CNV as 
pathogenic where evidence exists for incomplete penetrance is questionable.  The current 
approach we advocate for the reporting of risk factors and for which there is now a 
consensus agreement by the 8 regional genetics centres in Belgium, is that those CNVs with 
penetrance risk below 25% will not be routinely reported back in the prenatal setting, unless 
deemed to be clinically actionable.  Examples of those situations include; (i) the 15q11.2 
microdeletion (NIPA1 gene), penetrance risk 10.4% (Rosenfeld et al., 2013), associated with 
developmental delay, behavioural problems, and/or schizophrenia (Doornbos et al., 2009; 
Sahoo et al., 2011) and which would not be reported; (ii) the 22q11.2 duplication (TBX1 
gene), penetrance risk 21.9% (Rosenfeld et al., 2013), associated with cardiac anomalies.  In 
the absence of cardiac anomalies on initial clinical referral, this would nevertheless be 
reported and follow-up with detailed ultrasound examination for the presence of cardiac 
defects would be advised.  The main difference between our approach and those which 
provide all information revealed by array investigation is that the latter will report back; (i) 
rare/novel inherited CNVs of questionable pathogenicity, and (ii) imbalances for known ‘risk 
loci’ but where the future penetrance is uncertain and with low odds.   
Information from routine prenatal screening using chromosomal microarrays combined with 
subsequent long-term follow-up may provide additional valuable information in a cohort 
with less ascertainment bias than for postnatal diagnosis.  In turn, this will help to further 
determine the full phenotypic spectrum and penetrance risk for certain CNVs, thus allowing 
for more accurate prenatal counselling in the future.  The submission of prenatal CNV 
findings, along with the detailed prenatal phenotype as well as the subsequent long term 
outcome and additional postnatal phenotypes (if any) to current databases is needed.  This 
will aid the interpretation process for prenatal chromosomal microarray analysis as has been 
seen for postnatal use (de Leeuw et al., 2012).  Only if rare/novel CNVs identified prenatally, 
along with the associated phenotypes, are curated into those databases such as DECIPHER 
(http://decipher.sanger.ac.uk/) and ISCA (https://www.iscaconsortium.org/) can diagnostic 
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laboratories utilise this valuable information resource, enabling comparison of their findings 
with those of others thus aiding clinical interpretation.  Furthermore, this will likely lead to 
the detection of novel genes and loci associated with specific foetal abnormalities, as has 
been successfully observed in the postnatal setting. Nevertheless, the workflow for 
classification of CNVs, the subsequent interpretation of rare CNVs and risk loci, and the 
reporting back of results in the prenatal setting warrants further societal research to 
determine the best provision of care. 
The ethical questions posed and the lessons learned in the application of arrays to prenatal 
diagnosis will assist greatly as sequencing of the foetal exome / genome during pregnancy 
becomes a possibility.  Additionally, the experience currently being gained in research and 
clinical diagnostic exome / genome sequencing will also assist in considering how these 
techniques can be best offered in the prenatal setting, perhaps during pregnancy, and 
ultimately for non-invasive prenatal diagnosis. 
7.1.2. Non-Invasive Prenatal Testing (NIPT) for Foetal Aneuploidy Detection 
The ability to screen for foetal aneuploidy by non-invasive methods, i.e. by the analysis of 
cell-free foetal DNA or circulating foetal cells in maternal blood or plasma, has long been 
considered the ‘holy grail’ in prenatal genetic diagnosis.  The initial work of Lo et al identified 
circulating cell-free foetal DNA in maternal plasma (Lo et al., 1997).  Subsequently, this free 
foetal DNA was shown to be pregnancy-specific by rapid clearance from the maternal 
circulation after birth (Lo et al., 1999) and was derived from the trophoblast (Alberry et al., 
2007; Faas et al., 2012).  Cell-free DNA is fragmented with a size distribution of 160-180bp 
(Fan et al., 2010), and has been shown to be stable for a period of days post-sampling 
(Muller et al., 2011).  One of the most important factors in maternal blood sampling is the 
prevention of maternal cell lysis leading to large levels of contaminating cellular DNA 
(Barrett et al., 2011).  Although present at low percentages, from 3% to as much as 20% (Lo 
et al., 1998; Lun et al., 2008) against a high maternal DNA background, isolation of cell-free 
DNA has been shown to be feasible for a number of downstream applications of non-
invasive prenatal diagnosis (NIPD), including foetal sex assessment, (review and meta-
analysis from (Devaney et al., 2011)), and foetal rhesus D blood group genotyping (Finning et 
al., 2002).  NIPD for single gene disorders has thus far been applied for the detection of a 
broad range of monogenic disorders, but were typically restricted to X-linked disorders or 
paternally inherited alleles, reviewed by (Bustamante-Aragones et al., 2012).   
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Advances in detection of foetal cells from maternal circulation have been less successful 
than for cell-free foetal nucleic acids since foetal cell numbers in maternal circulation are 
very low and their enrichment and subsequent culture remain challenging (Calabrese et al., 
2012; Huang et al., 2011).  Clearly, single-cell ‘omics’ analysis has great potential for NIPD if 
methods for isolation of foetal cells from the maternal circulation improve.  Further research 
is needed to determine the correlation between individual circulating foetal cells and that of 
the true foetal genome.  Since circulating cell-free DNA is derived from many cells and also 
represents the entire foetal genome, this may prove to be more representative of the true 
foetal genome. 
Non-invasive foetal aneuploidy detection by massively parallel sequencing was first 
published by 2 separate groups in 2008, Chiu & Lo et al in Hong Kong (Chiu et al., 2008), and 
Fan & Quake et al in Stanford (Fan et al., 2008).  The massively parallel sequencing approach 
to aneuploidy detection applies counting statistics to tens or hundreds of millions of 
sequencing reads in order to identify respective changes in the small percentage of foetal 
DNA present in the total cell-free DNA sample (Chiu et al., 2009; Fan and Quake, 2010).  For 
example, if 10 million mapped reads are obtained and 1% (100,000 reads) map to 
chromosome 21 in a normal pregnancy, then a trisomy 21 pregnancy with a level of 10% 
free-foetal DNA in maternal plasma will contribute a higher proportion of reads to 
chromosome 21, in this case 1.05% (105,000 reads).  With sufficient sequencing coverage 
(>10 million reads) this small difference can be confidently detected in comparison to the 
mean and standard deviation (SD) of a normal cohort of pregnancies.  In order to distinguish 
between non-invasive prenatal diagnosis of single gene disorders and the screening for 
foetal aneuploidy (primarily by massively parallel sequencing), the term non-invasive 
prenatal testing (NIPT) is now increasingly used. 
Since these initial proof-of-principle studies the industry has expanded dramatically, with 
some tests rapidly reaching clinical use in some countries.  In one of the first large-scale 
clinical validation studies, groups from the UK, the Netherlands and Hong Kong 
demonstrated detection of trisomy 21 foetuses with 100% sensitivity and 97.9% specificity, 
which resulted in a positive predictive value of 96.6% and negative predictive value of 100%, 
using a 2-plex protocol (Chiu et al., 2011).  2-plex implies multiplexing of 2 samples labelled 
with unique DNA sequence indices clustered within a single lane of a sequencing flow cell.  
Multiplexing of samples reduces costs per sample, but at the expense of lower sequencing 
coverage per sample.  In comparison, the 8-plex protocol detected 79.1% of the trisomy 21 
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foetuses and 98.9% specificity, giving a positive predictive value of 91.9% and negative 
predictive value of 96.9%.  Other studies have reported similar high levels of sensitivity and 
specificity and for additional chromosomes (Palomaki et al., 2012; Ehrich et al., 2011), 
reviewed in (Verweij et al., 2012).  In one of the largest studies to date, Dan et al recently 
reported on the clinical use of massively parallel sequencing for aneuploidy detection in cell-
free DNA from maternal plasma in > 11,000 pregnancies (Dan et al., 2012).  143 cases of 
trisomy 21 and 47 cases of trisomy 18 were identified correctly, with one false positive case 
of trisomy 21, one false positive case of trisomy 18 and no false negative cases, indicating 
100% sensitivity and 99.96% specificity for the detection of trisomies 21 and 18.  Routine 
clinical use could avoid about 98% of invasive prenatal diagnostic procedures. 
Other approaches use targeted strategies for aneuploidy detection of chromosomes 13, 18, 
21, X and Y only.  Those methods include the analysis of epigenetic differences between 
foetal and maternal cell-free DNA nucleic acids.  One technique uses methylated DNA 
immunoprecipitation (MeDIP) and real-time quantitative polymerase chain reaction (real-
time qPCR) to identify differentially methylated regions (DMRs) between maternal and 
foetal cell-free DNA (Patsalis et al., 2012; Della et al., 2010; Papageorgiou et al., 2011).  This 
technique was recently shown in a blinded validation study to detect trisomy 21 with 100% 
sensitivity and 99.2% specificity (Tsaliki et al., 2012). 
 
7.2 Congenital Diaphragmatic Hernia 
The exact origins of the early pleuroperitoneal fold (PPF) tissue remain to be resolved, and 
the mechanisms which are involved in normal PPF development and disrupted in CDH are 
uncertain.  Animal models will remain essential in unravelling these early stages of PPF 
formation and CDH development due to the difficulties in studying this early stage of foetal 
development in humans.  It has been reported that it is decreased cell proliferation in the 
PPF which underlies CDH development in the nitrofen rodent model and not increased 
apoptosis (Clugston et al., 2009).  While the nitrofen rodent model has advanced knowledge 
of diaphragm formation and CDH development, it may not be applicable to understanding 
the genetic factors involved in human CDH.  For this reason, there will likely be a continued 
shift towards the use of genetic mouse models rather than the nitrofen rodent model to 
better understand the molecular mechanisms underlying PPF development and the causes 
of CDH.  Expression microarrays have been performed in the hypoplastic lungs of the 
nitrofen rodent as well as in the hyperplastic lungs of a normal rodent model following 
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tracheal ligation (Mesas-Burgos et al., 2010b; Mesas-Burgos et al., 2009).  However, global 
transcriptome analysis has not yet been reported for CDH subsequently treated with 
tracheal ligation (TL), in the nitrofen rodent or any other model.  Recently, the transcriptome 
of the developing PPFs and muscular diaphragm was investigated in a normal mouse model 
providing valuable information on which genes are expressed during development of the 
PPFs and development of the muscular diaphragm in the normal situation (Russell et al., 
2012).  Of great interest will be future studies in different genetic mouse models of CDH to 
determine which genes and biological pathways are disrupted in comparison to this normal 
mouse model dataset.  This may help to reveal common developmental network(s) of genes 
which are dysregulated in specific genetic models of CDH, such as for GATA4, ZFPM2 and 
NR2F2.  Surgical animal models of CDH and lung hypoplasia may also provide a more 
accurate reflection of response to therapy than with the nitrofen model or genetic models 
and even identify novel therapeutic targets.  We are currently investigating by RNA-
Sequencing the effects of tracheal occlusion on gene expression in a surgical rabbit model of 
CDH, and CDH treated with TO.  These results will provide a better understanding of the 
molecular processes involved in development of lung hypoplasia due to (surgical) CDH and 
the molecular effects induced by subsequent TO.  This will help to identify the biological 
pathways affected in the hypoplastic lungs due to CDH, as well as the changes induced by 
TO, thus identifying potential therapeutic targets for further study. 
In humans, CDH is considered to have a strong genetic component from classical cytogenetic 
investigations, reviewed in (Holder et al., 2007).  More recently chromosomal microarray 
analysis of CDH patients has identified novel risk loci and allowed for refinement of other 
loci (Klaassens et al., 2005; Kantarci et al., 2006; Shaffer et al., 2007; Klaassens et al., 2007; 
Scott et al., 2007; Wat et al., 2009b; Kantarci et al., 2010; Srisupundit et al., 2010; Rosenfeld 
et al., 2011; Wat et al., 2011; Yu et al., 2012; Brady et al., 2013a).  The two most recent 
microarray studies of mixed cohorts of isolated and non-isolated CDH patients revealed 
pathogenic CNVs in 8/45 (2 isolated; 6 non-isolated) and 16/256 (5 isolated; 11 non-isolated) 
patients investigated, respectively (Wat et al., 2011; Yu et al., 2012).  The study of Wat et al 
(Wat et al., 2011) also reported 16/45 cases with rare inherited CNVs of uncertain clinical 
significance.  Our evaluation into the use of chromosomal microarray analysis for 
identification of CNVs associated with isolated CDH revealed pathogenic submicroscopic 
CNVs to be a cause in ~9% of foetuses, thus demonstrating the value of chromosomal 
microarray analysis over conventional karyotyping for gene identification and for 
investigation of isolated CDH (Brady et al., 2013a).  This allowed for refinement of the CDH 
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locus at 15q26, thus highlighting deletion of NR2F2 as a cause of isolated CDH, and possibly 
cardiovascular malformations.  In addition we add further evidence for recurrent 
microdeletions at 15q25.2 and 16p11.2 as a cause of CDH, showing apparent high and low 
penetrance risks of CDH, respectively.  Novel loci and rare CNVs have also been identified by 
us and others revealing new candidate genes and which may be involved in CDH 
development (Srisupundit et al., 2010; Wat et al., 2011; Yu et al., 2012; Brady et al., 2013a).   
While chromosomal microarray analysis has increased the diagnostic yield, revealed novel 
loci and refined some others, this still does not resolve the genetic cause in the majority of 
CDH cases.  Hence, exome sequencing is an attractive approach for causal gene 
identification in familial cases of isolated and non-isolated CDH, sequencing all known genes 
for pathogenic variants responsible for CDH.  By applying exome sequencing in a family with 
2 prior foetuses affected with isolated CDH we identified a nonsense mutation causing a 
premature stop codon in the ZFPM2 gene.  The mutation is a cause of isolated CDH in two 
foetuses, and is also considered the cause of a cardiac defect and diaphragm eventration in a 
sibling who was shown to carry the same mutation.  However, there are also several 
asymptomatic carriers within this family.  These findings add further evidence for 
heterozygous loss of function mutations (or deletions) which cause haploinsufficiency of 
ZFPM2 as a cause of isolated CDH, diaphragm eventration, and possibly cardiovascular 
malformations.  Furthermore, the finding of the same mutation in apparently asymptomatic 
individuals within the same family demonstrates that ZFPM2 haploinsufficiency is also 
associated with reduced penetrance, as well as variable phenotypic expression.  Similar 
findings of incomplete penetrance were recently reported for the GATA4 gene, for which 
exome sequencing identified an inherited variant associated with familial CDH, also present 
in apparently asymptomatic carriers who were later shown by MRI to have mild diaphragm 
defects (Yu et al., 2013).  Taking these findings from exome sequencing and from microarray 
investigations, it is evident that NR2F2, ZFPM2, and GATA4 are all associated with both 
diaphragm and cardiovascular abnormalities, and that those anomalies can differ in their 
specific anatomical location and in their severity. 
Exome sequencing was also successfully applied to the investigation of syndromic CDH in a 
second family with 2 foetuses affected with multiple congenital anomalies including 
microphthalmia, CDH and neural tube defects.  A splice site mutation in the X-linked PORCN 
gene was identified, adding further evidence for involvement of PORCN and thus Wnt 
signaling in syndromic forms of CDH in combination with eye anomalies.  In a third family 
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investigated by exome sequencing, a homozygous missense mutation in the PIGN gene was 
identified as the cause of multiple congenital anomalies including CDH in a consanguineous 
family with a single affected foetus.  This finding highlights a possible role for defective GPI 
anchor synthesis as a cause of syndromic CDH and expands the phenotypic spectrum of 
developmental abnormalities associated with PIGN mutations.   
There will undoubtedly be an increase in the use of exome and whole genome sequencing to 
identify (novel) genetic variants in patients with isolated and non-isolated CDH for research 
purposes and also in the clinical setting.  Targeted mutation analyses on smaller panels of 
candidate CDH genes in retrospective patient cohorts will also help determine the 
prevalence in sporadic cases of isolated CDH.  By firstly screening for CNVs, followed by 
exome or whole genome sequencing in large cohorts of isolated CDH patients it becomes 
possible to search for an excess burden of rare variants in candidate CDH genes.  This 
technique has been applied to autism and to congenital heart disease (O'Roak et al., 2012; 
Zaidi et al., 2013).  To aid variant identification, the use of functional predictions and 
gene/variant prioritizations will play an increasing role (Sifrim et al., 2013). 
Exome sequencing is rapidly entering clinical use; however, it does have its limitations.  The 
capture methodology has advanced from ‘on array’ to ‘in solution’ capture kits, and the 
target designs continue to improve in an attempt to provide more even coverage of those 
target regions.  An example of the limitations of exome sequencing is a SMOC2 mutation 
causing major dental developmental defects which was missed by whole-exome sequencing, 
but was identified by homozygosity mapping of affected individuals and candidate gene 
prioritization (Bloch-Zupan et al., 2011).  Chromosomal microarrays are now in mainstream 
diagnostic use for postnatal use and rapidly entering the prenatal setting.  Given the costs of 
exome sequencing, an array is almost always performed beforehand to exclude pathogenic 
CNVs as the cause.  Copy number analysis has been demonstrated using exome sequencing 
data (Krumm et al., 2012), but the reliability for diagnostic purposes remains uncertain, and 
continued changes to capture design can complicate or preclude routine copy number 
detection.  There is therefore a ‘blind spot’ in the search for pathogenic variants between 
that offered by array (typically several kilobases to several hundred kilobases in size) to the 
single nucleotide variants and indels which are able to be detected by exome sequencing.  
Without the full picture, identifiable pathogenic variants in this range still go undetected. 
Numerous genes and genomic loci are associated with an increased risk of CDH, but none of 
those display full penetrance for CDH.  As our knowledge of the genetic factors influencing 
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CDH improves, identification of the genetic factors which influence CDH penetrance will 
become increasingly important and may reveal novel therapeutic targets.  The low familial 
recurrence risk for cases of isolated CDH (1-2%) points towards complex polygenic and/or 
epigenetic factors playing an important role.  Future studies may be undertaken to identify 
2nd genetic hits which may contribute to CDH penetrance in CDH patients with a primary 
pathogenic genetic variant detected.  Girirajan et al proposed a ‘two-hit model’ for severe 
developmental delay in association with the recurrent 16p12.1 microdeletion (Girirajan et 
al., 2010).  The same authors later demonstrated that among children with intellectual 
disability or congenital anomalies, 10.1% carried a second large copy-number variant in 
addition to the primary genetic lesion (Girirajan et al., 2012).  Our finding of a 17p12 
duplication (CMT1A locus; OMIM #118220) in a foetus with a 15q25.2 deletion and CDH may 
represent a ‘second CNV hit’ contributing to CDH penetrance or severity.  Can rare variants 
be identified which represent a 2nd genetic hit, either de novo or inherited?  Is it possible to 
identify candidate modifier genes influencing CDH penetrance in animal models, for 
example, the ZFPM2, NR2F2, and GATA4 mouse models?  The FREM1 gene was recently 
associated with CDH in humans and in the Frem1 (eyes2) mouse model (Beck et al., 2013b).  
The authors subsequently showed in an alternative Frem1 mouse model that variants 
affecting GATA4 and SLIT3 expression modulated certain phenotypic features (Beck et al., 
2013a).   
In addition to the whole genome sequence of an individual, the ongoing monitoring of other 
‘-omes’ (e.g. transcriptome, methylome, proteome, metabolome) from the same individual 
has been termed the integrated personal omics profile (or iPOP), and a proof of principle has 
been demonstrated (Chen et al., 2012).  This type of information combing the genetic 
background along with ongoing dynamic monitoring an individual’s physiological state may 
eventually lead to truly personalised medicine.  This integrated approach has the potential 
to improve assessment of an individual’s risk of disease, detect disease onset and monitor 
disease progression, aid with targeted treatments, improve our understanding of the 
biological processes underlying disease states and the variation in disease severity and 
response to treatment between individuals (Chen et al., 2012; Li-Pook-Than and Snyder, 
2013).  These types of techniques will increasingly be applied to the study of congenital 
malformations such as CDH.   
By applying RNA sequencing we sought to explore the gene expression profiles in the 
amniotic fluid cells in a cohort of isolated CDH foetuses.  This analysis identified 2 groups 
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representing potential molecular subtypes of CDH, each group comprising ~1/4 of the total 
studied.  In one group of CDH foetuses downregulation of TGFB1 and the upregulation of 
TNF are predicted to cause much of the downstream dysregulation in gene expression 
observed and may thus represent therapeutic targets.  This subtype also shows 
downregulation of CTGF, likely as a direct result of TGFB1 downregulation.  CTGF has 
previously been shown to be downregulated in the nitrofen rodent model of CDH and lung 
hypoplasia (Mesas-Burgos et al., 2010a; Mesas-Burgos et al., 2010b; Mesas-Burgos et al., 
2009).  Interestingly, tracheal ligation was shown to upregulate CTGF in the rodent model 
(Mesas-Burgos et al., 2010a; Mesas-Burgos et al., 2009).  In contrast to some of the targeted 
studies of human CDH, we did not observe significant dysregulation of key genes involved in 
retinol metabolism. Tracheal fluid can be retrieved from CDH patients undergoing FETO prior 
to tracheal occlusion and following balloon removal.  This may represent a valuable source 
of material which could be studied to better understand the differences in response to foetal 
therapy. 
The investigation of environmental factors is challenging in human subjects, however, there 
is some evidence which supports possible defects in foetal retinol metabolism (Beurskens et 
al., 2009).  Beurskens et al reported lower levels of retinol and RBP in cord blood of 
newborns with CDH compared to controls, independent of maternal levels (Beurskens et al., 
2010).  The same authors also reported an association between reduced dietary Vitamin A 
intake and an increased of CDH (Beurskens et al., 2013).  Targeted gene expression studies in 
foetal skin fibroblasts have demonstrated expression changes in genes involved in retinol 
metabolism in a small number of CDH patients (Goumy et al., 2010a).  These studies are few 
and on small cohorts, therefore these results need to be reproduced in larger populations to 
determine the significance of defects in foetal retinol metabolism. 
Novel cellular models are likely to play an increasing role in the study and treatment of CDH.  
It has been demonstrated that mesenchymal stem cells (MSCs) can be routinely isolated 
from the amniotic fluid (Zia et al., 2013).  These AF-MSCs provide a source of cells from the 
patient which can be studied and manipulated (Zia et al., 2013).  The availability of AF-MSCs 
represents a source of the patients own material which could potentially be used to 
engineer an autologous tissue patch during the pregnancy which is ready for repair of the 
diaphragm after birth (Turner et al., 2011).  A successful stem-cell-based tissue engineered 
tracheal replacement was recently performed in a child with congenital tracheal stenosis 
(Elliott et al., 2012).  The potential for tissue engineering an autologous lung by seeding a 
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decellularised extracellular matrix (ECM) scaffold has also been demonstrated using a 
refined protocol which retained the pulmonary vascular and bronchial microarchitecture 
(Maghsoudlou et al., 2013).  The potential for AF stem cells to rescue lung growth and 
function both in vivo and in vitro in the nitrofen rodent model of CDH and lung hypoplasia 
has also been shown (Pederiva et al., 2012). 
Over the past decade there has been a steady improvement in our understanding of the 
genetic factors contributing to CDH by the application of chromosomal microarrays and 
more recently exome sequencing.  Chromosomal microarrays are increasingly being used in 
the prenatal setting and it is likely that exome sequencing will be increasingly used for 
diagnostic purposes including prenatal diagnosis.  The treatment for CDH patients has also 
advanced and shifted to the prenatal setting in an attempt to improve lung growth and 
function prior to birth.  Advances in tissue engineering and the availability of foetal stem 
cells by amniocentesis sampling during pregnancy show great promise for improving the 
outcome and treatment options available.  The use of next generation sequencing 
technologies for exome / whole genome analysis and transcriptome studies in CDH patients 
and in animal models will continue to develop our understanding of the condition and the 
effects of available treatments, allowing for prediction of which patients will respond best to 
therapy and understanding why, thus leading to novel therapeutic treatments which in turn 
will reduce the high mortality rate and morbidity associated with congenital diaphragmatic 
hernia. 
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Popular Summary 
This doctoral research has focused on the application of recently emerging genetic 
technologies to prenatal genetic diagnosis.  Conventional cytogenetic analysis by karyotype 
visualizes stained chromosomes by light microscopy.  Karyotyping can detect numerical (e.g. 
trisomy 21, Down syndrome) and structural rearrangements to a resolution of ~10Mb.  
Furthermore, karyotyping requires the culturing of foetal cells obtained by invasive 
procedures which requires at least 8-10 days. 
Chromosomal microarray analysis is a recent technique which can detect Copy Number 
Variations (CNVs), i.e. gains or losses of regions of the genome, at a far superior resolution 
and in a faster timeframe compared to conventional karyotyping.  This makes chromosomal 
microarrays an attractive alternative to karyotyping for prenatal diagnosis.  The technology 
has entered mainstream clinical use over the past several years primarily for the genetic 
diagnosis of children with multiple congenital abnormalities, as well as isolated 
abnormalities such as congenital heart defects, children with developmental problems, and 
autism.  Prenatal diagnosis has been left lagging behind somewhat.  One of the major 
reasons for the slow introduction into prenatal diagnosis has been due to the detection of 
CNVs which, based upon our current knowledge, are of uncertain clinical significance.  These 
variants of uncertain significance (VOUS) are observed in 1-2% of patients and normal 
individuals studied.  Such findings during pregnancy can lead to increased anxiety for the 
parents and are difficult to counsel for.  Furthermore, CNVs may be detected which are 
associated with reduced penetrance (i.e. they have been observed in both normal 
individuals and in patients; for example, an affected child has inherited the same CNV from 
an apparently normal asymptomatic parent).  Alternatively, a CNV may be associated with 
variable expression for which a spectrum of phenotypic features have been observed in 
patients.  This creates particular challenges in the prenatal setting, since it is not possible to 
predict the phenotypic features, nor their severity, in the future child.  It should also be 
mentioned that all of us carry benign polymorphic CNVs, some of which may be common 
within particular populations, and some which are rare and only observed in individual 
families.  With increasing resolutions, the boundary between pathogenic CNVs and benign 
CNVs becomes blurred creating challenges for the interpretation and counseling of families.  
We therefore sought to investigate the clinical utility of prenatal genetic diagnosis by 
chromosomal microarray analysis in those pregnancies where foetal abnormalities were 
detected on ultrasound.  Furthermore, we also considered how to handle the reporting of 
different types of CNVs during pregnancy.  Our results demonstrated an increase in the 
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diagnostic yield of pathogenic variants compared to conventional karyotyping alone; in ~3% 
of cases a submicroscopic pathogenic CNV was detected which would have gone undetected 
by conventional karyotyping; in a further ~4% of cases with an abnormal karyotype but for 
which the chromosomes involved could not be fully elucidated, chromosomal microarray 
analysis provided valuable information aiding the interpretation; in ~3% of cases the genetic 
abnormality detected was also detected by karyotype.  These advantages however come 
with the detection of VOUS in 1-2% of foetuses (and parents) studied.   
Clearly pathogenic CNVs are always reported back to the parents, whereas common 
polymorphic CNVs are not routinely reported back in the diagnostic setting (both in the post- 
and prenatal setting).  In contrast to postnatal reporting criteria, we have taken the 
approach not to report VOUS back to parents during the pregnancy, since this is of limited 
(or no) clinical utility and may even cause more anxiety to the parents.  For those CNVs 
which pose a penetrance risk >25 %, these are reported and counseled for based upon the 
evidence from large case-control studies; those with a penetrance risk of <25%are not 
(routinely) reported to the parents unless actionable. 
Congenital Diaphragmatic Hernia (CDH) is an example of a foetal abnormality detectable by 
ultrasound during pregnancy.  The abnormal development and closure of the diaphragm 
during foetal development allows herniation of abdominal organs including the intestines, 
and often the liver, into the thoracic cavity.  This causes reduced space for the lungs to 
develop and grow resulting in hypoplastic lungs which are then underdeveloped at birth 
causing great difficulties for the newborn to breathe.  In association, the vasculature of the 
lungs is also abnormal causing pulmonary hypertension.  Until the newborn is stable it is not 
possible to surgically correct the diaphragm defect, and mortality remains high in the most 
severe cases.  UZ Leuven is a specialist referral centre for pregnant women with foetuses 
affected with isolated CDH.  In those with moderate-severe lung hypoplasia, a minimally 
invasive foetal therapy is offered by fetoscopic endoluminal tracheal occlusion (FETO).  This 
involves the placement of an inflatable balloon into the trachea of the foetus in utero.  By 
‘plugging’ the trachea, there is an increase in pressure within the lungs due to the natural 
secretion of lung fluids which are unable to escape.  This causes inflation of the lungs 
counteracting the effects of the herniated organs, and thus improves lung growth during 
pregnancy while the foetus does not need to breathe, thereby improving the outcome for 
the newborn and reducing the neonatal mortality to some degree. 
We have focused on identifying genetic factors which contribute to CDH pathogenesis in 
order to improve our understanding of the underlying genes and molecular mechanisms 
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involved.  By chromosomal microarray analysis we demonstrated that submicroscopic CNVs 
associated with CDH were detected in at least 10% of foetuses studied.  These genomic 
variants would have gone undetected by conventional karyotyping.  This is significantly 
higher than the increase in detection rate we observed in pregnancies with any ultrasound 
abnormality, as discussed above.  Thus, isolated CDH represents a valid reason for 
performing chromosomal microarray analysis and suggests that for these patients the utility 
of conventional karyotyping is of limited use. 
However, for the majority of patients still no genetic diagnosis can be obtained.  In order to 
further identify the genetic variants responsible, we applied next-generation sequencing 
(NGS) technologies in order to sequence the exome (all the genes in the human genome) in 
familial cases of isolated CDH, and non-isolated or syndromic CDH.  We demonstrated that in 
several families with a high likelihood of a genetic cause due to multiple affected foetuses, 
or due to a consanguineous relationship in the parents, this approach was able to identify 
the pathogenic mutation.  This provides identification of the cause and allows for a more 
accurate calculation of the recurrence risk for future pregnancies in these families, as well 
for other family members where appropriate. 
In conclusion, we have demonstrated that the use of chromosomal microarray analysis for 
prenatal diagnosis in the presence of ultrasound abnormalities increases the detection of 
genetic variants which explain the foetal abnormalities.  This provides families with an 
explanation for this occurrence and thus a more accurate assessment of the recurrence risk 
for future pregnancies.  We demonstrated that isolated CDH is particularly suited to 
chromosomal microarray analysis, by identification of novel CNVs, as well as confirming the 
association of other CNVs with CDH.  Furthermore, we show that where chromosomal 
microarray analysis does not reveal a cause that the use of NGS technologies for exome 
sequencing can provide a diagnosis for some families.  Chromosomal microarray analysis is 
now offered as the first-tier test for prenatal diagnosis in Leuven, and we anticipate that 
exome sequencing will increase in use as costs of NGS continue to fall.  However, caution 
must be maintained and the ethical challenges posed by these new techniques need to be 
carefully addressed in order to ensure that the benefits outweigh the concerns of potentially 
identifying ‘unsought for findings’ or ‘secondary variants’ which are unrelated to the initial 
reasons for investigation. 
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Samenvatting 
Prenatale genetische diagnostiek gebeurt traditioneel door middel van karyotypering.  
Foetale cellen worden verkregen van het amniosvocht of van chorionvlokken via een 
invasieve staalafname.  Deze cellen worden vervolgens opgekweekt en de metafase 
chromosomen worden gevisualiseerd door kleuring.  Karyotypering laat toe om numerieke 
afwijkingen (b.v. het syndroom van Down of trisomie 21) en structurele afwijkingen met een 
resolutie van ~10Mb te detecteren.  Dit duurt ongeveer 8 à 10 dagen.  
Chromosomale microarray analyse is een recente techniek die toelaat  deleties en 
duplicaties in het genoom, ook copy number variations (CNV’s) genoemd, sneller op te 
sporen en dit met een veel hogere resolutie in vergelijking met conventionele karyotypering. 
Hierdoor zijn chromosomale microarrays een heel interessant alternatief.  De technologie 
werd de laatste jaren klinisch ingevoerd voor de genetische diagnostiek van kinderen met 
ontwikkelingsstoornissen zoals hartafwijkingen, intellectuele beperking en autisme. De 
implementatie van microarrays in de prenatale diagnostiek verloopt echter moeizamer. Een 
belangrijke reden voor de moeizamere implementatie is dat voor een groot deel van de 
CNV’s met de huidige kennis de klinische betekenis nog onduidelijk is en dat het tot nog toe 
onmogelijk is om te voorspellen hoe deze CNV’s het toekomstige fenotype zullen 
beïnvloeden. 
Een eerste doel van deze thesis was de ontwikkeling en introductie van chromosomale 
microarrays in de klinische diagnostiek. Wij onderzochten het klinische voordeel van 
microarrays in de prenatale genetische diagnose van zwangerschappen waarbij foetale 
abnormaliteiten gedetecteerd werden via echografie. Daarnaast werd ook een methodiek 
ontwikkeld om welbepaalde CNV’s te rapporteren. Onze studie toonde een belangrijk 
diagnostisch voordeel in vergelijking met conventionele karyotypering.  In 3% van de 
gevallen werden submicroscopische pathogene CNV’s gedetecteerd die niet opgepikt 
werden met conventionele karypotypering.  In 4% van de foetussen werd een abnormaal 
karyotype gedetecteerd, maar leverde de microarray analyse waardevolle bijkomende 
informatie. 
Pathogene CNV’s worden altijd gerapporteerd aan de ouders, daar waar goedaardige CNVs 
binnen een diagnostische context (zowel post- als prenataal) niet worden gerapporteerd. In 
tegenstelling tot de rapporteringsmethodiek in  de postnatale diagnostiek, hebben we er 
voor gekozen om ouders tijdens een zwangerschap niet te informeren over CNV’s met 
ongekende gevolgen, gezien ze weinig of geen informatie bevatten en bovendien kunnen 
leiden tot een grotere ongerustheid bij de ouders. Een van de foetale afwijkingen die 
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echografisch zichtbaar is, is congenitale diafragmatische hernia (CDH). De abnormale 
ontwikkeling en sluiting van het diafragma (middenrif) tijdens de ontwikkeling van de foetus 
zorgt ervoor dat verschillende organen, waaronder de ingewanden en de lever, zich kunnen 
verplaatsen naar de borstholte. Dit beperkt de ruimte voor de groei van de longen waardoor 
deze onderontwikkeld zijn bij de geboorte. Hierdoor worden ernstige 
ademhalingsproblemen veroorzaakt bij de pasgeborene. Bovendien is ook het 
bloedvatenstelsel abnormaal wat pulmonale hypertensie veroorzaakt. Totdat de zuigeling 
stabiel is kan een dergelijk defect in het diafragma niet hersteld worden. Hierdoor is de 
mortaliteit groot bij de sterkst aangetaste patiënten. Het UZ Leuven heeft een 
gespecialiseerd centrum waarnaar de meeste vrouwen die zwanger zijn van een foetus met 
een geïsoleerde CDH doorverwezen worden.  Voor de foetussen die lijden aan een matige 
tot zware onderontwikkeling van de longen (longhypoplasie) wordt een zogenaamde 
Foetoscopische Endoluminele Tracheale Occlusie (FETO) aangeboden. Bij deze kleine 
chirurgische ingreep wordt in utero een kleine ballon aangebracht in de luchtpijp van de 
foetus. De luchtpijp wordt op die manier geblokkeerd waardoor het door de longen 
geproduceerde vocht vastgehouden wordt en de druk in de longen stijgt. Hierdoor gaan de 
longen wat opblazen wat de druk afkomstig van de migrerende organen tegenwerkt. 
Bovendien wordt de longgroei gestimuleerd terwijl de foetus niet hoeft te ademen, wat de 
impact van CDH in de pasgeborene vermindert en de neonatale mortaliteit gedeeltelijk 
reduceert.  
Hoewel er in modelorganismen verschillende genen werden geïdentificeerd die CDH kunnen 
veroorzaken, waren er voor de start van deze thesis nog maar weinig genetische oorzaken 
geïdentificeerd.  Deze thesis stelde zich als doel om de genetische factoren die bijdragen aan 
CDH te identificeren. Met behulp van chromosomale microarray analyse detecteerden we 
submicroscopische CNV’s geassocieerd met CDH in 10% van de bestudeerde foetussen. Deze 
genomische varianten konden tot nu toe niet gedetecteerd worden met  conventionele 
karyotypering. Deze analyse liet toe om een aantal genen te identificeren die bij een teveel 
of een tekort aanleiding kunnen geven tot CDH.  Het diagnostische voordeel  in deze groep is 
significant hoger dan het voordeel in de groep van zwangerschappen met een abnormale 
echografie (zie hoger). De echografische  detectie van CDH in een foetus is bijgevolg een 
indicatie om chromosomale microarray analyse uit te voeren. Hoewel CNV’s een belangrijke 
oorzaak zijn van CDH, kan voor de meerderheid van de patiënten de genetische oorzaak 
(nog) niet worden geïdentificeerd.  Recent werd het mogelijk om aan een redelijke kost de 
sequentie te bepalen van het volledige genoom (of alle exonen) van een individu. Om 
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mogelijke nieuwe genen te identificeren die betrokken zijn in de ontwikkeling van het 
diafragma, hebben we via next-generation sequencing (NGS) het exoom (al de genen van het 
humane genoom) in families met geïsoleerde of syndromische CDH geanalyseerd. Deze 
aanpak liet toe om een aantal pathogene mutaties te identificeren.  
Samenvattend kunnen we stellen dat chromosomale microarrays bij een abnormale 
echografie de detectie van oorzakelijke genetische mutaties verhoogt. Hierdoor kan de 
genetische oorzaak gerapporteerd worden aan de betrokken families en kan het risico voor 
volgende zwangerschappen berekend worden. Het gebruik van deze test liet ons toe om 
enerzijds nieuwe CNV’s oorzakelijk voor CDH te identificeren en anderzijds de associatie van 
welbepaalde CNV’s met CDH te bevestigen. Indien er geen pathogene CNV’s gedetecteerd 
werden met behulp van chromosomale microarray analyse, stelden we vast dat 
sequentiebepaling van het exoom toch toelaat om oorzakelijke mutaties te identificeren. 
Chromosomale microarray analyse is nu de test die bij voorkeur wordt aangeboden voor 
prenatale diagnose in het UZ Leuven, en we voorspellen dat het gebruik van exoom 
sequentiebepaling  zal stijgen met de steeds dalende prijzen. Wel dient het gebruik van deze 
nieuwe technologieën met enige voorzichtigheid te gebeuren en dienen de ethische 
aspecten ervan goed overwogen te worden. 
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Scientific Summary 
Chromosomal microarray analysis has gradually replaced conventional karyotyping over 
recent years in the postnatal setting which has revolutionized whole genome screening for 
genomic imbalances in patients.  We sought to evaluate the benefits and the challenges of 
applying chromosomal microarrays to prenatal diagnosis for referrals with abnormal 
ultrasound findings.  Our findings, presented in Chapter 3, demonstrate a diagnostic yield of 
~10%.  Importantly, ~3% are caused by submicroscopic CNVs which would go undetected by 
conventional karyotyping alone.  Furthermore, the higher resolution offered by 
chromosomal microarray analysis led to important additional information in ~4% of patients.  
Of particular interest we discover a novel and unexpected advantage of arrays; a 500kb 
paternal insertional translocation is the likely driver of a de novo unbalanced translocation, 
thus improving recurrence risk calculation in this family.  Our study has, in part, paved the 
way for the recent ‘Summary Guidelines for Prenatal Chromosomal Microarray Analysis and 
Genetic Counselling’ from the Belgian Society for Human Genetics 
[http://www.beshg.be/download/annex_2_summary_of_array_and_prenatal_guidelines_20
130502.pdf].  The implementation of prenatal chromosomal microarray analysis as the first 
tier test in place of conventional karyotyping brings the standard of prenatal diagnosis in line 
with that which is provided for postnatal genetic diagnosis. 
Congenital diaphragmatic hernia (CDH) is a life-threatening prenatal disorder detectable by 
ultrasound during pregnancy.  We sought to further unravel the genetic factors underlying 
isolated CDH by the design of a custom microarray covering genomic loci recurrently 
associated with CDH and candidate CDH genes.  Our retrospective screen of 79 isolated CDH 
patients using this custom microarray is presented in Chapter 4.  This study identified a novel 
duplication of the EFNB1 gene in a male patient which was considered likely to be 
pathogenic.  Since our publication, a second case of a male CDH patient with duplication of 
EFNB1 was reported, thus reinforcing EFNB1 dosage sensitivity as a cause of isolated CDH.  
In order to further identify (novel) CNVs and genes associated with isolated CDH, we 
undertook a prospective prenatal study using chromosomal microarrays with genome-wide 
coverage in 75 foetuses with isolated CDH, which is presented in Chapter 4.  This study 
revealed submicroscopic de novo pathogenic CNVs in 9.3% and rare inherited variants which 
may be involved in CDH in a further 4% of foetuses.  This diagnostic yield is significantly 
higher than the ~3% rate of pathogenic submicroscopic CNVs which we observed in our 
prenatal study using the same microarray platform.  Isolated CDH thus represents a valid 
cohort for CNV screening in the prenatal phase, and suggests that the clinical utility of 
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conventional karyotyping is questionable for this group of patients.  This study allowed us to 
further refine the critical region at 15q26 to only 2 genes, pinpointing NR2F2 as the causal 
gene.  We add further evidence for the 15q25.2 and 16p11.2 recurrent microdeletions as 
CDH loci, and we identify novel CNVs not previously observed in association with CDH, 
including a duplication of 4p15.2-p14. 
We next evaluated the use of exome sequencing for the investigation of isolated CDH and 
non-isolated CDH where a genetic cause was suspected.  Our results show that exome 
sequencing represents an effective technique with which to investigate familial CDH, 
described in Chapter 5.  In the first family studied, we identified a nonsense mutation in 
ZFPM2 in 2 individuals with isolated CDH, as well as a sibling with a congenital heart defect.  
Surprisingly, the mutation was shown to be transmitted from the unaffected mother, and is 
also carried by the maternal grandfather and the maternal sister, both of whom are also 
asymptomatic.  This intriguing finding highlights the complexity of CDH, reinforcing the 
involvement of additional as yet unidentified (epi)genetic factors in CDH penetrance.  In a 
second family with 2 male foetuses with MCA, we identify a mutation in the X-linked PORCN 
gene inherited from an unaffected mother who was shown to have extreme skewing of X-
inactivation.  This further implicates Wnt signaling as playing a role in CDH, as well as 
multiple aspects of foetal development.  In a third consanguineous family we identify a 
mutation in PIGN in a foetus with MCA, inherited from carrier parents.  PIGN is involved in 
GPI anchor synthesis and our finding adds to a growing body of evidence that defective GPI 
anchor synthesis causes multiple phenotypes in humans. 
Given the variation in severity of herniation and thus pulmonary hypoplasia, as well as 
differences in responses to foetal and / or neonatal therapy for CDH patients, we sought to 
explore whether gene expression analysis of amniotic fluid cells from CDH foetuses could 
identify dysregulated genes and biological pathways which may act as predictive biomarkers.  
In this exploratory study we applied RNA-sequencing to investigate gene expression in 
cultured cells sourced from amniotic fluid of isolated CDH patients, described in Chapter 6.  
This analysis identifies 2 potential molecular subtypes of isolated CDH, one of which is 
characterized by downregulation of TGFB1 and CTGF, and upregulation of TNF, IL6 and IL8.  
This highlights downregulation of TGFB signalling as a likely cause of much of of the 
downstream dysregulation in gene expression observed, including that of CTGF which has 
been previously implicated in the nitrofen rodent model of CDH.  Furthermore, this group of 
patients shows an apparent inflammatory response indicated by the upregulation of TNF, IL6 
and IL8 which may in turn exacerbate postnatal pulmonary hypertension.  These findings 
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direct future targeted studies in a larger cohort of isolated CDH patients to determine the 
clinical significance and therapeutic potential. 
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Wetenschappelijke samenvatting 
Chromosomale microarray analyse heeft de laatste jaren conventionele karyotypering 
geleidelijk aan vervangen als diagnostische test bij patiënten met ontwikkelingsstoornissen. 
Deze evolutie is het gevolg van de hogere resolutie van chromosomale microarray analyse 
waardoor kleinere oorzakelijke kopij variaties kunnen worden gedetecteerd. In deze thesis 
evalueerden we de voordelen evenals de verschillende uitdagingen betrokken bij de 
implementatie van chromosomale microarray analyse in de prenatale diagnostiek, vooral bij 
foetussen waar er een echografische afwijking werd gedetecteerd. Onze resultaten, 
beschreven in hoofdstuk 3, tonen bij 10% van de foetussen een pathogene kopij variatie 
(copy number variation of CNV). Hierbij wordt 3% veroorzaakt door submicroscopische 
CNV’s die niet gedetecteerd zouden worden met conventionele karyotypering. Bovendien 
zorgde de hogere resolutie van chromosomale microarray analyse voor belangrijke extra 
informatie bij ~4% van de patiënten. Daarnaast werd ook een nieuw en onverwacht 
voordeel van arrays ontdekt: de identificatie van een paternele insertionele translocatie die 
naar alle waarschijnlijkheid de oorzaak was van een de novo ongebalanceerde translocatie 
bij het kind. De mogelijkheid om dergelijke fouten te identificeren bij ouders, laat toe het 
risico voor volgende zwangerschappen accurater in te schatten. Onze studie heeft 
gedeeltelijk de krijtlijnen uitgezet voor de recente ‘Summary Guidelines for Prenatal 
Chromosomal Microarray Analysis and Genetic Counselling’ van de Belgian Society for 
Human Genetics 
[http://www.beshg.be/download/annex_2_summary_of_array_and_prenatal_guidelines_20
130502.pdf].  
Congenitale hernia diafragmatica (CDH) is een levensbedreigende prenatale aandoening die 
gedetecteerd kan worden via echografie. Hoewel er reeds veel informatie over de 
ontstaansmechanismen van CDH gekend is door de studie van modelorganismen, blijft de 
kennis over de genetische basis van deze aandoening bij de mens fragmentarisch. Gezien 
men op basis van de genetische afwijking een prognose kan maken over het 
ontwikkelingspotentieel van de foetus, zou dergelijke kennis kunnen helpen bij het 
beslissingsproces over het al dan niet overgaan tot foetale therapie. Daarnaast zou een 
betere kennis van de pathogenese van CDH kunnen leiden tot een betere foetale therapie. 
Ons doel was om de genetische factoren die geïsoleerde CDH veroorzaken verder te 
ontrafelen. Hiervoor ontwikkelden we een microarray die toeliet om kopij variaties te 
identificeren in loci en kandidaatgenen die eerder geïdentificeerd werden via klinische 
studies en studies in modelorganismen. Met behulp van deze microarray voerden we een 
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retrospectieve studie uit op 79 patiënten met geïsoleerde CDH, waarvan de resultaten zijn 
weergegeven in hoofdstuk 4. In deze studie rapporteren we een mannelijke patiënt met een 
duplicatie in EFNB1 als mogelijk nieuwe genetische oorzaak van CDH. Na onze publicatie 
werd ook in een tweede mannelijke patiënt een duplicatie van het EFNB1 gen vastgesteld, 
wat de evidentie versterkt dat gevoeligheid voor duplicaties en deleties van EFNB1 een 
oorzaak is van geïsoleerde CDH. Om vervolgens meer CNV’s en genen betrokken bij CDH te 
identificeren startten we ook een prospectieve prenatale studie in 75 foetussen met 
geïsoleerde CDH. De resultaten van deze studie, waarvoor we eveneens genoomwijde 
chromosomale microarrays gebruikten, worden ook beschreven in hoofdstuk 4. Deze studie 
ontdekte de novo submicroscopische pathogene CNV’s in 9.3% van de foetussen en 
zeldzame, overgeërfde varianten die mogelijks betrokken zijn bij CDH in 4% van de 
foetussen. Foetussen met geïsoleerde CDH vormen dus een waardevolle groep voor CNV 
screening tijdens de prenatale fase. Ons onderzoek toont bovendien aan dat voor deze 
groep het nut van conventionele karyotypering beperkt is. Deze studie liet ook toe om de 
kritische gedeleteerde regio op 15q26 te verfijnen tot 2 genen, waarbij NR2F2 als het 
oorzakelijke gen wordt aangeduid. We brengen ook extra evidentie aan dat 15q25.2 en 
16p11.2 recurrente microdeleties oorzakelijk zijn voor CDH. We identificeerden bovendien 
nieuwe CNV’s, waaronder een duplicatie van 4p15.2-p14, die nog niet eerder werden 
geassocieerd met CDH. 
Vervolgens evalueerden we mogelijkheid om de oorzaak van geïsoleerde en niet-geïsoleerde 
CDH te bepalen via exonische sequentiebepaling. Onze resultaten tonen aan dat exon 
sequencing een efficiënte techniek is om familiale CDH te onderzoeken, zoals beschreven in 
hoofdstuk 5. In een eerste familie werd een nonsense mutatie in ZFPM2 gedetecteerd in 2 
foetussen met geïsoleerde CDH, en in hun broer met een aangeboren hartafwijking. De 
mutatie werd onverwacht doorgegeven via de niet aangetaste moeder, en komt ook voor bij 
de maternele grootvader en de maternele tante die beiden asymptomatisch zijn. Deze 
resultaten wijzen op variabele penetrantie van de mutatie en tonen de moeilijkheid aan om 
mutaties oorzakelijk voor CDH te identificeren. In een tweede familie met 2 mannelijke 
foetussen met multipele afwijkingen werd een mutatie in het X-gebonden PORCN gen 
geïdentificeerd. De mutatie werd overgeërfd van de asymptomatische moeder waarbij 
‘skewed’ X-inactivatie werd vastgesteld. Gezien PORCN betrokken is in het intracellulaire 
transport van Wnt proteinen, wijst deze bevinding op een belangrijke rol van de Wnt 
signaaltransductieweg in verschillende aspecten van foetale ontwikkeling en CDH. In een 
derde, consanguine familie werd een homozygote mutatie gedetecteerd in PIGN in een 
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foetus met meerdere congenitale afwijkingen. Deze mutatie werd overgeërfd via elk van 
beide ouders. PIGN is betrokken in de synthese van ‘GPI anchors’ wat strookt met de 
stijgende evidentie dat defecten in de synthese van GPI ankers verschillende fenotypes 
kunnen veroorzaken.  
Aangezien de efficiëntie van de foetale en/of neonatale therapie bij CDH foetussen afhangt 
van de graad van de hernia en de pulmonaire hypoplasie zou het identificeren van 
biomerkers die gecorreleerd zijn met de ernst van deze aandoening de therapie kunnen 
sturen. Daarom besloten we te onderzoeken (i) of de genexpressie in amniosvocht van CDH 
foetussen een biomarker zou kunnen zijn voor de  ernst van de aandoening en het effect van 
de behandeling.. In deze studie gebruikten we, zoals beschreven in hoofdstuk 6, RNA 
sequencing om de genexpressie in gekweekte amnioscellen van geïsoleerde CDH foetussen 
te onderzoeken. Onze analyse identificeerde 2 mogelijke moleculaire subtypes van 
geïsoleerde CDH, waarvan één gekarakteriseerd is door een verminderde transcriptie van 
TGFB1 en CTGF en een verhoogde transcriptie van TNF, IL-6 en IL-8. Dit duidt erop dat 
verminderde transcriptie van TGFB een mogelijke oorzaak is van de geobserveerde 
gestoorde regulatie van de verschillende doelwitgenen. Daarnaast toont deze groep van 
patiënten een inflammatoire respons door de verhoogde expressie van TNF, IL6 en IL8 wat 
postnatale pulmonaire hypertensie kan versterken. Deze resultaten vormen een goede start 
voor toekomstige studies die in een grotere groep geïsoleerde CDH patiënten zou moeten 
uitgevoerd worden om de klinische betekenis en het therapeutische potentieel te bepalen. 
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